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ABSTRACT 
 
Studies from Africa report supplementation with Dichrostachys glomerata (DG; 
200–400 mg/d) has led to significant reductions in weight and fat in obese individuals, 
without exercise or diet intervention. The purpose of this study was to examine if adding 
DG to weight loss supplements with caffeine [WL+C] containing; DG (300mg), Clubmoss 
extract (10mg), Caffeine (150mg; XR [77% caffeine] | 250mg; anhydrous [98.5% 
caffeine]), Sensoril® (125mg), and Capsimax® (50mg) or without caffeine [WL] 
containing; DG (300mg), Sensoril® (250mg; Ashwaganda), Bioperine (5mg), Capsimax® 
(50mg; 4% Capsaicinoids), Rhodiola rosea extract (60mg), L-Theanine (100mg), 
Clubmoss extract (5mg), and Bacopa monneri extract (50mg), would promote weight loss 
in overweight persons, without exercise or dietary modification. In a double-blind, 
parallel, stratified random, placebo-controlled trial, participants (N=68 [M: 31, W: 37], 
37±5 yr, 88.9±16.6 kg, BMI: 25-34.9 kg/m2, Fat: 35.2±7.7%, Activity: 6,857±1,512 
steps/wk) ingested a DG containing weight loss supplement for 12 weeks. Measurements 
were obtained for body weight, body composition, anthropometry, blood chemistries, 
resting energy expenditure, and hunger and satiety at baseline and after 4, 8, and 12-weeks. 
Supplementation was shown, using GLM, to have no significant differences between 
groups for measures of body composition using the current dose. Supplement groups 
decreased in FM (WL: -0.56±0.95 [-1.02, -0.14]; WL: -0.63±1.47 [-1.23, -0.02] kg) at 
wk4 and wk8, respectively, and body fat (WL: -0.63±1.26 [-1.16, -0.10]; WL: -0.78±1.31 
[-1.45, 0.07] %) at wk8 and wk12, respectively, with indications of having greater effect 
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on males. As well, REE improved (WL+C: 111±220 [10, 207] kcal/d; WL+C: 1.57±2.37 
[0.5, 2.6] kcal/kg/d) by wk12. Supplement groups also reported less hunger and more 
satiety with some sleep quality improvements (diminished sleep quality for WL+C), 
overall. No significant effects or differences were observed in any other measure. The 
addition of caffeine did not incur additional benefits. Consequently, further research is 
required to determine an effective dose and thereafter, paired with a diet and/or exercise 
program for functional assessment of weight loss potential. 
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NOMENCLATURE 
WL+C  Supplement formula with caffeine 
WL  Supplement formula without caffeine 
PLA  Placebo group (6 grams of dextrose) 
FAM  Familiarization Session 
CHO  Carbohydrates 
PRO  Protein 
kcal(s)  kilocalorie(s) (1 Calorie = 1 kcal = 1,000 calories) 
~ or ≈ Approximately equal to 
e.g. Exempli gratia; “for sake of example”; for example 
i.e Id est; “that is”; in other words 
ea  Each 
g  Gram 
kg  Kilogram 
mg  Milligram 
km  Kilometer 
L  Liter 
mL  Milliliter 
kg/m2  Kilogram per square meter 
mRs  Milliradian 
mmol  Millimole 
min  Minute(s) 
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wk(s)  Week(s) 
/d per day 
BID Twice a day 
/wk per week 
mo  Month(s) 
yr(s) Year(s) 
y/o  Years old 
w/o Without 
CI Confidence Interval 
AE  Adverse Events 
NSAID Non-Steroidal Anti-inflammatory Drug 
T2DM  Type-2 Diabetes Mellitus 
O2  Oxygen 
CO2 Carbon Dioxide 
VO2  Oxygen consumption 
VCO2  Carbon Dioxide production 
REE Resting Energy Expenditure 
HR  Heart Rate 
BP Blood Pressure 
SBP  Systolic Blood Pressure 
DBP  Diastolic Blood Pressure 
BMI  Body Mass Index 
 x 
 
DEXA  Dual-Energy X-Ray Absorptiometry 
FM  Fat Mass 
FFM  Fat-Free Mass 
BMC  Bone Mineral Content 
BIA  Bioelectrical Impedance Analysis 
AST  Aspartate Aminotransferase 
ALT  Alanine Aminotransferase 
ALP  Alkaline Phosphatase 
BUN  Blood Urea Nitrogen 
CRE  Creatinine 
CK  Creatine Kinase 
LDH  Lactate Dehydrogenase 
LDL  Low Density Lipoprotein (Cholesterol) 
HDL  High Density Lipoprotein (Cholesterol) 
TRIG  Triglycerides 
RBC  Red Blood Cells 
RDW  Red Blood Cell Distribution Width 
MCV  Mean Corpuscular Volume 
MCH  Mean Corpuscular Hemoglobin 
MCHC  Mean Corpuscular Hemoglobin Concentration 
MPV  Mean Platelet Volume 
WBC  White Blood Cells 
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CHAPTER I  
INTRODUCTION AND RATIONALE 
 
Background 
In 2016, the World Health Organization (WHO)1 placed the global prevalence of 
obesity (BMI ≥ 30 kg/m2) and overweight (BMI ≥ 25 kg/m2) adults (≥18 y/o) at 13% (650 
million) and 39% (1.9 billion), respectively. Similarly, the 2015-2016 National Health and 
Nutrition Examination Survey (NHANES) data report obesity (BMI ≥ 30 kg/m2) in 39.6% 
of the U.S. adult (≥20 y/o) population.2 Therefore, weight loss remains an aspiration for 
people worldwide in an effort to improve health and reduce various co-morbid risk factors 
associated with obesity. Unfortunately, an exact cause or mechanism has yet to be 
pinpointed, and so many possible treatments are being explored. 
Primary areas of treatment include diet, exercise, and medical interventions, each 
with their own varying degrees of success as well as pitfalls. Yet, long-term maintenance 
of weight loss is a consistent struggle across all areas. While dietary modification and 
increased levels of physical activity may remain steadfast recommendations, consumers, 
healthcare practitioners and medical professionals continually seek alternative strategies 
in the form of dietary supplements. As such, some ingredients are frequently used for 
weight loss such as fiber, appetite suppressors, lipolytic agents, and stimulants like 
caffeine and ephedra to name a couple. 
Commonly, objections to the use of dietary supplements are that they often contain 
the aforementioned stimulants designed to increase metabolism. As such, consumers and 
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healthcare practitioners are wary of such formulae; hence, continued investigation of 
stimulant and non-stimulant supplements is warranted. For example, the use of a newer 
supplement Dichrostachys glomerata (DG), which shows potential antioxidant and 
hypoglycemic properties. Recent reports have stated occurrences of significant 
improvements in BMI, waist circumference, body fat, blood pressure, blood cholesterol, 
triglycerides and glucose, in obese (normoglycemic, type-2 diabetic, metabolic syndrome) 
patients. Also purported, was significant loss of weight (≈7-11 kg) and fat (≈3-5%), 
compared to placebo (≤1 [kg; %], respectively), over a two month period at 200-800 mg, 
30-60 min before eating, 1-2 times per day.3-5 
Other nutrients of interest are caffeine, capsaicin, and ashwagandha. Caffeine is a 
known stimulant and a defining constituent of coffee, tea, and energy drinks. It is also 
commonly used in dietary supplements targeting weight loss as a means of increasing 
thermogenesis, energy expenditure, and fat oxidation. Hence, it is thought to contribute to 
weight loss and maintenance, having some success.6-9 Capsaicin shows to improve fat 
metabolism, appetite suppression and with caffeine suppresses hunger, increases feelings 
of satiety, and increases postprandial thermogenesis.10-26 Ashwagandha improves weight 
and body-fat loss, muscle strength, stress, and mood. 27-35 
Thus, for this current study design, we examined two multi-ingredient nutritional 
supplement formulations using DG, whereby one contained caffeine (stimulant) and the 
other did not. 
The aim of this study was to examine whether or not including DG to a weight loss 
supplement with or without caffeine ([WL+C] DG, clubmoss, caffeine, ashwaganda, 
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capsaicin; [WL] DG, ashwaganda, bioperine, capsaicin, rhodiola rosea, L-theanine, 
clubmoss, bacopa monneri) affects weight loss in the absence of an exercise or diet 
intervention vs. a placebo (6g dextrose). The study took place over 12 weeks, with a 
primary focus on change in body weight. A secondary aim included body composition, 
other indices of anthropometry, blood chemistries relating to hepatorenal function, and 
hunger and satiety. Tertiary aims were components of metabolic syndrome summed and 
presented as z-scores (MetS-z), physical activity, potential side effects, and sleep effects. 
We hypothesized that the nutritional supplement formulation examined would produce 
significant weight loss, whether containing caffeine or not. 
Statement of the Problem 
Will weight loss, body composition, and cardiovascular health be affected by 
prolonged supplementation of a novel weight loss formula, with and without stimulants, 
in the absence of a secondary intervention such as exercise? 
Purpose 
The purpose of this study was to investigate if ingesting a weight loss supplement 
containing dichrostachys glomerata, with and without caffeine, promotes weight loss in 
individuals maintaining their usual diets and exercise practices. 
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General Study Overview 
Sixty-eight apparently healthy men and women (age 30-45) were recruited to 
participate in a double-blind, parallel group, stratified random, placebo-controlled trial 
examining the effects of two weight loss supplements (stimulant and non-stimulant) vs. a 
placebo control (6g dextrose). Supplements were ingested BID, with the stimulant formula 
containing 125 and 150 mg of caffeine for morning and afternoon doses, respectively. 
Participants were assessed at baseline and every 28-40 days (12-day buffer) for respective 
indices, over 12 weeks. Additional supplements were available pro re nata. 
Study outcomes (dependent variables) included; body weight [primary outcome]; 
body composition (fat/fat-free mass and body fat percent), anthropometrics (BMI and 
waist-to-hip ratio), blood chemistry measures (clinical health markers: ALP, AST, ALT, 
creatinine, BUN, CK, LDH, glucose, cholesterol, HDL, LDL, TG, and CBC with platelet 
differential), hunger and satiety, resting energy expenditure, and diet characteristics 
[secondary outcomes]; physical activity, side and sleep effects [tertiary outcomes]. 
To examine the effects of the supplements on weight loss, control measures were 
utilized. As an entrance criterion, for homogeneity, participants needed to be moderately 
active (≤3-4 d/wk), with a BMI of 25-34.9 (Overweight to Class I Obese). If medications 
were required, for metabolic-related issues, they needed to be in use for six or more 
months. At baseline, measures were taken, and groups assigned; (A: WL+C) Weight loss 
formula + caffeine, (B: WL) Weight loss formula without caffeine, or (C: PLA) Placebo. 
Stratified random grouping was used to balance five parameters; BMI, body-fat percent 
(via dual-energy x-ray absorptiometry [DEXA]), average step count, sex, and age.  
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Hypotheses 
H01: Body weight will decrease significantly in treatment groups compared to baseline 
and/or placebo 
H02: Body composition will improve significantly in treatment groups compared to 
baseline and/or placebo 
H03: Clinical health and safety markers will improve significantly in treatment groups 
compared to baseline and/or placebo 
H04: Resting energy expenditure will improve significantly in treatment groups 
compared to baseline and/or placebo 
H05: Diet characteristics in treatment groups will not significantly differ from baseline 
and/or placebo 
H06: Reported hunger and satiety will significantly decrease and increase, respectively, 
in treatment groups compared to baseline and/or placebo 
H07: Reported sleep quality in treatment groups will not significantly differ from 
baseline and/or placebo 
H08: Reported side effects in treatment groups will not significantly differ from baseline 
and/or placebo 
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Delimitations 
The study was conducted within the following parameters: 
1. The study population was limited to overweight and sedentary men and women 
recruited from the College Station, TX area. 
2. Participants were between ages 30-45; BMI 25-34.9 kg/m2; and active ≤ 3-4 d/wk. 
3. Participants’ weight did not change ±10 lb within three months prior to screening. 
4. Participants were not be pregnant or nursing within the past year, with no intent to be. 
5. Participants did not have any uncontrolled metabolic disorders. 
6. Participants were not currently, nor in the past 3 months, using dietary supplements 
for any condition or reason; otherwise, physician clearance was needed prior to start. 
7. Participants were asked not to make lifestyle alterations for the duration of the study. 
8. Those eligible attended a familiarization session to review study protocols; complete 
an informed consent and general health screening; as well, measure anthropometry. 
Limitations 
1. Recruitment was not truly random due to the limitation of Bryan/College Station, Tx, 
and those whom responded to recruitment fliers and emails. 
2. Testing sessions were performed at similar times for the duration of the study. 
3. Subjects may not have followed the supplement instructions as defined. 
4. Dietary data collected was self-reported, via four-day food logs. 
5. To reduce chances of error, equipment calibration abided manufacturer guidelines and 
samples were run in duplicate. Innate equipment limitations may have still persisted.  
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Assumptions 
1. Health screening questions, for eligibility, were answered honestly and accurately. 
2. Subjects followed the protocol explained to them during the familiarization session. 
3. Prior to each testing session, participants fasted 10-12 hours; did not consume alcohol 
or use NSAIDS for 24 hours; and refrained from exercise for 48 hours. 
4. Participants honestly and accurately completed the four-day food records. 
5. Participants complied with their assigned supplement regimen. 
6. The sample population was normally distributed. 
7. The variance among the population sample was approximately equal. 
8. All testing procedures was performed consistently, amongst lab personnel. 
9. Laboratory equipment was functioning and calibrated prior to all testing sessions. 
10. Subjects and researchers remained blinded to the supplements throughout the study. 
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CHAPTER II  
LITERATURE REVIEW 
 
 An ever-growing problem in modern society is the apparent encroachment of 
obesity around the world. Due to its multifaceted nature, and involvement with 
physiological systems, we currently lack a full understanding of the mechanisms at play. 
Although the relationship between food quality, energy intake and expenditure is known 
and a matter of common knowledge, it does not appear to be the sole correlate. Thus, it is 
clear there cannot be any one single intervention rather; an amalgamation of many is likely 
necessary, prompting continued research into less studied and/or ancillary interventions. 
And so, the purpose of this literature review is to convey the incidence and etiology of 
obesity, highlight prevalent health complications thereof, outline and assess the 
effectiveness of key intervention techniques, and delve into supplement use as an 
intervention with a focus on those showing promise yet, require more research. 
Obesity  
Prevalence & Etiology 
Obesity, a now recognized disease, has arguably reached the level of a pandemic 
according to the most recent data trends, which calculated approximately 266 million 
(10.8%) men and 375 million (14.9%) women (≥18 y/o) to be obese (BMI ≥ 30 kg/m2), of 
them 58 million men (2.3% of all men) and 126 million woman (5% of all women) are 
classified as severely obese (BMI ≥ 35 kg/m2), as of 2014. This same collaborative source 
suggested, in 2014, the global prevalence of obesity could reach 18% of men and surpass 
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21% of woman, with severe obesity making up 6% and 9% of those men and woman, 
respectively, by 2025.36 Consonantly, the World Health Organization (WHO)1, as of 2016, 
placed global prevalence of obesity (BMI ≥ 30 kg/m2) and overweight (BMI ≥ 25 kg/m2) 
adults (≥18 y/o) at 13% (650 million) and 39% (1.9 billion), respectively, with 11% obese, 
39% overweight men and 15% obese, 40% overweight women. Nevertheless, obesity is 
certainly acknowledged on an epidemic level in many places, for example the most recent 
National Health and Nutrition Examination Survey (NHANES) data, from 2015-2016, 
reports obesity (BMI ≥ 30 kg/m2) in 39.6% of the U.S. adult (≥20 y/o) population, 37.9% 
and 41.1% of men and women, respectively.2 
 When talking about the cause(s) of obesity it is almost impossible to pinpoint any 
one cause or reason, because it has come to be known as multi-factorial in origin, due to 
its roots in environmental influences, behavior and lifestyle, socioeconomic status, 
geographic location, physiology, and even genetics.37,38 Despite this, there is a common 
anecdote used to describe the primary cause of obesity “energy in vs. energy out”, stating 
that obesity stems from consuming more energy than is expended, thus leaving extra to be 
stored.1 Fundamentally this holds some merit, as it follows the straightforward logic of the 
first law of thermodynamics. Although hypothetically, energy imbalance as the cause 
would be paradoxical, in that simply reversing it or balancing intake and output has not 
been working overall. The WHO1 addresses reasons why this may occur, discussing 
increased intake of high-fat and energy-dense foods, convenient modes of travel and more 
sedentary jobs causing decreased physical activity, plus environmental factors related to 
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policies, food access and processing, and general education. Undoubtedly, all play a role 
in the etiology of obesity as a major health problem, as such requires consideration. 
Health Complications 
Obesity is associated with many poor health outcomes and comorbidities, the most 
well-known being the endocrine-related disorder Type 2 Diabetes Mellitus (T2DM). Other 
related health conditions include cardiovascular diseases (e.g. heart disease or stroke), 
musculoskeletal disorders (e.g. osteoarthritis), and even certain cancers (e.g. colon, renal, 
or ovarian) to name a few.37,39 In fact, the criteria for what is now known as Metabolic 
Syndrome are a collection of key signs and symptoms put together to serve as a screening 
method to assess a patients potential risk for developing T2DM.37,40 In general, clinicians 
look for distribution of fat around the visceral cavity (waist), hypertension (elevated blood 
pressure), low levels of high-density lipoprotein (HDL) cholesterol, increased levels of 
glucose, and high levels of triglycerides in the blood.37 It is obvious to see that these 
criteria fit other complications as well; suggesting the parameters for Metabolic Syndrome 
may just serve as good warning signs as opposed to diagnostic criteria. Metabolic 
Syndrome and Obesity share many commonalities and are both linked to T2DM, wherein 
if Metabolic Syndrome were kept as a risk assessment tool, and not a separate diagnosis, 
it would further highlight the need for obesity/weight loss interventions. 
Weight loss Interventions 
Within the past few decades, more so than any time prior, there has been a 
consequent uptrend in possible weight loss and/or management interventions, the most 
prominent being lifestyle based. Conceivably, this is in response to rising rates of obesity, 
 11 
 
but has seen mutable success typified by “human error”, with compliance likely being a 
problematic factor. Lifestyle interventions such as behavioral, diet, and exercise remain 
the preferred method for both weight loss and maintenance, short and long term. In 
opposition of this, obesity rates continue to climb, leading to more alternative medical 
interventions inclusive of medications and surgery, attempting to combat obesity. The 
following sections will discuss these weight loss interventions. 
Lifestyle 
Behavior. Often weight loss programs operate under the assumption that changes 
regarding a person’s behavior, diet, and physical activity are required, irrespective of any 
initial intervention used.41-44 However, each component of “lifestyle interventions” are, to 
some degree, capable of acting alone. Behavioral modifications are often lumped in with 
diet and/or exercise, as they can be one in the same. Behavioral changes, in absence of 
secondary intervention, have shown average weight loss of ~3 kg (95% CI: 4.02-2.01) in 
12-18 months by self-monitoring diet, exercise, weight45,46 or reducing speed of intake47, 
for example. In this context, behavioral change refers to identifying healthy food items, 
eating habits, altering daily routine and/or route of travel to avoid fast food establishments, 
eating in front of a television less, and other actions like this. 
Dietary. This receives a lot of attention when it comes to weight loss interventions, with 
much emphasis on the concept of calorie intake compared to calorie output. Thus, caloric 
restriction of 500 kcal/d, a reduction by 30% daily kcal needs, or a limit of 1200-1500 and 
1500-1800 kcal/d for women and men, respectively, with the goal of negative energy 
balance, are general dietary recommendations for weight loss.37,48 As a result, there has 
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been back-and-forth about whether to restrict fat or carbohydrate intake; a 2014 meta-
analysis of 7,286 people concluded that weight loss does not differ significantly (6 mo ≈ 
8 kg/ea; 12 mo ≈ 7 kg/ea), either way.49 The implication being, weight loss is achievable 
through caloric restriction of any nature, primarily short-term. An argument is therefore 
made to focus on improving diet quality, yielding similar results with normal calorie 
intake, but is significantly more effective in long-term maintenance and sustainable 
because it accounts for the weight- and calorie-independent effects (good or bad) dietary 
habits have on cardiovascular and metabolic disease risk.39,50 A few examples of 
recommendations focused on building positive eating habits with quality intake are the 
DASH, Mediterranean, and Heart Healthy diets, the details are provided in Table 1. 
 
 
Table 1: Overview of Key Clinical Diets 
Diet CHO/Fat/Pro (%) Emphasis Limit Rationale 
DASH:  
51-53 
55/27/18 
 
Vegetables, fruits, low-fat dairy products, whole grains, 
poultry, fish, beans, and nuts potassium, calcium, 
magnesium, and fiber 
Sweets, sugar-sweetened 
beverages, red meat, saturated 
fats, sodium (2,300 mg/d) 
Lowers BP, lipids, and CVD risk 
DASH-Sodium:  
52,54 
 
55/27/18 
 
Same as DASH Same as DASH;  
Sodium (1,500 mg/d) 
(U.S. avg 3,600 mg/d) 
Lowers BP more than DASH 
 DASH+:  
51,54 
48/27/25 DASH; Increased protein Same as DASH Lowers BP and lipids more than 
DASH 
  48/37/15 
 
DASH; Increased unsaturated fats Same as DASH  
Mediterranean:  
53,54 
 
55/30/15 Plant-based foods, fruits, vegetables, whole grains, 
legumes, nuts, olive oil, fish and poultry (≥2x’s/wk), 
eggs (≤4x’s/wk)  
Red meat (monthly), saturated 
fats, wine, sodium 
Lowers BP, glucose, lipids, and 
CVD risk 
 PREDIMED: 
55-57 
43/37/15 
 
Mediterranean; Increased unsaturated fats (extra virgin 
olive oil or nuts) 
Same as Mediterranean Lowers BP, glucose, and lipids 
more than Mediterranean 
 RESMENA:  
58,59 
40/30/30 
 
Mediterranean; 7 meals/d, polyunsaturated fatty acids  
(n-3 PUFAs), antioxidants, low glycemic carbohydrates 
 
Same as Mediterranean; High 
glycemic carbohydrates 
Lowers BP, oxidative stress 
markers, triglycerides; increased 
LDL cholesterol 
Heart Healthy: 
(AHA) 58,60 
 
55/30/15 
 
Fruits, vegetables, whole grains, fish, legumes, and 
poultry 
Trans fats, added sugars, red 
meat, sodium, and saturated fats 
Lowers BP, lipid profile, and 
CVD risk 
DASH; Dietary Approaches to Stop Hypertension, PREDIMED; Prevención con Dieta Mediterránea, RESMENA; Reducción Del Síndrome Metabólico Navarra-España , 
AHA; American Heart Association, CVD; Cardiovascular Disease, BP; Blood Pressure 
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Exercise.  Physical activity is the final, and arguably most established, of the lifestyle 
interventions. The current recommendations for adults, in the U.S., suggest aerobic 
physical activity (e.g. running, power-walking, etc.) at either a moderate-intensity for 150-
300 min/wk, a vigorous-intensity for 75-150 min/wk, or a combination of both and 
muscle-strengthening activities ≥2 d/wk.61 Following these guidelines, health benefits 
have been reported independent of weight loss, as early as after a single bout. Such 
improvements include blood pressure, insulin sensitivity, sleep, anxiety, and “day-of” 
cognition, most showing greater improvement with increased regular activity. Reduced 
disease risk (i.e. cardiovascular/metabolic) appears as a function of time and consistency 
in following an exercise program.62  
Exercise has been studied for far longer than the previously discussed interventions 
and is still, anecdotally, believed by many to be the most and maybe the only important 
factor when it comes to weight loss and maintenance. Obviously, this is an 
oversimplification but, it does accurately highlight the impact physical activity can have 
and simultaneously ignoring the consequences of a one-sided weight loss program. For 
example, resistance training without dietary adjustments may increase lean mass with little 
to know effect on fat mass or cardiovascular health, sometimes having a negative 
influence63; similarly, aerobic training without dietary adjustments might reduce fat mass 
as well as lean mass, in extreme cases result in severe health complications.63 Meta-
analysis of trials indicate dietary changes alone, over a 12 month period, can lead to weight 
loss of ~1.38 kg, while the addition of regular exercise resulted in a loss of ~3.34 kg, 
retaining a greater weight loss for up to 2+ years.64 Interestingly, the type of physical 
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activity (aerobic or resistance; high or low intensity) do not appear to be effectively 
different in overall weight loss, with the concession that a higher intensity tends to lose 
weight quicker.65 Congruently, if the interventions are paired in the wrong way, i.e. intense 
and frequent exercise with calorie restriction, the initial result is drastic weight loss 
typically followed by weight regain (sometimes more than lost) and a decreased and 
altered resting metabolism that seemingly favors fat storage lasting 6 years or more.66 
Related, is the often-overlooked behavioral aspect. Physical activity (and diet) can 
be effective, especially short-term, but, for long-term maintenance and avoiding potential 
complications, the interventions need to be realistic and sustainable for the individual. 
According to the Physical Activity Guidelines for Americans, only 26% of men and 19% 
of women report meeting activity (aerobic and resistance) guidelines.61 In the look 
AHEAD trial, ~68% of participants lost ≥5% of their initial body weight at year 1 (avg 
loss ~8.5%) compared to ~50% (25.8% had lost 5-10%) of participants at year 8 (avg loss 
~4.7%); wherein activity levels doubled at year 1, decreasing by year 4 (avg loss ~4.4%), 
and dropping almost back to baseline levels by year 8.67 
Medical 
While lifestyle interventions are a steadfast, making great strides and work for 
many people, they are not without their faults. A usual intervention expects to see and 
sustain between 5-10% weight loss, within 6 months, often failing in this goal.60,68 
Regardless of the efforts made, the obesity rate continues to climb worldwide. Several 
global agencies release guidelines addressing these and other facets, updating them 
periodically based on current research.43,44,69,70 Due to the ongoing nature of treating 
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obesity, many medications, surgical procedures, and devices were created as additional/ 
supplementary to lifestyle interventions and is the focus of this section. 
Medication. As far as medication is concerned there are many known to have effects on 
weight, some intended and some not. More often, classes of drugs will have similar 
influences on weight. For instance, antipsychotics, antihistamines, adrenal steroids, and 
adrenergic blockers either have no effect or lead to weight gain, the latter medication being 
largely neutral. In comparison, medications such as antiepileptic/anticonvulsants, 
antidiabetics, and mood stabilizers/antidepressants have an equal chance of going in either 
direction, the latter favoring weight-gain.71 On the other hand, there are medications 
intended for the treatment of obesity. These medications are typically long-term (e.g. 
pancreatic enzyme inhibitors) and have shown weight loss anywhere from 3-15% body 
weight within 1 year, whereas the lesser used short-term medications (<12 wks; e.g. Trace-
amine associated receptor-1 [TAAR1] agonists) lead to an average loss of 5-10% body 
weight over 12-28 weeks.37,72-74 The regulatory guidelines on use of pharmacotherapy to 
treat obesity states that individuals (BMI ≥ 27 kg/m2 with comorbidity; or ≥ 30 kg/m2) 
who fail to achieve and/or maintain clinically meaningful weight loss (≥5% body weight) 
are eligible for medication to assist a management program; however, behavioral, diet, 
and exercise (lifestyle) modifications are promoted in obesity management for BMI ≥ 25 
kg/m2.50,75 Any medication is deemed ineffective and recommended to cease if the patient 
losses < 5% of their body weight after 3 months.75 See Table 2. 
Surgery/Devices. Surgical procedures and medical devices are akin to medications in the 
sense that their intended use is for when lifestyle interventions do not appear effective by 
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themselves. In that scenario the Endocrine Society recommends that bariatric surgery be 
considered if the patient also has a BMI ≥ 35 kg/m2 with comorbidity or ≥ 40 kg/m2.75 
Bariatric surgeries include; sleeve gastrectomy, involving the placement of staples along 
the curve of the stomach from esophagus to small intestine, narrowing the stomach, 
followed by excision of the other half (1.3% re-operation; 5.5% complications); and 
gastric bypass, the most common being Roux-en-Y, which is the anastomosis of proximal 
stomach and small intestine that physically re-directs the path of foodstuffs through the 
gastrointestinal tract (1.8% re-operation; 10.7% complications).76 Other variations of the 
gastric bypass procedure differ in where the anastomosis occurs, i.e. what sections of the 
small intestine and stomach are attached to one-another. Bariatric surgery seemingly 
“avoids” the metabolic backlash reported with rapid weight loss in intense diet and 
exercise programs.66 Both cause metabolic rate to diminish, however, bariatric patients 
return close to pre-operation rates in 6-24 months77, whereas lifestyle alteration shows 
diminished metabolic rates for several years after.66,78 In relation, resting metabolic rate 
strongly correlates with fat-free mass (FFM) pre- and post-operation.79 Here, better 
understanding of mechanisms are needed, as an argument can be made for the initial post-
surgery drop being due to removal of a sizeable mass of metabolically active tissue 
followed by slow healing and adapting (returning to equilibrium) plus an inherent food 
quantity restriction. In contrast, FFM lost in intense exercise and diet is slower and from 
stimuli rather than removal. 
Various devices also exist for managing weight, many of them requiring minimally 
invasive surgery. A well-known example is the gastric band, a fluid-filled band placed 
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under and around the gastro-esophageal sphincter where the constant pressure stimulates 
vagal afferent nerves, affecting the down-stream signaling of fullness. This procedure 
shows a ~7% re-operation and ~7.8% complication rate.50 Other devices currently in use 
include; gastric balloons; electric stimulators systems (3.7% AE80); bypass liners; and an 
oral apparatus. Table 2 provides a general list of other devices, surgeries, and medications 
with a brief description, the average weight lost and over what interval of time. One other 
device of interest is the gastric emptying system, e.g. Aspire Assist (Aspire Bariatrics, 
King of Prussia, PA, USA), which is a small aspirating system that removes up to 33% of 
a person’s stomach content shortly after consumption, through a gastric tube in the 
abdomen, essentially mimicking bulimia nervosa with a machine. Of note, while this 
device has shown ~12-14% loss of body weight, it was paired with extensive lifestyle 
(behavioral) counseling, psychological evaluations and was compared to the ~4-5% loss 
seen in lifestyle counseling alone.68,81,82  
 
Table 2: Medical Interventions 
Treatment  Description Weight loss  Interval 
Medication:  Controls/Limits Intake (chemically)    
Long-term 
 
Pancreatic enzyme inhibitors, 5-HT and GLP-1 receptor agonists ~3-15%  1 yr 37,72,73 
 Short-term 
 
TAAR1 agonists (releases monoamines) ~5-10%  12-28 wk 73,74 
Bariatric Surgery:  Re-Directs/Limits Intake (functionality)    
 Sleeve Gastrectomy 
 
Staple placement along curvature of the stomach with removal of the closed-off half ~16.8-19.8%  6-18 mo 82 
 Roux-en-Y Gastric 
Bypass 
 
Anastomosis of proximal stomach and small intestine at various points ~24.8% 
~30-35% 
 6 mo 83 
1-3 yr 83,84 
Devices:  Controls/Limits Intake (mechanically)    
Gastric Band 
 
Fluid-filled band under gastro-esophageal sphincter, stimulating vagal afferent nerves ~10.3-18%  3 mo-20 yr 68,84,85 
Intragastric Balloon 
 
Swallowable pill which is filled, typically with fluid, and rests in the stomach ~6.6-12.2%  6 mo 86-89 
Electric Stimulator  Electrodes in vagal nerve trunk, connect to neuro-regulator, influencing nerve signals:  
Vagal Block or Pacemaker 
~9.2%          
~13.3-15.7% 
       ¦     1 yr90 
1-2 yr91,92 
Gastric Emptying System  Aspirating unit removes stomach content via gastronomy tube and port in abdomen ~12.1-14.2%  1 yr 68,81,82 
Bypass Liner  Fluoropolymer sleeve, of various lengths, used to cover segments of the small intestine ~5-13.3%   6-12 mo68,82,93 
Oral apparatus  A mouthpiece occupies space, forcing smaller bites and slower intake ~7.3-11%      3 mo -3 yr94 
¦ ; vagal block, GLP-1; Glucagon-Like Peptide, 5-HT; Serotonin 
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Supplements 
 As the previous sections indicate, lifestyle and medical interventions are still 
largely being studied relative to weight loss. However, an area in weight loss coinciding 
with diet is supplementation, excluding nutritional supplements for preventing/treating 
electrolyte imbalances or related conditions resulting from significant decrements of 
weight. Considering the overall success and limitations of dieting, discussed above, it 
stands to reason the next step would be to fine tune and/or simply add to a diet program, 
by way of supplements, attempting to improve weight loss outcomes.  
Many supplements have garnered attention in this respect, such as thermogenic 
compounds including caffeine, ephedrine, or even capsaicinoids (commonly used as 
cayenne powder), to name a few. These are sought primarily for their purported ability to 
suppress appetite and/or increase satiety and the “thermic effect of food” (thermogenesis), 
evidently increasing resting metabolic rate and ultimately weight loss.16,17,95,96 Whereas, 
supplements such as ashwaganda, bacopa monniera, clubmoss, rhodiola rosea, and 
theanine are investigated for their potential to reduce stress/anxiety, depression, and 
improve sleep, essentially affecting mood and vigilance, touching on the mental health 
influence in weight and health. Others including clubmoss, dichrostachys glomerata, and 
piperine are considered for their possible antioxidant, anti-inflammatory, or GI and 
bioavailability effects, where they have typically been incorporated with the purpose of 
accompanying or aiding other supplements to increase their effects. 
However, many of these supplements lack a sizeable body of literature. Therefore, 
in an effort to understand the effects, possible mechanisms, and how it all might fit 
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together, these sections will review several of the aforementioned herbal and non-
stimulant supplements believed to influence weight, as primary nutrients, as well as 
nutrients which work synergistically towards the same goal, such as caffeine. 
Purported Primary Nutrients 
Dichrostachys glomerata. DG is a spice used in Cameroon, said to have potential 
antioxidant and hypoglycemic properties. Recent reports have also shown DG to 
significantly improve BMI, waist circumference, body fat, blood pressure, blood 
cholesterol, triglycerides and glucose in obese, normoglycemic and type-2 diabetic, 
subjects when administered 400 mg (BID), 30-60 minutes before eating lunch and dinner 
(800 mg total). Participants exhibited weight loss of ~7.5 kg, with a little more than 3% 
drop in body fat, compared to placebo (-1.3 kg, -0.7%, respectively).4 An essentially 
identical study, from the same group, also corroborated the antioxidant effects in obese, 
normocglycemic, diabetics (T2DM).5 Similar responses to the former and latter 
experiments, again from the same group, were also observed in obese individuals with 
metabolic syndrome when administered 200 mg. This time participants dropped around 
11 kg body weight, with an almost 5% decrease in body fat, compared to placebo (-0.5 kg, 
-0.2%, respectively).3 However, this particular study’s conclusions should not be taken at 
face value; due to the fact the amount given is never clarified. It is only ever apparent that 
participants received at least 200 mg per day, since the abstract states administration of 
“200 mg, 30-60 minutes before lunch and dinner”, then contradicts this in their methods 
by stating “200 mg, 30-60 minutes before lunch or dinner”, with no specified daily total. 
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Otherwise, DG shows some promise within the realm of weight loss and related 
complications but requires more research outside of this group. 
Ashwagandha. Also known as Withania somnifera, this is an herbal adaptogen 
(substances which help attenuate damaging effects of stress) commonly used, in the Indian 
medical practice of Ayurveda, for a variety of health related reasons ranging from stress 
and cognition, to Alzheimer’s disease and cancer.27 It is more commonly known for its’ 
potential anxiety reducing (anxiolytic) properties. Animal models, primarily mice and/or 
rats, have reported attenuating chronic and acute stress-related outcomes inclusive of 
glucose intolerance, increased stress hormones, gastric ulcers, male sexual dysfunction, 
and immunosuppression.97,98 Ashwagandha has also been shown to have an additive 
benefit in rats given Diazepam, a common antidepressant, where the drug effects seemed 
to be enhanced.99 Several related animal studies support the herbs prospects for 
neuroprotection98, hypocholesterolemic100, antioxidant100,101, and anti-inflammatory 
effects.102,103 
In human trials, evidence supports an anxiolytic effect while supplementing 125, 
250, 50028, up to 2,250 mg29,32,33, reaching as high as 5g30 and 12g31. Interestingly, some 
studies showcased other potential benefits such as cognitive improvements34, weight 
loss32, reduced body fat, improved muscle strength (w/o exercise)35, stress relief, and 
antidepressant effects.28-33 Ashwaganda has also been used to reduce chemo-therapy 
induced fatigue.104 Yet, despite the seemingly promising research, there remains no real 
consensus on an effective dose or mechanism of action in either animal or human models. 
Table 3 offers a list of mostly human studies, primary reported outcomes, and dose used.  
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Table 3: Primary and Synergistic Supplements 
Supplement  Dose Duration Primary Outcomes Notes 
Purported Primary Nutrients 
Dichrostachys glomerata  200-400 mg 8 wk Weight loss 
3    ˹Weight - DG: -11.15±0.18 kg │ PLA: -0.53±0.11kg˺ 
˻Fat -       DG: -4.73±0.11%     │ PLA: -0.20±0.10% ˼ 
 
 
 
 
800 mg 8 wk Weight loss 4*  
Antioxidant 5 
˹Weight - DG: -7.67±0.36 kg   │ PLA: -1.32±0.21kg˺ 
˻Fat -       DG: -3.20±0.20%     │ PLA: -0.70±0.11% ˼ 
* Normoglycemic, obese subjects.  
Obese T2-diabetics had similar results
 [4]
 
Ashwaganda  125 mg -12g 2-12 wk Anxiolytic/Antistressor/Antidepressant; Weight loss; ↑ Cognition 28-34 Stress focused [30] 
(Withania Somnifera)  750; 1000; 1250 mg 4 wk ↓ Body fat; ↑Muscle strength (w/o Ex) 35  
 (Rat)  0.75-1.5g ≤1-28 d Antioxidant/Anti-inflammatory 100,103 1 g/kg [103]; 0.75 & 1.5 g/d [100] 
Capsaicinoid   2 mg -- Minimum effective dose 10,11 Meta-Analysis [10]; Review [11] 
  ≡ 3.09 mg 24-36 hr ↔ Satiety; ↓ Ghrelin; ↑ Metabolic Rate 12-14 │≈ 0.3%  capsaicinoids    
 ≡ 4.59 mg 1-6 wk ↓ Appetite/↑ Satiety 13,15 │≈ 0.3%  capsaicinoids    
 ≡ 30 mg ≤1-7 d ↑ Metabolic Rate; Lipid Oxidation; Thermogenesis 13,16,17 │≈ 0.3%  capsaicinoids   
 Capsinoids  6.9 mg 6 wk ↓ Appetite/↑ Satiety 15  
 Capsaicin ≡ 0.19 mg ≤1-7 d No effect 13,18 │≈ 0.3%  capsaicin 
  ≡ 2.77 mg ≤1 d ↓ Appetite/↑ Satiety 18 │≈ 0.3% capsaicin 
  ≡ 1.2-6.75 mg 1 wk Tolerable Dose; No other effects 13 🔥│≈ 1.2-1.35% capsaicin 
  ≡  6.75; 7.68 mg 36-48 hr ↓ Appetite/↑ Satiety 19,20; ↑ Lipid Oxidation 21 │≈ 0.25%  capsaicin 
  ≡ 18; 30 mg ≤1 d ↓ Appetite/↑ Satiety; ↓ Blood Glucose 22,23 │≈ 3 g/kg  capsaicin 
   26.6 mg ≤1 d ↓ Blood Glucose (maintained Insulin) 22,23 │(5g) = 26.6 mg  capsaicin 
   135; 150 mg ≤1-84 d ↑ Lipid Oxidation 24,25  
       
Purported Synergistic Nutrients 
Caffeine+ /[Theanine]  40/[9] mg       ≤1 d ↑ Attention, Alertness; ↓ Tiredness 105  
   40/[97] mg ≤1 d ↑ Attention 106  
   50/[100] mg ≤1 d ↑ Vigilance, Attention, Memory 107  
   150/[250] mg ≤1 d ↔ ↑ Vigilance, Memory; ↓ Tiredness, Headache frequency 108,109  
/[Capsaicin]  25/[0.2] mg ≤1 d ↑ Thermogenesis; No cardiac effects 26  
  ≡ 231/[4.59] mg 6 wk ↓ Hunger/↑ Satiety 15 │(1530mg) ≈ 0.3%  capsaicinoids   
Piperine (Rat/Mice)  0.5-20 mg/kg ≤1 d ↓ GI motility 110-113 Review [112] 
(Rat/Mice)  20-142 mg/kg ≤1-56 d ↑ Gastric Acid Secretion; Bioavailabilty in humans (20mg/kg) 112,114,115  
(Rat/Mice)  1; 1.3; 4; 8; 16; 32 mg/kg 1-8 wk ↓ GI motility; Anti-diarrheal 110-113  
L-Theanine   50 mg -- Relaxant 116 Review [116] 
    100; 200; 250 mg ≤1 d ↑ Attention/Vigilance 108,117; Antistressor; Anxiolytic/Relaxant 109,116-119  
    400 mg 6 wk Anxiolytic/Relaxant 120; ↑ Sleep 121 Review [116] 
Rhodiola rosea   60mg 5 wk Anti-inflammatory 122  
    100; 144; 170; 400; 576 mg 1-4 wk ↓ Fatigue/↑ Cognition; Antistressor 123-127 (144; 170mg) ≈ 2.3% Salidroside 
    370; 555 mg ≤1 d ↓ Fatigue/↑ Cognition 128  
   364 mg 6 wk ↑ Fatigue 129  
   340; 680; 1020; 1360 mg 6-12 wk Antidepressant 130-132  
Bacopa monniera  225 mg 6 mo ↓ ADHD symptoms 133  
   250; 300 mg ≤1d-12wk ↑ Memory/Cognition; Attention; Anxiolytic/Antidepressant 134-140  
   300; 450 mg 12 wk ↑ Information Retention 141; ↔ Attention, Cognition or Anxiety 141,142  
Clubmoss   500 mg/kg ≤1 d Anti-inflammatory 143  
Huperzine-A  0.03-0.45 mg -- ↑ Memory/Cognition 144 Review [144] 
 (Cell culture)  100 nM --   
: Reported as Capsicum/Red Pepper/Cayenne; 🔥: Capsimax; ≡: Calculated, Refer to Notes; ↔: No Change; ↑: Increase; ↓ Decrease 
 
 
Capsaicinoids.  The compounds found in chili-peppers (Capsicum genus) responsible 
for the “hot” sensation felt when eaten, or contact is made with a mucus membrane (e.g. 
eyes or nostrils). This is due to their binding of the nociceptor group associated with 
transmitting signals of burning or acidic pain.11,145 There are many molecules classified as 
a capsaicinoid, all of which are relatively similar in structure, with capsaicin and 
dihydrocapsaicin approximating 90% of the total structures on average.146 That being said, 
capsaicin is considered to be the primary active constituent, causing the previously 
mentioned side effects, along with likely being responsible for any medicinal properties.145 
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In the same way, there are various naturally occurring capsinoids that happen to be 
structurally akin to capsaicin, subsequently exhibiting similar effects related to appetite 
suppression, with the primary difference being the lack of a burning sensation.15 
Capsaicinoids, mostly capsaicin, are reported to have roles in pain relief 147, weight 
loss/management10,11, thermogenesis17, anticancer therapy and antioxidant activity.146,148 
Supplementation in humans has concluded that 2 mg of capsaicinoids is the minimal 
effective dose, even causing some appetite suppression.10,11 However, the amount of 
capsaicin involved is not clear for this recommendation. The studies reporting on 
capsaicinoids as a whole have shown increases in metabolic rates, appetite suppression, 
satiety, lipid oxidation, and thermogenesis using 3.09, 4.59, and 30 mg of capsaicinoids, 
which are doses calculated from the total dose of the supplement given (e.g. cayenne 
powder) and reported as 0.3% of total dose.12-17 Fortunately, capsaicin data exists 
reporting average doses of ~2 mg, with 0.19 and 1.2-1.35 mg (reported as 0.3% and 1.2-
1.35% of total supplement dose, respectively) having no effect, while 2.4-2.7 and 2.77 mg 
(reported as 1.2-1.35% and 0.3% of total supplement dose, respectively) show tolerability, 
appetite suppression, and increased satiety.13,18 Other studies have tested capsaicin doses 
ranging from 6.75 to 150 mg, having an almost consistent outcome of appetite suppression 
and increased satiety19-21,23, with increased lipid oxidation and glucose uptake maintenance 
being less frequent but, prevalent.21-25 
The sensation of burning pain, mentioned earlier is recognized by the Transient 
Receptor Potential Vanilloid subtype-1 (TRPV1) receptor family, which typically activate 
at temperatures ≥40°C (104°F) or in acidic conditions like a drop in pH from 7.4 to 6.3 
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(Noxious stimuli) via binding of vanilloid compounds, therefore allowing the sensation of 
warmth or burning.149,150 For example, if a room was too hot the TRPV1 receptors would 
eventually be activated, ultimately stimulating a cascade geared toward assessing the heat 
for danger and/or worsening pain, and to some degree, stimulating the central nervous 
system to activate thermoregulatory processeses.150 Capsaicin has a vanilloid-like 
structure and is therefore able to bind TRPV1 receptors, activating the sensory signal 
cascade responsible for feeling its trademark burning pain, hence why these receptors are 
also known as “capsaicin receptors”. Subsequently, it could stand to reason that capsaicin 
might cause reactions such as sweating, among other things, as a thermoregulatory 
response.151 In this regard, there is a potential explanation for hunger suppression, given 
capsaicin’s analgesic-like effect through desensitization.149 However, more research needs 
to be done in relation to mechanisms. 
While data does support many of the claims, much of the human data are not 
consistent and lack clear mechanisms of action. This may be due, in part, to inconsistent 
supplements as well as reporting, where using cayenne and red chili’s/capsicum is 
concerned. Many studies will convey “capsaicin” was administered at the milligram dose 
actually used for the supplement the capsaicin was in (e.g. cayenne or chili); or they will 
describe the amount and/or percent capsacinoid content but, will go on to report only about 
capsaicin without assigning and value to it, making consistent dose effects difficult to 
assess. See Table 3 for examples. 
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Purported Synergistic Nutrients 
Caffeine.  A well-known component of coffee, tea, and energy drinks, estimates 
suggest that ~85% of adults living in the U.S. regularly consume caffeine in some form.152 
Caffeine is a methylxanthine that stimulates, broadly, the central nervous system, muscle, 
and heart. It also increases gastric activity such as acid secretion, motility, and acts as a 
diuretic.153 It has been shown to increase thermogenesis, dose-dependently7, energy 
expenditure, and fat oxidation.9 Hence, it has been connected to weight loss, with some 
success in loss and maintenance8; possibly contributing via increased fat oxidation from 
sympathetic activation of the CNS along with increasing fluid loss.6,7 Habitual use 
however, may lead to caffeine tolerance and diminished effects.6 Caffeine has the ability 
to interact with the body and metabolism in far too many ways for the scope of this review 
so, here (Table 3) some prominent roles caffeine may play in weight loss and in 
combination with other supplements are highlighted. 
Presently, there are not many experiments showing caffeine in combination with 
the supplements discussed above, aside from theanine, capsaicin, and mixtures of multiple 
ingredients, indicating a need for this research given the popularity of some combinations 
in commercially available products. Caffeine (25-231 mg) reported in combination with 
capsaicinoids/capsaicin (0.2-4.59 mg) shows to increase thermogenesis and satiety, plus, 
reduce hunger.15,26 For healthy adults, caffeine intake up to 400-500 mg/d poses no real 
safety concerns154,155, correspondingly, 3-6 mg/kg is recommended for ergogenic effects 
in trained populations.156 Then again, sleep disturbances, nervousness, jitters and shaking, 
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with possible toxicity, may occur with intake of 15 mg/kg, leading to nausea, vomiting, 
tachycardia, seizures, and cerebral edema.153 
Piperine.  Piperine is the active component of Black Pepper, a well-known food 
ingredient and spice, having been attributed various benefits related to health and well-
being. In Ayurveda Black Pepper is believed to mostly benefit oxidative damage, 
inflammation, hypertension, and fertility.157 One well established action, in animal and 
human trials, is its ability to increase bioavailability of compounds paired with it, 
curcumin being one of the more studied of them.114 Deriving from that research, using 20 
mg/kg, is the suggested dose of 20 mg to aid in the bioavailability of a substance. The 
other influence it is most known for having is increasing gastric secretions, slowing the 
rate of gastric emptying, and intestinal transit times in mice/rats110-112, likely contributing 
to bioavailability of a substance, although not corroborated in humans. Piperine has also 
been shown to stimulate CNS activity and, in conjunction with capsaicin, shows promise 
as an analgesic through binding of the Vanilloid receptors found in both the central and 
peripheral nervous system.147,157 An important distinction is, the vast majority of 
documented effects observed and tested are in animal models and, while relevant and 
necessary, human data is currently limited (see Table 3). 
Theanine.  L-Theanine is an amino acid, non-proteinaceous, with a similar structure 
to glutamine. It is purported to have benefits in several related areas of mental processes, 
given its ability to cross the blood brain barrier and directly affect metabolism in the 
brain.158,159 Thus, given its structural similarity and ability to enter the brain it is not 
surprising that animal models have shown theanine interact with various aspects of 
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glutamate metabolism and γ-aminobutyric acid (GABA).118 Human trials (Table 3) 
reported exhibiting more “sedative” outcomes, such as; decreased stress, improved sleep, 
relaxing, and anxiolytic effects at 50, 200, 250, and 400 mg.109,116-121 In direct contrast to 
this, increases in attention and aspects of vigilance were demonstrated at 100 and 200 
mg.108,117 A 2016 systematic review attempted to reconcile some of these data, focused on 
studies using 200-400 mg of theanine, and concluded supplementation could help reduce 
acute stress and anxiety but, only to individuals experiencing the acute stressors at the time 
of ingestion, i.e. not likely to help with generalized or chronic problems.160 There has also 
been research showing the effects of caffeine partnered with theanine and capsaicin, 
separately. Caffeine with theanine has shown improvements in attention, vigilance, 
memory, and decreases in reported tiredness or exhaustion following administrations of 
40-150 mg caffeine paired with 9-250 mg theanine.105-109 
Rhodiola rosea.  Another adaptogenic herb, also used in Eastern medicine for heart 
disease as well as depression161 and anxiety131, rhodiola rosea has also been associated 
with a litany of other benefits for instance, decreased fatigue125, cognitive dysfunction162, 
antioxidant163, neuroprotective164,165, and anti-inflammatory effects.122 Although most of 
the results come from animal and cell culture models, there are a fair number of human 
studies which show anti-inflammatory122 and antidepressant130-132 effects, plus reductions 
in fatigue and stress123,128 with improvements in cognitive abilities126,127 using dosages of 
60 up to 1360 mg, Table 3 lists dosage details. In opposition, several systematic reviews 
and meta-analysis’ as recently as 2016 have gone over the available human data and 
concluded that not only is there not enough but, a lot of what exists is not reliable. For 
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several previously mentioned outcomes this conclusion was unanimous in four different 
reviews, spanning four years (2011, -12, -14, and -16), each with a different focus; e.g. 
trial design166, fatigue (physical and mental)167, heart disease168, and cognition with 
emphasis on Alzheimer’s disease169. All acknowledged the potential this herb has, based 
on animal and cell models, they also agree existing human research was not properly 
controlled or tested in most cases and often over extrapolated.  
Bacopa monnieri. Bacopa monnieri is another herbal adaptogen used in Ayurvedic 
medicine, primarily associated with affecting memory and cognition. Other health claims 
are related to improved attention, anxiety and depression as well as antioxidant, anti-
inflammatory, and antidiabetic effects.170 Evidence supports the use for aiding stress and 
anxiety relief171, in mice, and also for anti-depressant capabilities.171-174 Collectively, this 
interaction is purported in relation to the dopamine and serotonin systems. Diabetic rat 
models have observed anti-hyperglycemic175 (preventing high serum glucose) as well as 
anti-hyperlipidemic176 activity, suggesting a role in treating diabetes. Other research, in 
mice and rats, indicates potential anti-inflammatory177, antioxidant, and neuro-protective 
functionality too.178,179 
Unfortunately, studies performed with humans are less clear; having yielded mixed 
results (see Table 3). Currently human research with bacopa monnieri has the most support 
for improving memory and cognitive abilities, predominantly exhibited with a 300 mg 
dose135-140 but, has also been shown using 250 mg.134 Investigations using 300 mg have 
also proposed anxiolytic and antidepressant properties136,137,140, even improvements in 
overall attentiveness.136 A 2014 study sought to examine attention-deficit hyperactivity 
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disorder (ADHD) symptoms in an adolescent population, resulting in an overall reduction 
in such symptoms as impulsivity, restlessness, and attention with 225 mg.133 Despite some 
evidence with different amounts, 300 mg is most commonly tested and so it possesses the 
larger number of associated benefits. As such, it has taken on the role of “suggested dose” 
without regard for the lack of scientific literature establishing a recommendation. 
Conversely, bacopa monnieri has demonstrated no effect on attention, cognition, or 
anxiety at 300 or 450 mg but, still had improvements in new information retention.141,142 
Thus, the verdict is not out yet on memory and/or cognitive effects. 
Clubmoss.  Also known as Devil’s Claw, is used in Eastern medicine for its effects on 
memory, wound healing, and as an analgesic.143 Generally, the healing claims have been 
demonstrated in mice at 500mg/kg (clubmoss), resulting in anti-inflammatory effects in 
response to experimentally induced damages.143 Other research, looking at memory, 
focuses on the main active component, Huperzine-A, due to the neuroprotective properties 
exhibited in human cell cultures as a cholinesterase inhibitor.180 Mouse models have 
reported enhanced learning and memory, showing cholinesterase inhibition, suggesting 
Huperzine as a potential treatment for Alzheimer’s disease.181 The primary obstacle in the 
literature is the weak presence of human trials, wherein existing dose recommendations 
stem from a 2006 review stating 0.03-0.45 mg improved subjects’ memory and cognition. 
Conversely, a more recent (2013) meta-analysis concluded Huperzine-A (0.02-0.8 mg) 
seemingly yields some memory and cognitive benefits but, a wider dose margin was 
assessed than the 2006 review, additional studies are required with better, more clear 
methodologies/reporting. As a result, directives were given to take the results with care.182 
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Summary 
Taken all together, obesity is a growing problem worldwide that has been assessed 
by many different disciplines with mediocre success, at best, when weighed against the 
grander scheme of things. Major strides have been made towards treating this condition 
within medicine, dietetics, and exercise physiology showing great success both 
individually and concomitantly. Despite this, collectively we are far from overcoming the 
obstacle that is obesity, suggesting a need for more research and possibly further extension 
into other areas of study. One such region to consider is supplementation, herbal or 
otherwise. Ample research has come forward in recent years about some supplements 
including Ashwaganda, Bacopa monniera, Capsaicinoids, Clubmoss, Dichrostachys 
glomerata, Piperine, Rhodiola rosea, and Theanine where some were paired with another 
or even with caffeine, with promising results, Table 3 summarizes research, primarily 
human, for each of these nutrients. Exploration into this realm is still in its infancy and 
requires more support, specifically with regards to human trial data looking at individual 
and combined supplementation, in order to more definitively tease out individual or 
synergistic mechanisms and benefits. 
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CHAPTER III  
METHODS 
 
The purpose of the present study design was to assess prolonged supplementation 
responses for two novel weight loss formulas, one containing a stimulant (WL+C) and the 
other not (WL), in the absence of a secondary intervention such as exercise. Supplements 
or placebo were ingested for a 12-week period and assigned in a double-blind, parallel, 
stratified random manner, with repeated measures. The study was performed in the 
Exercise & Sport Nutrition Laboratory (ESNL) at Texas A&M University, with approval 
from Texas A&M University Institutional Review Board (IRB2016-0829FX) and signed 
informed consent from each participant. The ensuing sections review the procedures used 
and thereafter, detailed methodologies. 
Participants 
Sixty-eight apparently healthy, recreationally active men (N=31) and women 
(N=37), between ages 30 and 45 (avg 37±5 yrs), were recruited to participate in this study. 
Individuals who expressed interest via response to study email or flyer advertisements 
were asked to come in for an interview, to determine if they met initial screening eligibility 
for participation in this study. Those who met initial screening qualifications then attended 
a familiarization session where the details of the study were explained, human subject 
consent forms were signed, personal and medical history information was collected, and 
the participant had a general clinical physical exam, to determine further eligibility. 
 
 31 
 
Participant Inclusion Criteria 
Eligibility required subjects be healthy, moderately active (≤3-4 d/wk), men and 
women ranging 30-45 years of age with a Body Mass Index (BMI) between 25 and 34.9 
(Overweight to Class I Obese). Participants taking medications for hyperlipidemia, 
hypertension, glucose regulation and thyroid conditions were eligible if the medication 
had been taken for a minimum of six months prior to starting the study.  
Participant Exclusion Criteria 
Participants were ineligible if they; had a recent history of weight change (±10 lb) 
within three months prior to their start date; had uncontrolled metabolic or cardiovascular 
disorders, heart disease, hypertension, arrhythmias, diabetes, hypogonadism, hepatorenal, 
musculoskeletal, autoimmune, neurologic or thyroid disease, or known electrolyte 
abnormalities; drank excessively (≥12/wk); were currently taking medications (except 
birth control) for less than six months; consumed dietary supplements for thyroid, 
hyperlipidemia, hypoglycemia or weight loss (e.g., ephedra or thermogenic compounds, 
etc.) three months before the start of the study; currently, recently (within the past year) 
or were planning to become pregnant and/or lactating during the study; or if they had an 
intolerance to caffeine and/or other natural stimulants. Exception was given to participants 
whose primary physician believed the condition or history to be controlled and thus not a 
limiting factor to their involvement. In which case, we required their physician complete 
a Physician Clearance form (Appendix F), allowing them to return. Ineligible parties were 
kept on file, as prospects, for potential entry into similar future studies, unless they 
objected.  
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Independent and Dependent Variables 
The target variables measured as study outcomes are inclusive of; body weight 
[primary outcome]; followed by body composition (i.e. fat/fat-free mass, and fat percent) 
and anthropometric measurements (i.e. BMI and waist-to-hip ratio), blood chemistry 
measures (i.e. ALP, AST, ALT, creatinine, BUN, CK, LDH, glucose, total cholesterol, 
HDL, LDL, triglycerides, and whole blood complete blood count with platelet 
differential), hunger and satiety questionnaires, resting energy expenditure (indirect 
calorimetry), and diet characteristics [secondary outcomes]; lastly, cardiometabolic 
syndrome risk factors (i.e. body composition, blood pressure, serum glucose, Insulin, 
HOMA-IR, and lipoproteins) expressed as a summated z-score, physical activity, side 
effects, and sleep effects [tertiary outcomes]. These study outcomes serve as dependent 
variables, while the supplement interventions act as independent variables. 
Familiarization Session 
At the familiarization (FAM/T1) participants received printed and verbal 
explanations of the study design, protocols, procedures, equipment, and blood measures, 
lastly, a tour of the facility and testing areas. Informed Consent forms (Appendix D) were 
read and signed, personal/medical histories taken, and anthropometric measurements 
assessed (height, weight, BMI, blood pressure, and heart rate). Participants completed a 
General Health Screening form (Appendix E), reviewed by a registered nurse, whom if 
indicated, assessed fasting blood to rule out diabetes. Additionally, participants were 
shown and given instructions on dietary logs and activity trackers; trackers were worn 5 
consecutive days (3 week, 2 weekend; Weds-Sun/Sun-Weds) and returned at baseline.  
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Testing Protocol 
Participants were to refrain from exercise 48 hours prior to each testing session 
and be approximately 12 hours fasted. Upon arrival, on day one, activity trackers had been 
collected to calculate average step count for a five-day period and to assess if it met our 
goal activity range (5,000 to 9,999 steps/d). If so, baseline testing proceeded; if not, the 
individual discontinued the study. Participants meeting criteria were randomly assigned 
to a placebo-control group (6g dextrose, PLA) or one of two weight loss supplement 
groups (Figure 1); with caffeine (WL+C A.M. 125 mg | P.M. 150 mg) or without caffeine 
(WL), balancing for BMI, body fat percent, step count, sex, and age.  
 
 
Figure 1. Study Formulas. 
Stimulant Formula (WL+C)   Non-Stimulant Formula (WL)  
AM Dose   AM Dose 
Dietary Ingredient (mg/dose)   Dietary Ingredient (mg/dose) 
XR Caffeine (77% Caffeine) 150   Sensoril® Ashwaganda (Withania somnifera) 250 
Sensoril 125   Bioperine 5 
Caffeine Anhydrous 98.5% 100   
Capsimax® Cayenne (Capsicum annuum) fruit 
extract (4% Capsaicinoids) 
25 
Capsimax™ Capsicum Extract 4% Capsaicinoids 25   Rhodiola rosea extract 60 
Other Ingredients     Other Ingredients  
Capsule, Gelatin, Size 00, White/White 120   Capsule, Gelatin, Size 00, White/White 120 
Microcrystalline Cellulose 102 250   Microcrystalline Cellulose 102 250 
Magnesium Stearate 14   Magnesium Stearate 14 
Total Quantity 784   Total Quantity 724 
     
PM Dose   PM Dose 
Dietary Ingredient (mg/dose)   Dietary Ingredient (mg/dose) 
DygloFit™ Dichrostachys glomerata extract 300   DygloFit™ Dichrostachys glomerata extract 300 
Caffeine Anhydrous 98.5% 150   
Capsimax® Cayenne (Capsicum annuum) fruit 
extract (4% Capsaicinoids) 
25 
Capsimax™ Capsicum Extract 4% Capsaicinoids 25   L-Theanine 100 
Clubmoss Ext 1% Huperzine 10   
Toothed clubmoss (Huperzia serrata) aerial 
parts extract (1% Huperzine A) 
5 
      Bacopa monneri extract  50 
Other Ingredients     Other Ingredients   
Capsule, Gelatin, Size 00, White/White 120   Capsule, Gelatin, Size 00, White/White 120 
Microcrystalline Cellulose 102 230   Microcrystalline Cellulose 102 230 
Magnesium Stearate 15   Magnesium Stearate 15 
Total Quantity 850   Total Quantity 845 
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During baseline (T2) and subsequent sessions (T3, T4, and T5), measures of body 
weight was collected first, followed by a review of the diet log. Then we measured, 
Resting Energy Expenditure (REE), body composition (DEXA), with a radiation exposure 
questionnaire filled out prior, body water (BIA), heart rate, and blood pressure. Afterward, 
BMI was calculated, and waist and hip circumference was measured. At this point 
questionnaires were administered including; a physical activity questionnaire, eating 
satisfaction survey, sleep index, and side effects inventory. Lastly, participants donated 
blood (≈ 20 ml), using standard venipuncture techniques, from the median cubital vein in 
the antecubital fossa of the arm. The remaining sessions (T3, T4, and T5) had been 
scheduled 28-40 days apart. Each participant also needed to retrieve an activity tracker 
about one week prior to the final session and wear it for another 5 consecutive days (3 
week; 2 weekend days), returned at the final visit to calculate the final average step count. 
Figure 2 offers an overview of the study protocol and timeline. 
Supplementation Protocol 
Supplements were double-blind, having been packaged and bottled, with no 
content indicators. The bottles were plain, white, and labeled A, B, or C with an A.M. or 
P.M. designator. Participants received two bottles (A.M.; P.M.) of their respective 
supplement after each session, with a 40-day supply. Supplement consumption was twice 
a day, one capsule in the morning from the A.M. bottle and one in the afternoon from the 
P.M. bottle; suggested 7:00-9:00 a.m. and 2:00-4:00 p.m. or a minimum 5 hours, but less 
than 9 hours, between A.M. and P.M. doses. ESNL staff counted the remaining pills at 
following visits, ensuring compliance, and distributing more. 
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Figure 2. Study Protocol. Overview of the study timeline and testing procedures in the order they were performed. Week 0/Baseline (T1) and Randomization occurred 
simultaneously, followed by Week 4 (T2); Week 8 (T3); and Week 12 (T5) as the final assessment. 
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Testing Methodologies 
Food Intake 
Dietary records (Food Logs; Appendix I) were used to assess general intake prior 
to baseline and between visits, totaling four. Instruction, ongoing support, and review for 
reporting food intake was performed by a certified chef, trained in clinical dietetics. Each 
record detailed any four days, consecutive or not, of usual intake (3 week; 1 weekend) on 
non-testing days. Dietary records were input and analyzed using the Food Processor 
Nutrition Analysis Software, Version 11.3.285 (ESHA Nutrition Research, Salem, OR). 
Physical Activity 
The International Physical Activity Questionnaire (IPAQ; Appendix J) is a 
globally validated surveying tool for adults age 15-69, using set domains, over a 7-day 
period.183-185 The “short-form” iteration of the IPAQ was used, comprised of 7 questions, 
in 4 domains (leisure-, domestic-, occupational-, transportation-related), aimed at 3 
activity types (walking, moderate and vigorous intensity). Question responses provided 
frequency and duration of each activity type, which was gauged by its metabolic 
equivalents (METs), producing weekly averages (MET min) for each type. In addition, 
one question concerning time spent sitting was omitted, as per IPAQ scoring protocol.  
Body Composition 
Bone mineral density and body composition (fat mass; fat-free mass; lean mass; 
percent fat) was gathered by means of dual energy x-ray absorptiometry (DEXA; Hologic 
Inc, Waltham, MA, USA) scan, with APEX Software (APEX Corporation Software, 
Pittsburg, PA, USA), determining tissue density with low-dose x-ray radiation.186,187 
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Hence, participants completed a Radiation Consent form (Appendix G) prior to each scan. 
Quality Control (QC) calibrations were done on testing days by scanning a phantom spine 
(Discovery W-Caliber Model DPA/QDR-1). Each scan gives 1.5 mRs of whole-body 
radiation exposure over 6 minutes, totaling 6 mRs (4 scans) for 12 weeks. Our labs test-
retest reliability studies on male athletes, repeated days, show a CV range of 0.31-0.45% 
for total bone mineral content and fat-free mass with a mean intraclass correlation (ICC) 
of 0.98. Cranium data was excluded from the analysis. 
Total Body Water 
Total body water was determined with an ImpediMed SFB7 bioelectrical 
impedance analyzer (BIA; ImpediMed, San Diego, CA, USA), which uses a weak electric 
current to approximate body composition and water content based on how, and to what 
degree, conduction is affected by various tissue densities. Measurements were performed 
in a supine position, with two electrodes placed on the dorsal side of the hand and two on 
the dorsal side of the foot, lasting 10-15 seconds. BIA has shown to be a valid method of 
determining total body water.188,189 Test-retest reliability from this lab yield an SEM of 
0.75 and 0.02% of grand mean, CV range of 0.23-0.26, and an ICC range of 0.94-0.98, 
consistent with previous studies.190-192 
Anthropometry 
Body mass (kg) and height (cm) were evaluated on a Health-O-Meter Professional 
500KL (Pelstar LLC, Alsip, IL, USA) self-calibrating digital scale (±0.02 kg). Waist and hip 
circumference (cm) measures used standard measuring tape, as per ACSM’s Guidelines 
for Exercise Testing and Prescription.193 Both rounded to the nearest tenth or hundredth. 
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Resting Energy Expenditure 
Resting Energy Expenditure (REE) measures used an open-circuit method of 
indirect calorimetry with the ParvoMedics TrueMax 2400 Metabolic Measurement 
System (Parvomedics Inc, Sandy, UT). At the start of each testing session day, quality 
control (QC) procedures were performed for gas and flowmeter calibration. The gas 
analyzer was calibrated against known concentrations, and the flowmeter with the Hans 
Rudolph series 5530 three-liter syringe (Hans Rudolph Inc., Kansas City, MO) following 
standard procedures. Per manufacturer, the coefficient of variation (CV) used for 
apparently healthy individuals is ±2%. For testing, the participant remained supine for 
approximately 30 minutes, occasionally longer if measurements were not stable enough, 
with a plastic dome (hood) covering their head and plastic sheet covering the upper body, 
preventing external air entry, while their legs remained elevated on a foam box. The 
participants were asked to relax and stay awake during the procedure, and informed that a 
lab technician would check in regularly. Resting pulmonary exchange was measured, 
whereby expiration passively diffused from the hood, through tubing; to a metabolic cart 
measuring gas exchange (i.e. [VO2] O2 consumed ↔ [VCO2] CO2 expired) by comparing 
inspired and expired concentrations of O2 and CO2 from air within the hood. Data output 
every minute was utilized by averaging five consecutive time points varying the least 
(<5%) in rate of VO2 and VCO2, after the first ten minutes, for principle variables of 
interest (i.e. VO2 L/min; REE kcal/d; RQ [VCO2/VO2]).
194,195 Percent glucose and fatty 
acid utilization was calculated via nonprotein RQ equation (Appendix A).196 
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Blood Collection 
Participants donated roughly 20 mL of (8-12 hrs) fasted blood from the median 
cubital vein in the antecubital fossa of the arm, at each testing session. Whole blood was 
collected at the end of every visit, into two 7.5 mL BD Vacutainer® serum separation tubes 
and one 3.5 mL BD Vacutainer® K2 EDTA tube (Becton, Dickinson and Company, 
Franklin Lakes, New Jersey). Tubes sat at room temperature for 15-minutes, afterwards 
the 7.5 mL tubes were centrifuged, 3500 rpm for 10-minutes, in a refrigerated (4°C) bench 
top Thermo Scientific Heraeus MegaFuge 40R Centrifuge (Thermo Electron North 
America LLC, West Palm Beach, FL, USA). Tubes were kept at 4°C for 3-4 hours before 
analysis or storage. Serum was stored at -80°C, in polypropylene microcentrifuge tubes. 
Blood Chemistry 
Serum.  Samples were analyzed for the following: alkaline phosphatase (ALP), 
aspartate transaminase (AST), alanine transaminase (ALT), creatinine, blood urea 
nitrogen (BUN), creatine kinase (CK), lactate dehydrogenase (LDH), glucose, total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL; calculated), 
and triglycerides (TG) using a Cobas® c111 (Roche Diagnostics, Basel, Switzerland) 
automated clinical chemistry analyzer. Calibration of the analyzer was run daily, per 
manufacturer guidelines, and is known to be valid and reliable from previously published 
reports.197 Internal QC uses two levels of control fluids, from the manufacturer, to calibrate 
acceptable standard deviation (SD) and CV values for all assays. Samples were re-run if 
the values observed fell outside control values and/or clinical averages, according to 
standard procedures. In our lab, prior analysis has yielded a test-to-test reliability CV 
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ranging from 0.4-2.4% and 0.6–1.9% with precisions of 0.8-2.4% and 0.5–1.7% for low 
and high controls, respectively.  
Additionally, fasting insulin and leptin were measured using a commercially 
available enzyme linked immunosorbent assay kit (ELISA; ALPCO Diagnostics, Salem, 
NH). A BioTek ELX-808 Ultramicoplate reader (BioTek Instruments Inc, Winooski, VT) 
was used with an optical density of 450 nm against known standard curves, following 
standard procedures from the BioTek Gen5 Analysis software. The intra-assay CV has 
shown to range from 5.1-10.3%, and the inter-assay CV ranges from 6.7-16.6%. The 
following equation; 
(𝑔𝑙𝑢𝑐𝑜𝑠𝑒
𝑚𝑚𝑜𝑙
𝐿
)(𝑖𝑛𝑠𝑢𝑙𝑖𝑛
μIU
mL
)
22.5
 was used to calculate Homeostatic Model of 
Assessment for Insulin Resistance (HOMA-IR).198 
Whole Blood. A complete blood count (CBC) with platelet differential (hemoglobin, 
hematocrit, red blood cell counts, mean corpuscular volume [MCV], mean corpuscle 
hemoglobin [MCH], mean corpuscular hemoglobin concentration [MCHC], red blood cell 
distribution width [RDW], white blood cell counts, lymphocytes, granulocytes, and mid-
range absolute count [MID]) was measured using an Abbott Cell-Dyn 1800 (Abbott 
Laboratories, Abbott Park, IL, USA) automated hematology analyzer. The internal QC 
was performed using three levels of control fluids, from the manufacturer, to calibrate 
acceptable SD and CV values for whole blood cell parameters. Test-to-test reliability 
assessment of assays, evaluated in previous studies, have yielded mean CV’s < ±6.3% with 
r-values > 0.9. 
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Hemodynamic Assessment 
Resting heart rate and blood pressure was assessed with the participant in a supine 
position. Heart rate was determined by palpating the radial or ulnar artery, with blood 
pressure being measured thereafter. Blood pressure assessment used standard stethoscopes 
and sphygnanometers, listening to Korotkoff sounds, from the brachial artery, in the 
antecubital region of the elbow.199,200 
Psychosocial Evaluation 
A battery of questionnaires were utilized for the purpose of evaluating physical 
activity (described previously), general feelings of hunger and satiety, individual quality 
of sleep, and self-reported side effects between testing days. Instructions were provided 
on each document.  
Hunger/Satiety. The Eating Satisfaction Survey (Appendix K), developed by the ESNL 
for Curves®, used a visual analogue scale (VAS) to rate severity of diet related symptoms 
(0; none, 10; severe) such as, appetite, hunger, satisfaction from food, fullness, energy, 
and overall diet quality. This survey has been used in similarly designed studies from our 
lab along with being published and deemed as a valid tool.201 Day-to-day variability, in 
our lab, has shown an SEM of 0.07 and 0.01% of grand mean, CV range of 0.16-0.29, and 
ICC range 0.73-0.86. 
Sleep Quality. A Sleep Quality Index (SQI; Appendix L) was also administered at each 
visit, to determine the tolerability and potential sleep related symptoms of 
supplementation. The SQI is an effective device in evaluating quality and patterns of sleep; 
discerning “poor” from “good” sleep quality by inspecting sleep duration, sleep quality, 
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enthusiasm, and sleep disturbances of the past 48 hours. Furthermore, it possesses a 10-
item “yes” or “no” question addressing sleep troubles including; falling asleep within 30 
minutes, waking sporadically, frequent bathroom use, breathing complications, feeling 
cold or hot, bad dreams, pain, and any others. Day-to-day variability, in our lab, has shown 
an SEM of 0.38 and 8.2% of grand mean, CV range of 0.22-2.2, and an ICC range of -1.3-
0.92. 
Side Effects. The Weekly Follow-Up Assessment (Appendix M) documented how well 
the supplements were tolerated, or perceived, and help monitor adherence to the protocol. 
Assessment was administered at baseline (T2) and weeks 4 (T3), 8 (T4), and 12 (T5); 
collecting reported symptoms of dizziness, headache, tachycardia, heart skipping or 
palpitations, shortness of breath, nervousness, blurred vision, and any other adverse 
effects. Participants were asked to rate the frequency and severity of their symptoms, 
respectively, using 0 (none), 1 (minimal 1-2/wk), 2 (slight 3-4/wk), 3 (occasional 5-6/wk; 
moderate), 4 (frequent 7-8/wk; severe), or 5 (severe ≥ 9/wk; very severe). 
Statistical Analysis 
All statistical analysis were performed with IBM SPSS® 25.0 (IBM Statistics, 
Chicago, IL; IBM Corp., Armonk, NY, USA). Data analysis used general linear models 
(GLM), with repeated measures, multivariate analysis of variance (MANOVA). The 
sample size was determined based on the expectation of a 5% improvement in weight loss 
with corresponding power of 0.80. Baseline demographic data analysis used one-way 
analysis of variance (ANOVA). Delta (∆) change values were calculated and used to 
determine changes from baseline. Overall multivariate effects are expressed through 
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Wilks’ Lambda distributions. Greenhouse-Geisser univariate tests of within-subjects; time 
(T), group x time (GxT), sex x time (SxT), and group x sex x time (GxSxT) effects and 
between-subjects; group (G), sex (S), and group x sex (GxS) effects are reported for each 
variable analyzed, to control for sphericity. For hematologic assessment, blood chemistry 
measurements were weighed relative to normal clinical limits, where the frequency in 
which a variable deviated outside of normal clinical limits, from baseline to 12 weeks, 
using a Chi-square analysis for each group as follows: (1) normal at baseline and week 12, 
(2) normal at baseline, high at week 12, (3) high at baseline, normal at week 12, (4) high 
at baseline and week 12. Data was considered statistically significant when the probability 
of type I error (α-level) is ≤0.05 with trends noted when the probability of error (p-level) 
range is 0.05-0.10 (0.05< p <0.10). If a significant treatment and/or interaction α-level was 
observed, Fisher’s least significant difference post-hoc analysis was performed to 
determine where significance was obtained. When a non-significant treatment and/or 
interaction α-level was observed, analyses of mean change from baseline with 95% CI and 
Sidak adjustment, was performed. Partial Eta squared effect sizes (η𝑝
2) are reported as an 
indicator of effect size. Mean changes with 95% CI’s completely above or below baseline 
were considered significantly different.202 Missing data was extrapolated from the average 
of one time point immediately before and after; for week 12 (T5), the last observed value 
was carried forward (LOCF). Data is presented as mean ± SD and mean change ± 95% CI 
as appropriate. Data in figures include ∆-change from baseline and/or mean ± SD. 
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CHAPTER IV  
RESULTS 
 
Study Participants 
Ninety-two participants were initially recruited for this study, wherein they 
completed a familiarization session and signed a consent form. Of the original 92 
participants, 11 of them dropped, or were dropped, from the study prior to baseline, 
because 2 participants did not meet the activity criteria (average steps per day), 2 
participants had scheduling conflicts, 1 participant had a family complication arise, and 6 
participants gave no reason and/or were unable to be contacted. The remaining 81 
individuals, 33 men (M) and 48 women (F), completed a baseline session and were then 
randomized into groups, allocating 27 (M 11; F 16) to the placebo (PLA), 24 (M 10; F 14) 
to the weight loss supplement (WL), and 30 (M 12; F 18) to the weight loss supplement 
with caffeine (WL+C) groups. Of these 81, 13 participants dropped, or were dropped, 
throughout the course of the study; 5 were due to reported side effects, 4 did not follow 
the supplementation protocol, 2 had scheduling conflicts, and 2 were unable to be 
contacted. Sixty-eight men (N=31) and women (N=37) completed the 12-week 
intervention, with group totals of; 22 (M 10; F 12) participants in PLA, 23 (M 10; F 13) 
participants in WL, and 23 (M 11; F 12) participants in WL+C. Figure 3 represents a 
Consolidated Standards of Reporting Trials (CONSORT) diagram for study participants. 
This investigation was performed in accordance with the Declaration of Helsinki and 
approved by the Texas A&M University Institutional Review Board (#2016-0829FX). 
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Figure 3. CONSORT Diagram.  
 
Baseline Characteristics 
Univariate analysis revealed no significant differences between groups for age 
(37±5 yrs), height (170.5±11.3 cm), weight (88.9±16.6 kg), BMI (30.4±3.3 kg/m2), body 
fat (35.2±7.7%), or activity (6,857±1,512 steps/wk). Pairwise analysis showed significant 
interaction effects of sex (p<0.001) with males being taller (M 179.8±9.5; F 162.7±4.9 
cm) and weighing more (M 98.9±16.4; F 80.4±11.3 kg) overall, but females had greater 
body fat (M 28.3±4.9; F 40.9±3.9%), for all groups. Initial body fat ranged 18.6-47.4% 
(same in PLA), 22.3-46.6% in WL+C, and 21.6-46% in WL. Lastly, were generally more 
active (M 7,739±1,521; F 6,087±768 steps/wk) than females, in PLA. Yet, females in WL 
were more active than in other groups (WL 6,303±1,375; PLA 6,087±768; WL+C 
7,595±1,707 steps/wk). Table 4 presents participant baseline characteristics. 
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Table 4: Baseline Characteristics 
 
Energy Utilization and Body Measurements 
Energy and Macronutrient Intake 
Repeated measures MANOVA analyses revealed overall Wilks' Lambda Sex 
(p<0.01) and Time (p=0.09) effects, with no significant Group (p=0.22), Group x Time 
(p=0.13), Sex x Time (p=0.27), Group x Sex (p=0.47), or Group x Time x Sex (p=0.64) 
effects for the energy and macronutrient variables, calories (kcal/d), protein (g/d), 
carbohydrate (g/d), and total fat (g/d). Greenhouse-Geisser univariate analysis showed 
significant effects of sex (p<0.01) for all measures; of time (p<0.05) for calories and 
protein; also of group x sex (p<0.05) for fat. Conversely, no group x time, sex x time, or 
group x time x sex effects were seen among intake variables. Pairwise analysis showed 
supplement groups (WL+C and WL) did not significantly differ from each other but, were 
consistently lower than PLA at all time points and measures of intake. Protein intake was 
  Group 
 
Overall      
Variable   PLA   WL   WL+C   Mean   Effect p-Level 𝛈𝒑
𝟐 
Age  37 ± 5 
 
37 ± 5 
 
37 ± 4 
 
37 ± 5 
 
Group 0.93 0.002 
(years) F 38 ± 5 
 
36 ± 5 
 
36 ± 4 
 
36 ± 5 
 
Sex 0.24 0.02 
 M 37 ± 4   38 ± 6   39 ± 4   38 ± 5   G x S 0.28 0.04 
Weight  90.52 ± 17.55 
 
88.58 ± 14.99 
 
87.54 ± 17.72 
 
88.86 ± 16.58 
 
Group 0.70 0.01 
(kg) F 80.23 ± 12.70 ⚥ 82.22 ± 12.34 ⚥ 78.61 ± 8.97 ⚥ 80.40 ± 11.26 ⚥ Sex <0.001 0.32 
 M 102.87 ± 14.53 ⚥ 96.84 ± 14.56 ⚥ 97.29 ± 20.06 ⚥ 98.95 ± 16.39 ⚥ G x S 0.64 0.01 
Height  171.51 ± 13.71 
 
170.95 ± 10.48 
 
169.16 ± 9.65 
 
170.53 ± 11.25  Group 0.33 0.04 
(cm) F 161.58 ± 4.25 ⚥ 164.02 ± 6.41 ⚥ 162.53 ± 3.58 ⚥ 162.74 ± 4.91 ⚥ Sex <0.001 0.60 
 M 183.43 ± 11.27 ᶜ⚥ 179.97 ± 7.34 ⚥ 176.40 ± 8.97 ᵃ⚥ 179.82 ± 9.47 ⚥ G x S 0.17 0.05 
BMI  30.64 ± 3.41 
 
30.17 ± 3.32 
 
30.51 ± 3.23 
 
30.44 ± 3.27  Group 0.86 0.005 
(kg/m2) F 30.67 ± 3.86 
 
30.49 ± 3.39 
 
29.73 ± 2.60 
 
30.30 ± 3.26  Sex 0.74 0.002 
 M 30.59 ± 3.00   29.74 ± 3.35   31.37 ± 3.74   30.59 ± 3.34   G x S 0.47 0.02 
Body Fat  35.49 ± 8.16 
 
34.69 ± 7.64 
 
35.38 ± 7.71 
 
35.18 ± 7.72  Group 0.58 0.02 
(%) F 41.53 ± 4.15 ⚥ 40.46 ± 3.70 ⚥ 41.00 ± 4.03 ⚥ 40.98 ± 3.87 ⚥ Sex <0.001 0.69 
 M 28.24 ± 5.23 ⚥ 27.18 ± 3.69 ⚥ 29.25 ± 5.78 ⚥ 28.25 ± 4.92 ⚥ G x S 0.80 0.007 
Activity  6,838 ± 1,417 
 
7,198 ± 1,548 
 
6,534 ± 1,554 
 
6,857 ± 1,512  Group 0.37 0.03 
(Steps/wk) F 6,087 ± 768 ᵇ⚥ 7,595 ± 1,707 ᵃᶜ 6,303 ± 1,375 ᵇ 6,687 ± 1,482  Sex 0.25 0.02 
  M 7,739 ± 1,521 ⚥ 6,683 ± 1,204   6,785 ± 1,760   7,060 ± 1,546   G x S 0.02 0.13 
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.97), Sex (p<0.01), and Group x Sex (p=0.15) effects for baseline demographic variables. 
Univariate p-levels are listed for Group (G), Sex (S), and Group x Sex (G x S) interaction effects. Pairwise comparison is indicated by the following superscripts: ⚥ = p<0.05 
difference between Sexes; a = p<0.05 difference from PLA; b = p<0.05 difference from WL; c = p<0.05 difference from WL+C.  
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significantly lower than PLA in WL at week 8 (PLA 82.6±29.7; WL 69.2±26.3 g/d) and 
in both supplement groups at week 12 (PLA 82.1±30.2; WL 67.3±23.7; WL+C 69.0±22.6 
g/d). Furthermore, carbohydrate intake significantly decreased in PLA from baseline to 
week 12 (PLA 206.6±93.0; PLA 171.9±80.9 g/d), as did fat intake in WL (WL 67.7±27.9; 
WL 52.8±19.4 g/d). In addition, males overall had greater intake of calories (F 1,488±73; 
M 2,018±80 kcal/d), protein (F 63.8±2.9; M 91.9±3.2 g/d), carbohydrates (F 161.8±8.9; 
M 206.1±9.7 g/d), and fat (F 58.1±3.4; M 77.2±3.7 g/d). Table 5 presents energy and 
macronutrient intake within each group. These data fail to reject H05: Diet characteristics 
in treatment groups will not significantly differ from baseline and/or placebo. 
Physical Activity 
Overall Wilks' Lambda revealed no significant Group (p=0.34), Time (p=0.84), 
Group x Time (p=0.98), Sex (p=0.29), Sex x Time (p=0.97), Group x Sex (p=0.70), or 
Group x Time x Sex (p=0.92) effects on physical activity variables, walking, moderate, 
vigorous, and total activity (MET/min). Univariate analysis indicated no interaction 
effects among physical activity variables as well. Pairwise analysis showed no significant 
differences among treatments. Pairwise analysis of truncated IPAQ data indicated a drop 
in baseline reported walking for WL by week 4 (WL 1,775±1,412; WL 1,225±1,286 MET 
min) and an increase by week 12 for females of WL+C (WL+C 1,247±1,323; WL+C 
2,278±1,806 MET/min). Otherwise, results were similar to analysis of non-truncated data. 
Tables 6-6.1 present the International Physical Activity Questionnaire (IPAQ) and 
truncated results, respectively, within each group.  
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Table 5: Energy and Macronutrient Intake 
      Weeks      Mean     
 Group  0  4  8  12  (SEM)  Effect p-Level 𝛈𝒑
𝟐 
Calories PLA  2,047 ± 706 ᶜ 1,846 ± 587 † 1,843 ± 623 
 
1,835 ± 749 ᶜ 1,927 ± 95 ᶜ Group 0.07 0.08 
(Kcals/d) WL  1,748 ± 568 
 
1,676 ± 545 
 
1,640 ± 615 
 
1,573 ± 467 
 
1,702 ± 93 
 
Time 0.02 0.05 
 WL+C  1,674 ± 561 ᵃ 1,665 ± 578 
 
1,631 ± 518 
 
1,534 ± 534 ᵃ 1,630 ± 92 ᵃ G x T 0.74 0.02  
Time    1,820 ± 626   1,728 ± 568   1,703 ± 586   1,645 ± 599 †                
F  1,615 ± 438 ⚥ 1,521 ± 414 ⚥ 1,421 ± 327 †⚥ 1,384 ± 398 †⚥ 1,488 ± 73 ⚥ Sex <0.001 0.28  
M   2,064 ± 729 ⚥ 1,974 ± 631 ⚥ 2,039 ± 650 ⚥ 1,955 ± 654 ⚥ 2,018 ± 80 ⚥ S x T 0.31 0.02  
PLA F 1,666 ± 353 ⚥ 1,610 ± 230 ⚥ 1,518 ± 221 ⚥ 1,420 ± 292 ⚥ 1,553 ± 128 ⚥ G x S 0.09 0.08  
 M 2,505 ± 765 ᶜ⚥ 2,130 ± 759 †⚥ 2,234 ± 731 ⚥ 2,334 ± 835 ᶜ⚥ 2,301 ± 140 ᶜ⚥ G x T x S 0.30 0.04  
WL F 1,514 ± 383 ⚥ 1,376 ± 412 ⚥ 1,298 ± 343 ⚥ 1,316 ± 337 ⚥ 1,376 ± 123 ⚥     
 M 2,054 ± 641 ⚥ 2,067 ± 448 ⚥ 2,084 ± 615 ⚥ 1,906 ± 403 ⚥ 2,028 ± 140 ⚥     
WL+C F 1,674 ± 569 
 
1,588 ± 532 
 
1,457 ± 379 
 
1,422 ± 549 
 
1,535 ± 128 
 
   
 
  M 1,674 ± 579 ᵃ 1,749 ± 638   1,821 ± 597   1,656 ± 513 ᵃ 1,725 ± 133 ᵃ       
Protein PLA  89.5 ± 31.2 
 
81.8 ± 26.4 
 
82.6 ± 29.7 ᵇ 82.1 ± 30.2 ᵇᶜ 85.8 ± 3.8 ᵇ Group 0.04 0.10 
(g/d) WL  78.2 ± 34.0 
 
70.2 ± 27.2 
 
69.2 ± 26.3 ᵃ 67.3 ± 23.7 ᵃ 73.3 ± 3.8 ᵃ Time 0.01 0.06  
WL+C  79.6 ± 29.4 
 
72.8 ± 23.6 
 
75.2 ± 22.1 
 
69.0 ± 22.6 ᵃ 74.4 ± 3.7 
 
G x T 0.97 0.01  
Time    82.3 ± 31.6   74.9 ± 25.8 † 75.6 ± 26.4 † 72.7 ± 26.1 †                
F  69.4 ± 22.0 ⚥ 63.8 ± 17.7 ⚥ 62.8 ± 17.9 ⚥ 58.6 ± 17.2 †⚥ 63.8 ± 2.9 ⚥ Sex <0.001 0.40  
M   97.8 ± 34.4 ⚥ 88.1 ± 28.0 †⚥ 90.8 ± 26.9 ⚥ 89.5 ± 25.1 ⚥ 91.9 ± 3.2 ⚥ S x T 0.69 0.01  
PLA F 66.8 ± 15.1 ⚥ 69.5 ± 14.1 ⚥ 64.3 ± 8.5 ⚥ 64.1 ± 18.5 ⚥ 66.2 ± 5.2 ⚥ G x S 0.05 0.09  
 M 116.9 ± 21.9 ᶜ ⚥ 96.6 ± 30.6 †⚥ 104.5 ± 31.6 ᶜ⚥ 103.8 ± 27.3 ᶜ⚥ 105.4 ± 5.7 ᵇᶜ⚥ G x T x S 0.49 0.03  
WL F 66.3 ± 23.4 ⚥ 55.7 ± 15.6 ⚥ 55.5 ± 20.6 ⚥ 52.5 ± 13.1 ⚥ 57.5 ± 5.0 ⚥     
 M 93.6 ± 40.3 ⚥ 89.1 ± 28.0 ⚥ 87.1 ± 22.5 ⚥ 86.7 ± 20.3 ⚥ 89.1 ± 5.7 ᵃ⚥     
WL+C F 75.2 ± 26.6 
 
66.8 ± 20.9 
 
69.1 ± 20.3 
 
59.9 ± 19.0 ⚥ 67.7 ± 5.2 
 
   
 
  M 84.3 ± 32.8 ᵃ  79.5 ± 25.5   81.9 ± 23.0 ᵃ 79.0 ± 22.7 ᵃ⚥ 81.1 ± 5.4 ᵃ       
Carbohydrate PLA  206.6 ± 93.0 
 
188.1 ± 66.3 
 
185.6 ± 57.6 
 
171.9 ± 80.9 † 190.7 ± 11.5 
 
Group 0.28 0.04 
(g/d) WL  204.2 ± 77.6 
 
185.1 ± 68.7 
 
176.5 ± 70.5 
 
188.3 ± 62.4 
 
192.0 ± 11.3 
 
Time 0.06 0.04  
WL+C  171.9 ± 64.2 
 
172.1 ± 68.9 
 
171.9 ± 64.9 
 
158.7 ± 60.0 
 
169.2 ± 11.2 
 
G x T 0.65 0.02  
Time    194.1 ± 79.4   181.7 ± 67.3   177.9 ± 64.0   173.0 ± 68.3 †                
F  176.1 ± 69.5 ⚥ 166.3 ± 55.7 ⚥ 153.7 ± 51.6 ⚥ 151.5 ± 59.0 †⚥ 161.8 ± 8.9 ⚥ Sex <0.01 0.16  
M   215.5 ± 86.0 ⚥ 200.1 ± 75.9 ⚥ 206.8 ± 66.0 ⚥ 198.7 ± 70.6 ⚥ 206.1 ± 9.7 ⚥ S x T 0.63 0.01  
PLA F 179.4 ± 78.2 
 
171.1 ± 35.3 
 
166.9 ± 38.3 
 
128.5 ± 44.7 †‡⚥ 161.5 ± 15.5 ⚥ G x S 0.48 0.02  
 M 239.1 ± 103 ᶜ 208.6 ± 88.7 
 
208.0 ± 70.2 
 
224.1 ± 85.3 ᶜ⚥ 219.9 ± 17.0 ⚥ G x T x S 0.14 0.05  
WL F 176.2 ± 69.7 ⚥ 166.9 ± 68.7 
 
147.0 ± 53.9 ⚥ 172.9 ± 56.1 
 
165.7 ± 14.9 ⚥     
 M 240.7 ± 75.1 ᶜ ⚥ 208.8 ± 64.3 
 
214.8 ± 73.5 ⚥ 208.5 ± 67.2 
 
218.2 ± 17.0 ⚥     
WL+C F 172.7 ± 66.1 
 
160.7 ± 60.7 
 
147.6 ± 61.4 ⚥ 151.5 ± 69.6 
 
158.1 ± 15.5 
 
   
 
  M 171.1 ± 65.4 ᵃ ᵇ 184.5 ± 77.8   198.5 ± 60.3 ⚥ 166.6 ± 49.5 ᵃ 180.2 ± 16.2         
Total Fat PLA  75.6 ± 32.7 
 
73.1 ± 27.0 
 
74.9 ± 33.8 ᶜ 76.9 ± 33.1 ᵇᶜ 76.5 ± 4.4 ᵇ Group 0.06 0.09 
(g/d) WL  67.7 ± 27.9 
 
62.6 ± 25.9 
 
62.1 ± 25.0 
 
52.8 ± 19.4 ᵃ†‡ 63.0 ± 4.4 ᵃ Time 0.11 0.03 
 WL+C  68.1 ± 29.0 
 
64.1 ± 26.9 
 
61.1 ± 22.0 ᵃ 60.3 ± 25.9 ᵃ 63.4 ± 4.3 
 
G x T 0.35 0.04  
Time    70.4 ± 29.7   66.5 ± 26.6   65.9 ± 27.6   63.2 ± 28.1 †                
F  60.9 ± 22.7 ⚥ 60.3 ± 21.2 ⚥ 54.8 ± 12.9 ⚥ 55.4 ± 21.7 ⚥ 58.1 ± 3.4 ⚥ Sex <0.001 0.19  
M   81.7 ± 33.2 ⚥ 73.9 ± 30.6 ⚥ 79.1 ± 34.1 ⚥ 72.4 ± 32.1 ⚥ 77.2 ± 3.7 ⚥ S x T 0.28 0.02 
 PLA F 58.6 ± 11.7 
⚥ 63.9 ± 13.6 ⚥ 59.9 ± 11.1 ⚥ 63.3 ± 19.6 ⚥ 61.4 ± 6.0 ⚥ G x S 0.04 0.10 
 
 M 95.9 ± 38.5 ᶜ ⚥ 84.2 ± 35.0 ᶜ 92.9 ± 43.0 ᶜ⚥ 93.3 ± 39.2 ᵇᶜ⚥ 91.6 ± 6.6 ᶜ⚥ G x T x S 0.84 0.01 
 WL F 56.0 ± 16.3 
⚥ 51.8 ± 19.5 ⚥ 47.1 ± 12.4 ⚥ 44.6 ± 14.1 
 
49.9 ± 5.8 ⚥    
 
 M 83.0 ± 33.1 ⚥ 76.7 ± 27.2 ⚥ 81.6 ± 24.0 ⚥ 63.6 ± 20.6 ᵃ†‡ 76.2 ± 6.6 ⚥    
 WL+C F 68.4 ± 34.1 
 
65.8 ± 27.2 
 
58.0 ± 12.1 
 
59.3 ± 26.8 
 
49.9 ± 6.0 
 
   
  M 67.7 ± 23.9 ᵃ  62.1 ± 27.7 ᵃ 64.4 ± 29.6 ᵃ 61.5 ± 26.2 ᵃ 63.9 ± 6.3 ᵃ    
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.22), Time (p=0.09), Group x Time (p=0.13), Sex (p<0.01), Sex x Time (p=0.27), and 
Group x Sex (p=0.47), Group x Time x Sex (p=0.64) effects for energy and macronutrient variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), 
Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; 
b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group 
means only (excluding Time and Sex data), on the above table. 
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Table 6: International Physical Activity Questionnaire (IPAQ) Results 
      Weeks      Mean     
 Group   0    4    8   12  (SEM)  Effect p-Level 𝛈𝒑
𝟐 
Walking PLA  925 ± 1,158 ᵇ 1,527 ± 2,506 
 
1,145 ± 1,619 
 
1,392 ± 1,473 
 
1,217 ± 416 
 
Group 0.40 0.03 
MET Minutes WL  2,498 ± 3,011 ᵃ 1,810 ± 3,139 
 
1,679 ± 2,594 
 
2,075 ± 3,310 
 
1,965 ± 409 
 
Time 0.86 0.003 
 WL+C  1,586 ± 2,333 
 
1,837 ± 2,675 
 
1,971 ± 3,080 
 
2,024 ± 2,203 
 
1,834 ± 405 
 
G x T 0.69 0.02  
Time    1,681 ± 2,368   1,727 ± 2,752   1,605 ± 2,502   1,837 ± 2,443                  
F  1,929 ± 2946 
 
2,007 ± 3420 
 
2,132 ± 3188 
 
2,241 ± 2897 
 
2,069 ± 320 
 
Sex 0.10 0.04  
M   1,384 ± 1392   1,394 ± 1634   976 ± 1020   1,354 ± 1677   1,274 ± 349   S x T 0.73 0.01  
PLA F 1,001 ± 1399 ᵇ 2,096 ± 3267 
 
1,543 ± 2107 
 
1,558 ± 1609 
 
1,549 ± 561 
 
G x S 0.97 <0.001  
 M 833 ± 847 
 
845 ± 815 
 
668 ± 478 
 
1,193 ± 1348 
 
885 ± 614 
 
G x T x S 0.81 0.01  
WL F 2,881 ± 3708 ᵃ 1,929 ± 3806 
 
2,274 ± 3293 
 
2,335 ± 3925 
 
2,355 ± 539 
 
   
 
 M 2,000 ± 1830 
 
1,655 ± 2174 
 
904 ± 899 
 
1,737 ± 2454 
 
1,574 ± 614 
 
   
 
WL+C F 1,825 ± 3069 
 
2,002 ± 3433 
 
2,566 ± 4048 
 
2,823 ± 2682 
 
2,304 ± 561 
 
   
 
  M 1,326 ± 1213   1,656 ± 1646   1,322 ± 1398   1,152 ± 1079   1,364 ± 586         
Moderate PLA  365 ± 304 
 
529 ± 578 
 
755 ± 1,139 
 
435 ± 502 
 
531 ± 205 
 
Group 0.34 0.03 
MET Minutes WL  835 ± 1,116 
 
1,059 ± 1,539 
 
903 ± 1,092 
 
1,024 ± 1,939 
 
956 ± 202 
 
Time 0.54 0.01  
WL+C  567 ± 1,040 
 
955 ± 2,455 
 
710 ± 1,888 
 
638 ± 761 
 
719 ± 200 
 
G x T 0.92 0.01  
Time    592 ± 912   852 ± 1,707   789 ± 1,405   703 ± 1,251                  
F  607 ± 1053 
 
872 ± 2156 
 
677 ± 1157 
 
593 ± 1417 
 
680 ± 158 
 
Sex 0.64 0.004  
M   574 ± 725   829 ± 962   924 ± 1664   834 ± 1026   791 ± 172   S x T 0.75 0.01  
PLA F 290 ± 292 
 
285 ± 291 
 
690 ± 1347 
 
396 ± 575 
 
415 ± 277 
 
G x S 0.93 0.002  
 M 454 ± 310 
 
822 ± 708 
 
832 ± 893 
 
482 ± 424 
 
648 ± 303 
 
G x T x S 0.43 0.03  
WL F 817 ± 1183 
 
1,089 ± 1775 
 
1,025 ± 1401 
 
871 ± 2273 
 
950 ± 266 
 
   
 
 M 858 ± 1086 
 
1,020 ± 1259 
 
744 ± 499 
 
1,224 ± 1491 
 
962 ± 303 
 
   
 
WL+C F 697 ± 1358 
 
1,223 ± 3336 
 
287 ± 347 
 
490 ± 674 
 
674 ± 277 
 
   
 
  M 425 ± 559   662 ± 912   1,171 ± 2694   800 ± 849   765 ± 289         
Vigorous PLA  829 ± 726 
 
803 ± 851 
 
658 ± 856 
 
596 ± 770 
 
737 ± 159 
 
Group 0.20 0.05 
MET Minutes WL  1,205 ± 1,151 ᶜ 1,024 ± 1,089 
 
1,236 ± 1,357 
 
1,023 ± 1,266 
 
1,128 ± 157 ᶜ Time 0.53 0.01  
WL+C  557 ± 710 ᵇ 630 ± 851 
 
965 ± 1,645 
 
579 ± 1,112 
 
673 ± 155 ᵇ G x T 0.79 0.01  
Time    864 ± 916   819 ± 938   957 ± 1,334   735 ± 1,078                  
F  899 ± 980 
 
766 ± 968 
 
999 ± 1492 
 
749 ± 1196 
 
847 ± 122 
 
Sex 0.99 <0.001  
M   822 ± 848   883 ± 914   907 ± 1138   717 ± 937   845 ± 134   S x T 0.87 0.003  
PLA F 733 ± 613 
 
642 ± 735 
 
487 ± 647 
 
410 ± 664 
 
568 ± 215 
 
G x S 0.20 0.05  
 M 944 ± 863 
 
996 ± 977 
 
864 ± 1055 
 
820 ± 863 
 
906 ± 235 
 
G x T x S 0.95 0.01  
WL F 1,200 ± 1311 
 
911 ± 1128 
 
1,152 ± 1526 
 
1,052 ± 1363 
 
1,079 ± 206 
 
   
 
 M 1,212 ± 974 ᶜ 1,172 ± 1076 
 
1,344 ± 1171 
 
984 ± 1200 
 
1,178 ± 235 ᶜ     
WL+C F 740 ± 853 
 
733 ± 1046 
 
1,347 ± 1971 
 
760 ± 1406 ‡ 895 ± 215 
 
   
 
  M 356 ± 475 ᵇ 516 ± 601   549 ± 1146   382 ± 681   451 ± 224 ᵇ       
Total PLA  2,118 ± 1,341 ᵇ 2,859 ± 2,541 
 
2,558 ± 2,535 
 
2,423 ± 1,661 
 
2,485 ± 558 ᵇ Group 0.14 0.06 
MET Minutes WL  4,538 ± 3,663 ᵃᶜ 3,893 ± 4,367 
 
3,817 ± 3,560 
 
4,122 ± 4,498 
 
4,049 ± 548 ᵃ Time 0.92 0.002 
 WL+C  2,710 ± 2,904 ᵇ 3,421 ± 3,607 
 
3,645 ± 4,775 
 
3,241 ± 2,629 
 
3,226 ± 544 
 
G x T 0.75 0.02  
Time    3,137 ± 2,969   3,399 ± 3,569   3,352 ± 3,738   3,275 ± 3,204                  
F  3,435 ± 3606 
 
3,645 ± 4250 
 
3,808 ± 4138 
 
3,584 ± 3478 
 
3,597 ± 428 
 
Sex 0.28 0.02  
M   2,781 ± 1960   3,106 ± 2570   2,807 ± 3177   2,906 ± 2855   2,910 ± 468   S x T 0.94 0.002  
PLA F 2,024 ± 1557 ᵇ 3,022 ± 3132 
 
2,719 ± 3195 
 
2,364 ± 1910 
 
2,532 ± 752 
 
G x S 0.74 0.01  
 M 2,231 ± 1098 
 
2,663 ± 1729 
 
2,364 ± 1564 
 
2,495 ± 1403 
 
2,438 ± 824 
 
G x T x S 0.97 0.01  
WL F 4,898 ± 4473 ᵃ 3,929 ± 5046 
 
4,451 ± 4459 
 
4,258 ± 4792 
 
4,384 ± 722 
 
   
 
 M 4,070 ± 2385 
 
3,847 ± 3559 
 
2,992 ± 1769 
 
3,945 ± 4333 
 
3,714 ± 824 
 
   
 
WL+C F 3,261 ± 3684 
 
3,959 ± 4573 
 
4,199 ± 4711 
 
4,073 ± 2908 
 
4,384 ± 752 
 
   
 
  M 2,108 ± 1692   2,834 ± 2212   3,042 ± 4997   2,334 ± 2043   2,579 ± 785      
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.34), Time (p=0.84), Group x Time (p=0.98), Sex (p=0.29), Sex x Time (p=0.97), and 
Group x Sex (p=0.70), Group x Time x Sex (p=0.92) effects for physical activity variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), Sex (S), 
Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following superscripts: 
† = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; b = p<0.05 
difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group means only 
(excluding Time and Sex data), on the above table. 
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Table 6.1: International Physical Activity Questionnaire (IPAQ) Results (Truncated) 
      Weeks      Mean 
     
  Group     0       4       8     12   (SEM)   Effect p-Level 𝛈𝒑
𝟐 
Walking PLA  893 ± 1,050 ᵇ 1,086 ± 1,166 
 
997 ± 1,206 
 
1,284 ± 1,291 
 
1,045 ± 215 
 
Group 0.36 0.03 
MET Minutes WL  1,775 ± 1,412 ᵃ 1,225 ± 1,286 † 1,257 ± 1,350 
 
1,352 ± 1,360 
 
1,394 ± 211 
 
Time 0.44 0.01 
 WL+C  1,285 ± 1,243 
 
1,372 ± 1,184 
 
1,398 ± 1,369 
 
1,740 ± 1,578 
 
1,442 ± 210 
 
G x T 0.37 0.03  
Time    1,324 ± 1,280   1,229 ± 1,201   1,221 ± 1,303   1,461 ± 1,410                  
F  1,348 ± 1443 
 
1,231 ± 1252 
 
1,444 ± 1522 
 
1,728 ± 1629 
 
1,437 ± 165 
 
Sex 0.10 0.04  
M   1,295 ± 1078   1,228 ± 1158   954 ± 936   1,143 ± 1031   1,150 ± 181   S x T 0.19 0.03  
PLA F 943 ± 1230 
 
1,287 ± 1399 
 
1,271 ± 1553 
 
1,558 ± 1609 
 
1,265 ± 290 
 
G x S 0.87 0.004  
 M 833 ± 847 
 
845 ± 815 
 
668 ± 478 
 
955 ± 709 
 
825 ± 318 
 
G x T x S 0.57 0.02  
WL F 1,815 ± 1686 
 
1,107 ± 1145 † 1,528 ± 1597 
 
1,376 ± 1461 
 
1,456 ± 279 
 
   
 
 M 1,723 ± 1039 
 
1,378 ± 1499 
 
904 ± 899 
 
1,322 ± 1293 
 
1,332 ± 318 
 
   
 
WL+C F 1,247 ± 1323 
 
1,309 ± 1310 
 
1,526 ± 1530 
 
2,278 ± 1806 †‡ 1,590 ± 290 
 
   
 
  M 1,326 ± 1213   1,440 ± 1090   1,259 ± 1228   1,152 ± 1079   1,294 ± 303         
Moderate PLA  365 ± 304 
 
529 ± 578 
 
667 ± 880 
 
435 ± 502 
 
510 ± 154 
 
Group 0.22 0.05 
MET Minutes WL  772 ± 987 
 
976 ± 1,277 
 
903 ± 1,092 
 
795 ± 1,214 
 
862 ± 151 
 
Time 0.41 0.01  
WL+C  483 ± 710 
 
631 ± 1,125 
 
527 ± 1,036 
 
638 ± 761 
 
573 ± 150 
 
G x T 0.91 0.01  
Time    543 ± 738   715 ± 1,045   699 ± 1,006   625 ± 880                  
F  555 ± 872 
 
645 ± 1149 
 
644 ± 1051 
 
502 ± 925 
 
579 ± 118 
 
Sex 0.43 0.01  
M   528 ± 550   798 ± 918   765 ± 963   772 ± 815   718 ± 129   S x T 0.64 0.01  
PLA F 290 ± 292 
 
285 ± 291 
 
590 ± 1019 
 
396 ± 575 
 
390 ± 208 
 
G x S 0.87 0.004  
 M 454 ± 310 
 
822 ± 708 
 
760 ± 722 
 
482 ± 424 
 
630 ± 227 
 
G x T x S 0.40 0.03  
WL F 817 ± 1183 
 
960 ± 1339 
 
1,025 ± 1401 
 
612 ± 1349 
 
853 ± 199 
 
   
 
 M 714 ± 714 
 
996 ± 1262 
 
744 ± 499 
 
1,032 ± 1032 
 
872 ± 227 
 
   
 
WL+C F 537 ± 847 
 
663 ± 1421 
 
287 ± 347 
 
490 ± 674 
 
494 ± 208 
 
   
 
  M 425 ± 559   596 ± 748   789 ± 1444   800 ± 849   653 ± 217         
Vigorous PLA  829 ± 726 
 
803 ± 851 
 
658 ± 856 
 
596 ± 770 
 
737 ± 158 
 
Group 0.11 0.07 
MET Minutes WL  1,163 ± 1,066 ᶜ 1,024 ± 1,089 
 
1,173 ± 1,236 
 
1,023 ± 1,266 
 
1,105 ± 155 
 
Time 0.57 0.01  
WL+C  557 ± 710 ᵇ 630 ± 851 
 
965 ± 1,645 
 
579 ± 1,112 
 
673 ± 154 
 
G x T 0.78 0.02  
Time    850 ± 876   819 ± 938   936 ± 1,290   735 ± 1,078                  
F  874 ± 910 
 
766 ± 968 
 
961 ± 1420 
 
749 ± 1196 
 
832 ± 121 
 
Sex 0.94 <0.001  
M   822 ± 848   883 ± 914   907 ± 1138   717 ± 937   845 ± 133   S x T 0.90 0.002  
PLA F 733 ± 613 
 
642 ± 735 
 
487 ± 647 
 
410 ± 664 
 
568 ± 213 
 
G x S 0.20 0.05  
 M 944 ± 863 
 
996 ± 977 
 
864 ± 1055 
 
820 ± 863 
 
906 ± 233 
 
G x T x S 0.91 0.01  
WL F 1,126 ± 1169 
 
911 ± 1128 
 
1,042 ± 1314 
 
1,052 ± 1363 
 
1,033 ± 205 
 
   
 
 M 1,212 ± 974 ᶜ 1,172 ± 1076 
 
1,344 ± 1171 
 
984 ± 1200 
 
1,178 ± 233 ᶜ     
WL+C F 740 ± 853 
 
733 ± 1046 
 
1,347 ± 1971 
 
760 ± 1406 ‡ 895 ± 213 
 
   
 
  M 356 ± 475 ᵇ 516 ± 601   549 ± 1146   382 ± 681   451 ± 222 ᵇ       
Total PLA  2,087 ± 1,255 ᵇ 2,418 ± 1,554 
 
2,322 ± 2,020 
 
2,315 ± 1,543 
 
2,292 ± 376 ᵇ Group 0.13 0.06 
MET Minutes WL  3,710 ± 2,349 ᵃᶜ 3,225 ± 2,755 
 
3,333 ± 2,418 
 
3,170 ± 2,727 
 
3,362 ± 369 ᵃ Time 0.95 0.001 
 WL+C  2,325 ± 1,860 ᵇ 2,633 ± 1,888 
 
2,890 ± 3,222 
 
2,957 ± 2,154 
 
2,689 ± 366 
 
G x T 0.69 0.02  
Time    2,717 ± 1,991   2,763 ± 2,130   2,856 ± 2,604   2,821 ± 2,201                  
F  2,777 ± 2270 
 
2,642 ± 2075 
 
3,049 ± 2754 
 
2,979 ± 2334 
 
2,848 ± 289 
 
Sex 0.28 0.02  
M   2,645 ± 1631   2,909 ± 2220   2,626 ± 2437   2,633 ± 2052   2,713 ± 315   S x T 0.57 0.01  
PLA F 1,967 ± 1410 ᵇ 2,214 ± 1437 
 
2,347 ± 2455 
 
2,364 ± 1910 
 
2,223 ± 506 
 
G x S 0.76 0.01  
 M 2,231 ± 1098 
 
2,663 ± 1729 
 
2,292 ± 1467 
 
2,257 ± 1043 
 
2,361 ± 555 
 
G x T x S 0.94 0.01  
WL F 3,758 ± 2828 ᵃ 2,978 ± 2584 
 
3,594 ± 2863 
 
3,040 ± 2823 
 
3,343 ± 487 
 
   
 
 M 3,649 ± 1679 
 
3,546 ± 3073 
 
2,992 ± 1769 
 
3,338 ± 2737 
 
3,381 ± 555 
 
   
 
WL+C F 2,524 ± 2055 
 
2,706 ± 2099 
 
3,160 ± 2991 
 
3,528 ± 2177 
 
3,343 ± 506 
 
   
 
  M 2,108 ± 1692   2,553 ± 1728   2,597 ± 3580   2,334 ± 2043   2,398 ± 529      
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.32), Time (p=0.49), Group x Time (p=0.89), Sex (p=0.27), Sex x Time (p=0.58), and 
Group x Sex (p=0.54), Group x Time x Sex (p=0.78) effects for truncated physical activity variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), 
Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; 
b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group 
means only (excluding Time and Sex data), on the above table. 
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Body Composition and Anthropometrics 
Body Composition.  Multivariate analysis revealed overall Wilks' Lambda Time 
(p=0.07) and Sex (p<0.01), with no Group (p=0.94), Group x Time (p=0.88), Sex x Time 
(p=0.67), Group x Sex (p=0.94), or Group x Time x Sex (p=0.99) effects for body 
composition variables, body weight (kg), fat mass (FM; kg), fat free mass (FFM; kg), body 
fat (BF; %), and bone mineral content (BMC; g). Univariate analysis found significant 
effects of sex (p≤0.01) but, not group, time, group x time, sex x time, group x sex, or group 
x time x sex interactions for any body composition measure. Pairwise analysis bore no 
differences amid groups at any time point. Conversely, males exhibited weight loss from 
baseline at week 4 in supplement groups WL (WL 96.84±14.56; WL 95.75±14.91 kg) and 
WL+C (WL+C 97.29±20.06; WL+C 96.13±19.26 kg). No other effects occurred for body 
weight (Table 7). Still, WL lost FM, by weeks 4 and 8 (WL 28.01±7.13; Wk4 27.44±6.92; 
Wk8 27.38±7.22 kg) and BF at weeks 8 and 12 (WL 34.69±7.64; W8 34.06±7.82; Wk12 
33.9±7.58 %). Analysis of change from baseline [95% CI] (Figures 4-6) also showed FM 
loss at weeks 4 and 8 (WL -0.56±0.95 [-1.02, -0.14]; Wk8 -0.63±1.47 [-1.23, -0.02] kg) 
with BF at weeks 8 and 12 (WL -0.63±1.26 [-1.16, -0.10]; Wk12 -0.78±1.31 [-1.45, 0.07] 
%). Sex differences implied females weighed less (F 80.15±2.35; M 98.5±2.56 kg), with 
less FFM (F 43.46±1.34; M 64.86±1.46 kg) and BMC (F 1.69±0.06; M 2.4±0.07 g) thus, 
more FM (F 30.34±1.21; M 25.58±1.32 kg) and BF (F 40.73±0.75; M 28.01±0.82 %). 
These data both reject H01: Body weight will decrease; and fail to reject H02: Body 
composition will improve; significantly in treatment groups compared to baseline and/or 
placebo. 
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Table 7: Body Composition and Anthropometric Data 
           Weeks           Mean      
  Group     0       4       8     12 (SEM) Effect p-Level 𝛈𝒑
𝟐 
Body Weight PLA  90.52 ± 17.55 
 
90.21 ± 17.54 
 
90.27 ± 18.19 
 
90.22 ± 18.87 
 
91.33 ± 3.05 
 
Group 0.67 0.01 
(kg) WL  88.58 ± 14.99 
 
87.91 ± 14.96 
 
88.12 ± 15.59 
 
88.15 ± 15.85 
 
89.12 ± 3.00 
 
Time 0.20 0.03  
WL+C  87.54 ± 17.72 
 
86.95 ± 17.03 
 
86.91 ± 17.07 
 
87.06 ± 17.08 
 
87.51 ± 2.98 
 
G x T 0.97 0.003  
Time    88.86 ± 16.58   88.33 ± 16.34 † 88.41 ± 16.77   88.45 ± 17.08                  
F  80.40 ± 11.26 ⚥ 80.24 ± 11.23 ⚥ 80.09 ± 11.35 ⚥ 80.05 ± 11.73 ⚥ 80.15 ± 2.35 ⚥ Sex <0.001 0.31  
M   98.95 ± 16.39 ⚥ 97.99 ± 16.37 †⚥ 98.33 ± 16.92 ⚥ 98.48 ± 17.19 ⚥ 98.50 ± 2.56 ⚥ S x T 0.42 0.01  
PLA F 80.23 ± 12.70 ⚥ 80.16 ± 12.56 ⚥ 80.08 ± 12.75 ⚥ 79.69 ± 13.59 ⚥ 80.04 ± 4.12 ⚥ G x S 0.63 0.01  
 M 102.87 ± 14.53 ⚥ 102.27 ± 15.12 ⚥ 102.51 ± 16.39 ⚥ 102.85 ± 16.75 ⚥ 102.63 ± 4.51 ⚥ G x T x S 0.93 0.01  
WL F 82.22 ± 12.34 ⚥ 81.88 ± 12.37 ⚥ 81.78 ± 12.52 ⚥ 81.98 ± 12.63 ⚥ 81.97 ± 3.96 ⚥     
 M 96.84 ± 14.56 ⚥ 95.75 ± 14.91 †⚥ 96.36 ± 15.86 ⚥ 96.17 ± 16.58 ⚥ 96.28 ± 4.51 ⚥     
WL+C F 78.61 ± 8.97 ⚥ 78.54 ± 9.03 ⚥ 78.28 ± 9.01 ⚥ 78.31 ± 9.14 ⚥ 78.44 ± 4.12 ⚥     
  M 97.29 ± 20.06 ⚥ 96.13 ± 19.26 †⚥ 96.32 ± 19.10 ⚥ 96.60 ± 18.93 ⚥ 96.59 ± 4.30 ⚥       
Fat Mass  PLA  29.21 ± 7.98 
 
29.13 ± 8.09 
 
29.26 ± 8.80 
 
29.29 ± 9.19 
 
54.98 ± 1.74 
 
Group 0.67 0.01 
(kg) WL  28.01 ± 7.13 
 
27.44 ± 6.92 † 27.38 ± 7.22 † 27.29 ± 7.27 
 
54.91 ± 1.71 
 
Time 0.16 0.03  
WL+C  28.09 ± 7.42 
 
27.85 ± 7.27 
 
27.73 ± 7.38 
 
27.64 ± 6.92 
 
52.59 ± 1.69 
 
G x T 0.56 0.02  
Time    28.43 ± 7.42   28.12 ± 7.36 † 28.11 ± 7.74   28.06 ± 7.77                  
F  30.58 ± 6.58 ⚥ 30.42 ± 6.57 ⚥ 30.28 ± 6.84 ⚥ 30.09 ± 7.11 ⚥ 30.34 ± 1.21 ⚥ Sex 0.01 0.10  
M   25.86 ± 7.65 ⚥ 25.38 ± 7.41 †⚥ 25.51 ± 8.05 ⚥ 25.64 ± 7.93 ⚥ 25.58 ± 1.32 ⚥ S x T 0.36 0.02  
PLA F 31.07 ± 7.57 
 
31.14 ± 7.85 
 
31.24 ± 8.09 
 
31.10 ± 8.91 
 
31.14 ± 2.12 
 
G x S 0.74 0.01  
 M 26.98 ± 8.28 
 
26.71 ± 8.09 
 
26.88 ± 9.44 
 
27.12 ± 9.52 
 
26.92 ± 2.32 
 
G x T x S 0.99 0.003  
WL F 30.92 ± 6.88 ⚥ 30.44 ± 6.70 ⚥ 30.29 ± 6.80 ⚥ 30.06 ± 6.78 ⚥ 30.43 ± 2.04 ⚥     
 M 24.22 ± 5.75 ⚥ 23.54 ± 5.24 †⚥ 23.60 ± 6.13 ⚥ 23.69 ± 6.51 ⚥ 23.76 ± 2.32 ⚥     
WL+C F 29.71 ± 5.63 
 
29.68 ± 5.43 
 
29.30 ± 5.94 
 
29.10 ± 5.82 
 
29.45 ± 2.12 
 
   
 
  M 26.33 ± 8.93   25.84 ± 8.69   26.01 ± 8.64   26.05 ± 7.93   26.06 ± 2.21         
Fat Free Mass PLA  54.02 ± 13.90 
 
53.87 ± 14.04 
 
53.83 ± 14.18 
 
53.70 ± 14.26 
 
29.03 ± 1.57 
 
Group 0.53 0.02 
(kg) WL  53.54 ± 12.74 
 
53.52 ± 12.73 
 
53.70 ± 12.97 
 
53.79 ± 12.76 
 
27.10 ± 1.55 
 
Time 0.93 0.002  
WL+C  52.17 ± 14.09 
 
52.09 ± 13.64 
 
52.10 ± 13.59 
 
52.28 ± 13.47 
 
27.75 ± 1.53 
 
G x T 0.90 0.01  
Time    53.23 ± 13.40   53.15 ± 13.29   53.20 ± 13.40   53.25 ± 13.31                  
F  43.48 ± 5.35 ⚥ 43.50 ± 5.08 ⚥ 43.49 ± 5.23 ⚥ 43.57 ± 5.07 ⚥ 43.46 ± 1.34 ⚥ Sex <0.001 0.65  
M   64.87 ± 10.47 ⚥ 64.67 ± 10.57 ⚥ 64.79 ± 10.64 ⚥ 64.81 ± 10.55 ⚥ 64.86 ± 1.46 ⚥ S x T 0.92 0.002  
PLA F 42.93 ± 5.33 ⚥ 42.73 ± 4.65 ⚥ 42.60 ± 4.82 ⚥ 42.34 ± 4.42 ⚥ 42.65 ± 2.34 ⚥ G x S 0.51 0.02  
 M 67.33 ± 7.45 ⚥ 67.25 ± 8.31 ⚥ 67.31 ± 8.42 ⚥ 67.33 ± 8.49 ⚥ 67.30 ± 2.57 ⚥ G x T x S 0.84 0.01  
WL F 45.01 ± 6.28 ⚥ 45.05 ± 6.27 ⚥ 45.14 ± 6.44 ⚥ 45.42 ± 6.23 ⚥ 45.15 ± 2.25 ⚥     
 M 64.63 ± 10.10 ⚥ 64.53 ± 10.27 ⚥ 64.83 ± 10.62 ⚥ 64.68 ± 10.65 ⚥ 64.67 ± 2.57 ⚥     
WL+C F 42.38 ± 4.20 ⚥ 42.61 ± 3.97 ⚥ 42.59 ± 4.00 ⚥ 42.79 ± 4.01 ⚥ 42.59 ± 2.34 ⚥     
  M 62.85 ± 13.30 ⚥ 62.44 ± 12.89 ⚥ 62.47 ± 12.73 ⚥ 62.63 ± 12.47 ⚥ 62.60 ± 2.45 ⚥       
Body Fat PLA  35.49 ± 8.16 
 
35.44 ± 8.36 
 
35.50 ± 8.66 
 
35.47 ± 8.69 
 
34.86 ± 0.97 
 
Group 0.44 0.03 
(%) WL  34.69 ± 7.64 
 
34.23 ± 7.61 
 
34.06 ± 7.82 † 33.90 ± 7.58 † 33.36 ± 0.95 
 
Time 0.09 0.04  
WL+C  35.38 ± 7.71 
 
35.17 ± 7.62 
 
35.05 ± 7.63 
 
34.93 ± 7.22 
 
34.88 ± 0.95 
 
G x T 0.63 0.02  
Time    35.18 ± 7.72   34.94 ± 7.77   34.86 ± 7.94 † 34.76 ± 7.75 †                
F  40.98 ± 3.87 ⚥ 40.79 ± 3.93 ⚥ 40.65 ± 4.32 ⚥ 40.40 ± 4.48 †⚥ 40.73 ± 0.75 ⚥ Sex <0.001 0.68  
M   28.25 ± 4.92 ⚥ 27.95 ± 4.85 ⚥ 27.95 ± 5.25 ⚥ 28.03 ± 4.89 ⚥ 28.01 ± 0.82 ⚥ S x T 0.51 0.01  
PLA F 41.53 ± 4.15 ⚥ 41.56 ± 4.70 ⚥ 41.68 ± 4.91 ⚥ 41.52 ± 5.46 ⚥ 41.57 ± 1.31 ⚥ G x S 0.74 0.01  
 M 28.24 ± 5.23 ⚥ 28.10 ± 5.13 ⚥ 28.07 ± 5.76 ⚥ 28.22 ± 5.70 ⚥ 28.16 ± 1.44 ⚥ G x T x S 0.95 0.01  
WL F 40.46 ± 3.70 ⚥ 40.06 ± 3.73 ⚥ 39.85 ± 4.02 ⚥ 39.54 ± 3.82 †⚥ 39.98 ± 1.26 ⚥     
 M 27.18 ± 3.69 ⚥ 26.66 ± 3.21 ⚥ 26.53 ± 4.03 ⚥ 26.58 ± 3.92 ⚥ 26.74 ± 1.44 ⚥     
WL+C F 41.00 ± 4.03 ⚥ 40.83 ± 3.45 ⚥ 40.49 ± 4.19 ⚥ 40.22 ± 4.19 ⚥ 40.63 ± 1.31 ⚥     
  M 29.25 ± 5.78 ⚥ 29.00 ± 5.88 ⚥ 29.12 ± 5.88 ⚥ 29.16 ± 5.03 ⚥ 29.13 ± 1.37 ⚥       
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Figure 4. Body Weight. Data are presented as Δ-means ± 95% CI. Statistical notation (§) denotes a 
significant difference (p≤0.05) from baseline. 
 
 
 
Figure 5. Fat Mass. Data are presented as Δ-means ± 95% CI. Statistical notation (§) denotes a significant 
difference (p≤0.05) from baseline.  
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Figure 6. Body Fat. Data are presented as Δ-means ± 95% CI. Statistical notation (§) denotes a significant 
difference (p≤0.05) from baseline. 
 
Anthropometrics. (Table 7) Overall Wilks' Lambda Sex (p<0.01) effect was observed, 
with no significant Group (p=0.81), Time (p=0.42), Group x Time (p=0.97), Sex x Time 
(p=0.53), Group x Sex (p=0.97), or Group x Time x Sex (p=0.79) effects for the 
anthropometric variables, waist circumference (W/C; cm), hip circumference (H/C; cm), 
and waist-to-hip (W:H) ratio. Univariate analysis indicated significant effects of sex 
(p<0.01) for W/C and W:H but, no significant group, time, group x time, sex x time, group 
x sex, or group x time x sex interaction effects for any anthropometric variable. Pairwise 
analysis showed no real changes within groups other than WL+C increasing W:H, baseline 
to week 12 (WL+C 0.87±0.07; WL+C 0.89±0.08). Also, general sex differences were 
observed for W/C (F 94.8±1.56; M 102.12±1.7 cm) and W:H (F 0.84±0.01; M 0.92±0.01) 
where females had smaller measures than males. 
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Table 7 – Continued 
     Weeks Mean      
  Group     0       4       8     12 (SEM) Effect p-Level 𝛈𝒑
𝟐 
Bone Mineral  PLA  2.03 ± 0.48 
 
2.00 ± 0.47 † 2.01 ± 0.49 
 
2.01 ± 0.50 
 
2.05 ± 0.08 
 
Group 0.78 0.01 
Content (g) WL  2.04 ± 0.48 
 
2.04 ± 0.49 
 
2.02 ± 0.46 ‡ 2.03 ± 0.48 
 
2.08 ± 0.08 
 
Time 0.17 0.03 
 WL+C  1.99 ± 0.60 
 
1.98 ± 0.59 
 
1.99 ± 0.59 
 
1.98 ± 0.59 
 
2.00 ± 0.08 
 
G x T 0.25 0.04  
Time    2.02 ± 0.52   2.01 ± 0.51   2.01 ± 0.51   2.01 ± 0.52                  
F  1.69 ± 0.28 ⚥ 1.69 ± 0.29 ⚥ 1.69 ± 0.28 ⚥ 1.68 ± 0.28 ⚥ 1.69 ± 0.06 ⚥ Sex <0.001 0.48  
M   2.41 ± 0.46 ⚥ 2.39 ± 0.46 ⚥ 2.39 ± 0.46 ⚥ 2.39 ± 0.47 ⚥ 2.40 ± 0.07 ⚥ S x T 0.26 0.02  
PLA F 1.65 ± 0.14 ⚥ 1.65 ± 0.14 ⚥ 1.64 ± 0.13 ⚥ 1.64 ± 0.15 ⚥ 1.64 ± 0.11 ⚥ G x S 0.74 0.01   
M 2.48 ± 0.31 ⚥ 2.43 ± 0.36 †⚥ 2.46 ± 0.36 ⚥‡ 2.46 ± 0.37 ⚥ 2.46 ± 0.12 ⚥ G x T x S 0.51 0.03  
WL F 1.75 ± 0.33 ⚥ 1.75 ± 0.34 ⚥ 1.74 ± 0.32 ⚥ 1.74 ± 0.33 ⚥ 1.74 ± 0.11 ⚥ 
   
  
M 2.42 ± 0.37 ⚥ 2.42 ± 0.38 ⚥ 2.39 ± 0.35 ⚥‡ 2.42 ± 0.36 ⚥‡ 2.41 ± 0.12 ⚥ 
   
 
WL+C F 1.68 ± 0.34 ⚥ 1.68 ± 0.34 ⚥ 1.68 ± 0.34 ⚥ 1.67 ± 0.33 ⚥ 1.67 ± 0.11 ⚥ 
   
    M 2.33 ± 0.65 ⚥ 2.32 ± 0.63 ⚥ 2.32 ± 0.63 ⚥ 2.32 ± 0.64 ⚥ 2.32 ± 0.12 ⚥       
Waist  PLA 
 
98.00 ± 10.75 
 
98.23 ± 10.14 
 
98.89 ± 10.22 
 
98.89 ± 10.12 
 
98.86 ± 2.03 
 
Group 0.94 0.002 
Circumference WL 
 
96.88 ± 9.24 
 
97.74 ± 10.12 
 
97.33 ± 10.85 
 
98.40 ± 9.84 
 
97.88 ± 1.99 
 
Time 0.30 0.02 
(cm) WL+C 
 
97.73 ± 10.87 
 
98.72 ± 10.65 
 
98.31 ± 11.13 
 
98.95 ± 11.54 
 
98.64 ± 1.98 
 
G x T 0.98 0.01  
Time    97.53 ± 10.16   98.23 ± 10.16   98.17 ± 10.61   98.74 ± 10.38 †               
 
F 
 
93.88 ± 9.25 ⚥ 95.00 ± 9.13 ⚥ 94.97 ± 9.64 ⚥ 95.46 ± 9.30 †⚥ 94.80 ± 1.56 ⚥ Sex 0.002 0.14  
M   101.89 ± 9.59 ⚥ 102.09 ± 10.11 ⚥ 101.99 ± 10.59 ⚥ 102.67 ± 10.37 ⚥ 102.12 ± 1.70 ⚥ S x T 0.80 0.005  
PLA F 94.30 ± 10.92 ⚥ 94.26 ± 9.63 ⚥ 95.46 ± 10.04 
 
95.46 ± 9.68 
 
94.87 ± 2.73 ⚥ G x S 0.66 0.01   
M 102.44 ± 9.13 ⚥ 103.00 ± 8.97 ⚥ 103.00 ± 9.28 
 
103.00 ± 9.47 
 
102.86 ± 2.99 ⚥ G x T x S 0.37 0.03  
WL F 94.37 ± 9.27 
 
95.31 ± 10.14 
 
96.15 ± 9.98 
 
96.72 ± 9.26 † 95.64 ± 2.63 
    
  
M 100.14 ± 8.57 
 
100.90 ± 9.68 
 
98.87 ± 12.27 
 
100.58 ± 10.62 
 
100.12 ± 2.99 
    
 
WL+C F 92.92 ± 8.08 ⚥ 95.40 ± 8.21 † 93.19 ± 9.45 ⚥ 94.09 ± 9.57 ⚥ 93.90 ± 2.73 ⚥ 
   
 
  M 102.99 ± 11.41 ⚥ 102.35 ± 12.15   103.91 ± 10.41 ⚥ 104.26 ± 11.53 ⚥ 103.38 ± 2.86 ⚥       
Hip PLA 
 
113.09 ± 8.46 
 
114.02 ± 8.13 
 
113.90 ± 9.33 
 
113.15 ± 9.84 
 
113.49 ± 1.70 
 
Group 0.62 0.02 
Circumference WL 
 
111.79 ± 7.40 
 
111.40 ± 6.93 
 
111.54 ± 7.04 
 
111.65 ± 7.54 
 
111.45 ± 1.67 
 
Time 0.60 0.01 
(cm) WL+C 
 
111.78 ± 8.05 
 
111.65 ± 7.83 
 
111.62 ± 7.84 
 
111.01 ± 7.42 
 
111.51 ± 1.66 
 
G x T 0.68 0.02  
Time    112.21 ± 7.88   112.33 ± 7.62   112.33 ± 8.06   111.92 ± 8.24                 
 
F 
 
112.96 ± 7.90 
 
112.90 ± 8.04 
 
112.57 ± 8.43 
 
112.58 ± 8.90 
 
112.76 ± 1.31 
 
Sex 0.53 0.01  
M   111.31 ± 7.89   111.66 ± 7.15   112.05 ± 7.72   111.13 ± 7.45 ‡ 111.54 ± 1.43   S x T 0.46 0.01  
PLA F 113.98 ± 10.28 
 
114.47 ± 9.61 
 
114.09 ± 10.62 
 
113.56 ± 11.80 
 
114.03 ± 2.29 
 
G x S 0.91 0.003   
M 112.03 ± 5.95 
 
113.49 ± 6.38 
 
113.67 ± 8.06 
 
112.65 ± 7.45 
 
112.96 ± 2.51 
 
G x T x S 0.87 0.01 
 
WL F 113.13 ± 6.12 
 
112.54 ± 7.54 
 
112.05 ± 7.57 
 
112.64 ± 7.99 
 
112.59 ± 2.20 
    
  
M 110.05 ± 8.83 
 
109.92 ± 6.11 
 
110.87 ± 6.61 
 
110.36 ± 7.12 
 
110.30 ± 2.51 
    
 
WL+C F 111.76 ± 7.41 
 
111.71 ± 7.26 
 
111.60 ± 7.30 
 
111.55 ± 6.93 
 
112.59 ± 2.29 
    
 
  M 111.81 ± 9.07   111.59 ± 8.76   111.64 ± 8.75   110.43 ± 8.22   111.37 ± 2.39         
Waist:Hip Ratio PLA 
 
0.87 ± 0.08 
 
0.86 ± 0.07 
 
0.87 ± 0.06 
 
0.87 ± 0.07 
 
0.87 ± 0.01 
 
Group 0.70 0.01  
WL 
 
0.87 ± 0.06 
 
0.88 ± 0.06 
 
0.87 ± 0.06 
 
0.88 ± 0.06 
 
0.88 ± 0.01 
 
Time 0.17 0.03  
WL+C 
 
0.87 ± 0.07 
 
0.88 ± 0.06 
 
0.88 ± 0.07 
 
0.89 ± 0.08 † 0.88 ± 0.01 
 
G x T 0.90 0.01  
Time    0.87 ± 0.07   0.87 ± 0.06   0.87 ± 0.07   0.88 ± 0.07 †                
F 
 
0.83 ± 0.05 ⚥ 0.84 ± 0.05 ⚥ 0.84 ± 0.05 ⚥ 0.85 ± 0.06 †⚥ 0.84 ± 0.01 ⚥ Sex <0.001 0.39  
M   0.92 ± 0.05 ⚥ 0.91 ± 0.05 ⚥ 0.91 ± 0.07 ⚥ 0.92 ± 0.05 ⚥ 0.92 ± 0.01 ⚥ S x T 0.40 0.02  
PLA F 0.83 ± 0.06 ⚥ 0.83 ± 0.07 ⚥ 0.84 ± 0.06 ⚥ 0.84 ± 0.07 ⚥ 0.83 ± 0.01 ⚥ G x S 0.60 0.02   
M 0.92 ± 0.06 ⚥ 0.91 ± 0.05 ⚥ 0.91 ± 0.05 ⚥ 0.91 ± 0.06 ⚥ 0.91 ± 0.02 ⚥ G x T x S 0.17 0.05  
WL F 0.83 ± 0.05 ⚥ 0.85 ± 0.05 ⚥ 0.86 ± 0.04 ⚥ 0.86 ± 0.05 †⚥ 0.85 ± 0.01 ⚥ 
   
  
M 0.91 ± 0.03 ⚥ 0.92 ± 0.05 ⚥ 0.89 ± 0.08 ⚥ 0.91 ± 0.05 ⚥ 0.91 ± 0.02 ⚥ 
   
 
WL+C F 0.83 ± 0.04 ⚥ 0.85 ± 0.05 †⚥ 0.83 ± 0.06 ⚥ 0.84 ± 0.07 ⚥ 0.84 ± 0.01 ⚥ 
   
    M 0.92 ± 0.06 ⚥ 0.92 ± 0.07 ⚥ 0.93 ± 0.06 ⚥ 0.94 ± 0.05 ⚥ 0.93 ± 0.01 ⚥       
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.94), Time (p=0.07), Group x Time (p=0.88), Sex (p<0.01), Sex x Time (p=0.67), and Group 
x Sex (p=0.94), Group x Time x Sex (p=0.99) effects for body composition variables; and an overall Wilks' Lambda Group (p=0.81), Time (p=0.42), Group x Time (p=0.97), Sex 
(p<0.01), Sex x Time (p=0.53), and Group x Sex (p=0.97), Group x Time x Sex (p=0.79) effects for anthropometric variables. Greenhouse-Geisser univariate p-levels are listed 
for Group (G), Time (T), Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is 
indicated by the following superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = 
p<0.05 difference from PLA; b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by 
subscripts a, b, and c, for group means only (excluding Time and Sex data), on the above table. 
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Resting Energy Expenditure 
Energy Expenditure. Overall Wilks' Lambda Time (p<0.01), Sex (p<0.01), and Group x 
Time (p<0.05), effects were revealed, with no observed Group (p=0.70), Sex x Time 
(p=0.80), Group x Sex (p=0.75), or Group x Time x Sex (p=0.16) effects for resting energy 
expenditure (REE; kcal/d) and resting energy expenditure per kilogram (REE/kg; 
kcal/kg/d). Univariate analysis indicated time (p<0.01), sex (p<0.01), and group x time 
(p<0.05) effects, with no significant group, sex x time, group x sex, or group x time x sex 
interaction effects for resting energy expenditure measures.  
Pairwise analysis showed an increased REE for all groups, throughout the study. 
PLA raised baseline to weeks 4 and 8 (PLA 1,549.05±382.89; Wk4 1,711.22±375.83; 
Wk8 1,683.77±413.7 kcal/d) as WL increased from week 8 to 12 (WL 1,625.98±372.23; 
WL 1,725.34±418.95 kcal/d) and WL+C increased from baseline to week 12 (WL+C 
1,570.94±407.92; WL+C 1,681.45±317.91 kcal/d). A majority of WL+C changed 
between weeks 8 and 12 (WL+C 1,589.33±289.56; WL+C 1,681.45±317.91 kcal/d). 
Assessment of REE per kilogram was similar to unweighted REE. Baseline, REE/kg was 
lower in PLA than WL (PLA 17.23±3.08; WL 18.95±2.14 kcal/kg/d) and PLA increased 
from baseline at weeks 4 and 8 (PLA 17.23±3.08; Wk4 19.06±2.72; Wk8 18.61±2.36 
kcal/kg/d). Whereas, WL saw increase between weeks 8 and 12 (WL 18.45±2.69; WL 
19.57±3.23 kcal/kg/d), and WL+C increased from baseline at weeks 4 and 12 (WL+C 
17.84±1.98; Wk4 18.84±1.83; Wk12 19.41±1.93 kcal/kg/d). Analysis of change from 
baseline [95% CI] (Figures 7-9) also indicated increases at weeks 4, 8, and 12 in REE 
(PLA 162±277 [68, 266]; PLA 135±310 [31, 248]; WL+C 111±220 [10, 207] kcal/d) and 
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REE/kg (PLA 1.84±2.65 [0.84, 2.88]; PLA 1.38±2.75 [0.34, 2.49]; WL+C 1.57±2.37 [0.5, 
2.6] kcal/kg/d). Overall sex differences were seen for REE (F 1,429.42±39.06; M 
1,898.96±42.68 kcal/d) and REE/kg (F 17.96±0.32; M 19.41±0.34 kcal/kg/d), with males 
expending more kcals and kcals/kg. Table 8 presents the REE data within each group. 
These data fail to reject H04: Resting energy expenditure will improve significantly in 
treatment groups compared to baseline and/or placebo.  
 
Table 8: Resting Energy Expenditure Data 
           Weeks           Mean      
  Group     0       4       8     12 (SEM) Effect p-Level 𝛈𝒑
𝟐 
Resting Energy  PLA 
 
1,549 ± 383 
 
1,711 ± 376 †  1,684 ± 414 †  1,641 ± 393 
 
1,672 ± 51 
 
Group 0.63 0.01 
Expenditure WL 
 
1,670 ± 304 
 
1,642 ± 300 
 
1,626 ± 372 
 
1,725 ± 419 ‡ 1,694 ± 50 
 
Time 0.01 0.07 
(kcal/d) WL+C 
 
1,571 ± 408 
 
1,629 ± 304 
 
1,589 ± 290 
 
1,681 ± 318 †‡ 1,627 ± 50 
 
G x T 0.02 0.08  
Time    1,597 ± 366   1,660 ± 325 † 1,632 ± 358   1,683 ± 375 †‡               
 
F 
 
1,394 ± 210 ⚥ 1,457 ± 179 ⚥ 1,422 ± 227 ⚥ 1,450 ± 219 ⚥ 1,429 ± 39 ⚥ Sex <0.001 0.52  
M   1,840 ± 366 ⚥ 1,903 ± 292 ⚥ 1,883 ± 324 ⚥ 1,961 ± 331 †‡⚥ 1,899 ± 43 ⚥ S x T 0.52 0.01  
PLA F 1,323 ± 206 ⚥ 1,439 ± 174 ⚥ 1,408 ± 227 ⚥ 1,370 ± 231 ⚥ 1,385 ± 69 ⚥ G x S 0.44 0.03   
M 1,821 ± 374 ⚥ 2,038 ± 273 †⚥ 2,015 ± 336 ᶜ†⚥ 1,966 ± 283 ⚥ 1,960 ± 75 ⚥ G x T x S 0.12 0.05  
WL F 1,520 ± 147 ⚥ 1,491 ± 206 ⚥ 1,425 ± 229 ⚥ 1,492 ± 209 ⚥ 1,482 ± 66 ⚥ 
   
  
M 1,865 ± 350 ⚥ 1,839 ± 295 ⚥ 1,888 ± 367 ⚥ 2,029 ± 435 †‡⚥ 1,905 ± 75 ⚥ 
   
 
WL+C F 1,329 ± 223 ⚥ 1,438 ± 161 ⚥ 1,434 ± 245 ⚥ 1,486 ± 214 †⚥ 1,422 ± 69 ⚥ 
   
 
  M 1,835 ± 406 ⚥ 1,838 ± 289 ⚥ 1,759 ± 240 ᵃ⚥ 1,895 ± 276 ⚥‡ 1,832 ± 72 ⚥       
Resting Energy 
Expenditure 
PLA  17.23 ± 3.08 ᵇ 19.06 ± 2.72 †  18.61 ± 2.36 †  18.26 ± 2.79 
 
18.37 ± 0.41 
 
Group 0.50 0.02 
WL  18.95 ± 2.14 ᵃ 18.79 ± 2.34 
 
18.45 ± 2.69 
 
19.57 ± 3.23 ‡ 19.04 ± 0.40 
 
Time <0.001 0.09 
(kcal/kg/d) WL+C  17.84 ± 1.98 
 
18.84 ± 1.83 † 18.43 ± 2.19 
 
19.41 ± 1.93 †‡ 18.65 ± 0.40 
 
G x T 0.03 0.07  
Time    18.02 ± 2.51   18.90 ± 2.29 † 18.49 ± 2.39   19.09 ± 2.73 †‡                
F  17.45 ± 2.33 ⚥ 18.31 ± 2.18 †⚥ 17.85 ± 2.32 ⚥ 18.27 ± 2.54 †⚥ 17.96 ± 0.32 ⚥ Sex 0.003 0.13  
M   18.69 ± 2.59 ⚥ 19.59 ± 2.26 †⚥ 19.27 ± 2.27 ⚥ 20.07 ± 2.66 †‡⚥ 19.41 ± 0.34 ⚥ S x T 0.74 0.01  
PLA F 16.64 ± 2.26 ᵇ 18.21 ± 2.70 † 17.67 ± 2.05 ⚥ 17.43 ± 3.03 
 
17.49 ± 0.55 ⚥ G x S 0.77 0.01  
 M 17.93 ± 3.87 
 
20.09 ± 2.50 † 19.73 ± 2.31 †⚥ 19.26 ± 2.23 
 
19.25 ± 0.61 ⚥ G x T x S 0.12 0.05  
WL F 18.75 ± 2.49 ᵃᶜ 18.34 ± 2.09 
 
17.54 ± 2.40 ⚥ 18.35 ± 2.24 ⚥ 18.24 ± 0.53 ⚥     
 M 19.21 ± 1.68 
 
19.37 ± 2.62 
 
19.64 ± 2.69 ⚥ 21.16 ± 3.73 †‡⚥ 19.84 ± 0.61 ⚥     
WL+C F 16.86 ± 1.67 ᵇ⚥ 18.39 ± 1.85 † 18.35 ± 2.59 † 19.03 ± 2.24 † 18.16 ± 0.55 
 
   
 
  M 18.90 ± 1.78 ⚥ 19.34 ± 1.77   18.51 ± 1.77   19.83 ± 1.51 * 19.15 ± 0.58      
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.70), Time (p<0.01), Group x Time (p<0.05), Sex (p<0.01), Sex x Time (p=0.80), and 
Group x Sex (p=0.75), Group x Time x Sex (p=0.16) effects for resting energy expenditure values. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), 
Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; 
b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group 
means only (excluding Time and Sex data), on the above table. 
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Figure 7. Resting Energy Expenditure. Data are presented as Δ-means ± 95% CI. Statistical notation (§) 
denotes a significant difference (p≤0.05) from baseline.  
 
 
 
Figure 8. Resting Energy Expenditure per Kilogram. Data are presented as Δ-means ± 95% CI. Statistical 
notation (§) denotes a significant difference (p≤0.05) from baseline. 
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Figure 9. Respiratory Exchange Ratio. Data are presented as Δ-means ± 95% CI. Statistical notation (§) 
denotes a significant difference (p≤0.05) from baseline. 
 
Total Body Water.  Overall Wilks' Lambda Sex (p<0.01) effect was observed, with no 
significant Group (p=0.70), Time (p=0.42), Group x Time (p=0.34), Sex x Time (p=0.29), 
Group x Sex (p=0.43), or Group x Time x Sex (p=0.75) effects for body water variables 
total body water (TBW; L; %), intracellular water (ICW; L; %), or extracellular water 
(ECW; L; %). Univariate analysis also indicated significant effects of sex (p<0.001) with 
no group, time, group x time, sex x time, group x sex, or group x time x sex interaction 
effects for body water variable. Pairwise analysis showed WL+C decrease from baseline 
at weeks 4, 8, and 12 in TBW (WL+C 38.8±9.6; Wk4 37.5±8.3; Wk8 36.8±8.4; Wk12 
37.2±8.2 L) and ICW (WL+C 22.6±5.5; Wk4 21.6±4.5; Wk8 21.2±4.7; Wk12 21.6±4.5 
L). Baseline ECW reduced at weeks 8 and 12 (WL+C 16.2±4.4; Wk8 15.7±3.7; Wk12 
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45.1±1.0 L), ICW (F 19.1±0.5; M 25.7±0.6 L), ECW (F 13.3±0.4; M 19.4±0.4 L), TBW% 
(F 40.6±0.5; M 45.6±0.6%), and ECW% (F 41.1±0.2; M 43.1±0.2%); besides ICW% (F 
58.9±0.2; M 56.9±0.2%). Lastly, groups differed by sex at all time points, except PLA 
ICW% and ECW% at week 8 (ICW F 58.0±2.6; M 56.9±1.7 | ECW F 42.0±2.6; M 
43.1±1.7%) and week 12 (ICW F 58.5±1.8; M 57.3±3.6 | ECW F 41.5±1.8; M 42.7±3.6%). 
Table 9 presents the body water data. 
 
Table 9: Total Body Water Data 
   Weeks Mean    
Variable Group     0       4       8     12   SEM   p-Level 𝛈𝒑
𝟐 
Total Body Water PLA  39.4 ± 9.6 
 
39.0 ± 9.1 
 
38.5 ± 9.4 
 
39.8 ± 9.8 ‡ 39.9 ± 1.1 
 
Group 0.45 0.03 
(L) WL  37.6 ± 7.1 
 
37.8 ± 7.5 
 
38.2 ± 7.3 
 
38.0 ± 7.7 
 
38.6 ± 1.1 
 
Time 0.12 0.03 
 WL+C  38.8 ± 9.6 
 
37.5 ± 8.3 † 36.8 ± 8.4 † 37.2 ± 8.2 † 37.9 ± 1.1 
 
G x T 0.06 0.07 
 Time    38.6 ± 8.7   38.1 ± 8.2 † 37.8 ± 8.3 † 38.3 ± 8.5                  
F  32.5 ± 4.2 ⚥ 32.5 ± 4.6 ⚥ 32.2 ± 4.3 ⚥ 32.7 ± 4.5 ⚥ 32.4 ± 0.9 ⚥ Sex <0.001 0.61  
M   46.0 ± 6.7 ⚥ 44.7 ± 6.5 †⚥ 44.6 ± 6.7 †⚥ 45.1 ± 7.2 ⚥ 45.1 ± 1.0 ⚥ S x T 0.26 0.02  
PLA F 32.1 ± 4.6 ⚥ 32.3 ± 4.8 ⚥ 31.3 ± 4.4 ⚥ 32.9 ± 5.4 ⚥‡ 32.2 ± 1.5 ⚥ G x S 0.22 0.05  
 M 48.1 ± 6.0 ⚥ 47.0 ± 5.9 ⚥ 47.1 ± 5.6 ⚥ 48.1 ± 7.1 ⚥ 47.6 ± 1.7 ⚥ G x T x S 0.63 0.02  
WL F 33.3 ± 4.5 ⚥ 33.7 ± 5.4 ⚥ 34.1 ± 5.0 ⚥ 33.5 ± 4.9 ⚥ 33.6 ± 1.5 ⚥     
 M 43.3 ± 5.6 ⚥ 43.1 ± 6.6 ⚥ 43.5 ± 6.5 ⚥ 44.0 ± 6.6 ⚥ 43.5 ± 1.7 ⚥     
WL+C F 31.9 ± 3.8 ⚥ 31.5 ± 3.3 ⚥ 31.0 ± 2.8 ⚥ 31.5 ± 2.8 ⚥ 31.5 ± 1.5 ⚥     
  M 46.4 ± 8.0 ⚥ 44.0 ± 6.9 †⚥ 43.3 ± 7.6 †⚥ 43.4 ± 7.5 †⚥ 44.3 ± 1.6 ⚥       
Intracellular Water PLA  22.7 ± 5.2 
 
22.5 ± 4.9 
 
22.1 ± 5.2 
 
23.0 ± 6.0 ‡ 23.0 ± 0.7 
 
Group 0.55 0.02 
(L) WL  21.7 ± 4.1 
 
22.2 ± 4.5 
 
22.2 ± 4.4 
 
22.1 ± 4.4 
 
22.4 ± 0.7 
 
Time 0.23 0.02 
 WL+C  22.6 ± 5.5 
 
21.6 ± 4.5 † 21.2 ± 4.7 † 21.6 ± 4.5 † 21.9 ± 0.7 
 
G x T 0.07 0.06 
 Time    22.3 ± 4.9   22.1 ± 4.6   21.8 ± 4.7 † 22.2 ± 5.0                  
F  19.1 ± 2.9 ⚥ 19.3 ± 3.1 ⚥ 18.9 ± 2.9 ⚥ 19.2 ± 2.7 ⚥ 19.1 ± 0.5 ⚥ Sex <0.001 0.52  
M   26.1 ± 4.1 ⚥ 25.4 ± 3.8 ⚥ 25.3 ± 4.0 †⚥ 25.8 ± 4.7 ⚥ 25.7 ± 0.6 ⚥ S x T 0.45 0.01  
PLA F 18.8 ± 2.8 ⚥ 19.0 ± 2.8 ⚥ 18.2 ± 2.9 ⚥ 19.2 ± 3.1 ⚥ 18.8 ± 0.9 ⚥ G x S 0.21 0.05  
 M 27.3 ± 3.4 ⚥ 26.7 ± 3.2 ⚥ 26.8 ± 3.0 ⚥ 27.6 ± 5.4 ⚥ 27.1 ± 1.0 ⚥ G x T x S 0.81 0.01  
WL F 19.5 ± 2.9 ⚥ 20.3 ± 3.9 ⚥ 20.2 ± 3.4 ⚥ 19.8 ± 3.2 ⚥ 20.0 ± 0.9 ⚥     
 M 24.6 ± 3.7 ⚥ 24.6 ± 4.2 ⚥ 24.8 ± 4.3 ⚥ 25.1 ± 4.1 ⚥ 24.8 ± 1.0 ⚥     
WL+C F 19.0 ± 3.2 ⚥ 18.5 ± 2.1 ⚥ 18.1 ± 1.8 ⚥ 18.6 ± 1.8 ⚥ 18.6 ± 0.9 ⚥     
  M 26.5 ± 4.9 ⚥ 25.0 ± 4.1 †⚥ 24.5 ± 4.6 †⚥ 24.7 ± 4.5 †⚥ 25.2 ± 1.0 ⚥       
Extracellular Water PLA  16.7 ± 4.4 
 
16.5 ± 4.2 
 
16.4 ± 4.3 
 
16.7 ± 4.3 
 
16.9 ± 0.5 
 
Group 0.32 0.04 
(L) WL  15.9 ± 3.1 
 
15.6 ± 3.4 
 
16.0 ± 3.2 
 
15.9 ± 3.4 
 
16.2 ± 0.5 
 
Time 0.13 0.03 
 WL+C  16.2 ± 4.4 
 
15.9 ± 3.8 
 
15.7 ± 3.7 † 15.7 ± 3.7 † 16.0 ± 0.4 
 
G x T 0.32 0.04 
 Time    16.3 ± 4.0   16.0 ± 3.8 † 16.0 ± 3.7 † 16.1 ± 3.8                  
F  13.3 ± 1.5 ⚥ 13.2 ± 1.8 ⚥ 13.3 ± 1.6 ⚥ 13.4 ± 1.9 ⚥ 13.3 ± 0.4 ⚥ Sex <0.001 0.69  
M   19.8 ± 2.9 ⚥ 19.3 ± 2.7 †⚥ 19.3 ± 2.8 †⚥ 19.3 ± 2.8 †⚥ 19.4 ± 0.4 ⚥ S x T 0.18 0.03  
PLA F 13.3 ± 1.8 ⚥ 13.3 ± 2.0 ⚥ 13.1 ± 1.7 ⚥ 13.7 ± 2.5 ⚥ 13.4 ± 0.6 ⚥ G x S 0.28 0.04  
 M 20.8 ± 2.8 ᵇ ⚥ 20.3 ± 2.8 ⚥ 20.3 ± 2.9 ⚥ 20.4 ± 2.7 ⚥ 20.5 ± 0.7 ⚥ G x T x S 0.49 0.03  
WL F 13.7 ± 1.6 ⚥ 13.4 ± 2.1 ⚥ 13.8 ± 1.7 ⚥ 13.7 ± 1.8 ⚥ 13.7 ± 0.6 ⚥     
 M 18.7 ± 2.0 ᵃ ⚥ 18.5 ± 2.4 ⚥ 18.8 ± 2.3 ⚥ 18.9 ± 2.6 ⚥ 18.7 ± 0.7 ⚥     
WL+C F 12.9 ± 1.0 ⚥ 13.0 ± 1.4 ⚥ 12.9 ± 1.0 ⚥ 12.9 ± 1.2 ⚥ 12.9 ± 0.6 ⚥     
  M 19.9 ± 3.4 ⚥ 19.0 ± 2.9 †⚥ 18.7 ± 3.1 †⚥ 18.7 ± 3.1 †⚥ 19.1 ± 0.6 ⚥       
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Table 9 – Continued 
   Weeks Mean    
Variable Group     0       4       8     12   SEM   p-Level 𝛈𝒑
𝟐 
Total Body Water PLA  43.2 ± 4.2 
 
43.0 ± 4.3 
 
42.6 ± 4.9 
 
43.3 ± 6.4 
 
43.3 ± 0.7 
 
Group 0.58 0.02 
(%) WL  42.9 ± 3.3 
 
42.9 ± 3.8 
 
43.4 ± 3.5 
 
43.2 ± 3.9 
 
43.3 ± 0.6 
 
Time 0.65 0.01 
 WL+C  42.5 ± 5.6 
 
42.2 ± 3.6 
 
42.2 ± 4.5 
 
42.7 ± 3.6 
 
42.5 ± 0.6 
 
G x T 0.89 0.01 
 Time    42.9 ± 4.4   42.7 ± 3.9   42.7 ± 4.3   43.1 ± 4.7                  
F  40.8 ± 3.2 ⚥ 40.7 ± 3.2 ⚥ 40.3 ± 3.6 ⚥ 40.5 ± 3.5 ⚥ 40.6 ± 0.5 ⚥ Sex <0.001 0.42  
M   45.4 ± 4.4 ⚥ 45.1 ± 3.1 ⚥ 45.6 ± 3.2 ⚥ 46.1 ± 4.2 ⚥ 45.6 ± 0.6 ⚥ S x T 0.38 0.02  
PLA F 40.3 ± 2.7 ⚥ 40.4 ± 2.9 ⚥ 39.5 ± 3.6 ⚥ 40.0 ± 4.1 ⚥ 40.1 ± 0.9 ⚥ G x S 0.33 0.04  
 M 46.8 ± 2.6 ⚥ 46.2 ± 3.6 ⚥ 46.3 ± 3.6 ⚥ 47.2 ± 6.7 ⚥ 46.6 ± 1.0 ⚥ G x T x S 0.85 0.01  
WL F 41.4 ± 3.2 ⚥ 41.3 ± 4.0 ⚥ 41.9 ± 3.3 ⚥ 41.1 ± 3.6 ⚥ 41.4 ± 0.9 ⚥     
 M 44.8 ± 2.3 ⚥ 45.0 ± 2.2 ⚥ 45.4 ± 2.8 ⚥ 45.9 ± 2.2 ⚥ 45.3 ± 1.0 ⚥     
WL+C F 40.7 ± 3.8 ⚥ 40.2 ± 2.6 ⚥ 39.5 ± 3.7 ⚥ 40.4 ± 2.9 ⚥ 40.2 ± 0.9 ⚥     
  M 44.5 ± 6.6 ⚥ 44.3 ± 3.4 ⚥ 45.2 ± 3.4 ⚥ 45.2 ± 2.6 ⚥ 44.8 ± 0.9 ⚥       
Intracellular Water PLA  57.7 ± 1.4 
 
57.9 ± 1.4 
 
57.5 ± 2.3 
 
57.9 ± 2.8 
 
57.7 ± 0.3 
 
Group 0.69 0.01 
(%) WL  57.8 ± 1.7 
 
58.7 ± 3.1 
 
58.2 ± 2.2 
 
58.2 ± 1.5 
 
58.0 ± 0.3 
 
Time 0.49 0.01 
 WL+C  58.2 ± 2.9 
 
57.8 ± 1.7 
 
57.5 ± 1.6 
 
58.1 ± 1.8 
 
57.9 ± 0.3 
 
G x T 0.54 0.03 
 Time    57.9 ± 2.1   58.1 ± 2.2   57.8 ± 2.0   58.0 ± 2.1                  
F  58.8 ± 1.9 ⚥ 59.2 ± 2.3 ⚥ 58.6 ± 2.1 ⚥‡ 58.9 ± 1.5 ⚥ 58.9 ± 0.2 ⚥ Sex <0.001 0.38  
M   56.8 ± 1.8 ⚥ 56.8 ± 1.2 ⚥ 56.8 ± 1.5 ⚥ 57.0 ± 2.2 ⚥ 56.9 ± 0.2 ⚥ S x T 0.64 0.01  
PLA F 58.5 ± 1.0 ⚥ 58.8 ± 0.7 ⚥ 58.0 ± 2.6 
 
58.5 ± 1.8 
 
58.4 ± 0.4 ⚥ G x S 0.51 0.02  
 M 56.7 ± 1.3 ⚥ 56.8 ± 1.1 ⚥ 56.9 ± 1.7 
 
57.3 ± 3.6 
 
56.9 ± 0.4 ⚥ G x T x S 0.88 0.01  
WL F 58.6 ± 1.2 ⚥ 60.0 ± 3.5 †⚥ 59.3 ± 1.9 ⚥ 59.0 ± 1.2 ⚥ 59.2 ± 0.4 ⚥     
 M 56.6 ± 1.7 ⚥ 57.0 ± 1.3 ⚥ 56.8 ± 1.7 ⚥ 57.0 ± 1.1 ⚥ 56.8 ± 0.4 ⚥     
WL+C F 59.4 ± 2.9 ⚥ 58.8 ± 1.2 ⚥ 58.4 ± 1.5 ⚥ 59.2 ± 1.4 ⚥ 59.2 ± 0.4 ⚥     
  M 56.9 ± 2.4 ⚥ 56.7 ± 1.4 ⚥ 56.6 ± 1.3 ⚥ 56.8 ± 1.3 ⚥ 56.8 ± 0.4 ⚥       
Extracellular Water PLA  42.3 ± 1.4 
 
42.1 ± 1.3 
 
42.5 ± 2.3 
 
42.1 ± 2.8 
 
42.3 ± 0.3 
 
Group 0.68 0.01 
(%) WL  42.2 ± 1.7 
 
41.3 ± 3.1 
 
41.8 ± 2.2 
 
41.8 ± 1.5 
 
42.0 ± 0.3 
 
Time 0.50 0.01 
 WL+C  41.8 ± 2.9 
 
42.2 ± 1.7 
 
42.5 ± 1.6 
 
42.0 ± 1.8 
 
42.1 ± 0.3 
 
G x T 0.54 0.03 
 Time    42.1 ± 2.1   41.9 ± 2.2   42.2 ± 2.0   42.0 ± 2.1                  
F  41.2 ± 1.9 ⚥ 40.8 ± 2.3 ⚥ 41.4 ± 2.1 ⚥‡ 41.1 ± 1.5 ⚥ 41.1 ± 0.2 ⚥ Sex <0.001 0.38  
M   43.2 ± 1.8 ⚥ 43.2 ± 1.2 ⚥ 43.2 ± 1.5 ⚥ 43.0 ± 2.2 ⚥ 43.1 ± 0.2 ⚥ S x T 0.66 0.01  
PLA F 41.5 ± 1.0 ⚥ 41.3 ± 0.7 ⚥ 42.0 ± 2.6 
 
41.5 ± 1.8 
 
41.6 ± 0.4 ⚥ G x S 0.50 0.02  
 M 43.3 ± 1.3 ⚥ 43.2 ± 1.1 ⚥ 43.1 ± 1.7 
 
42.7 ± 3.6 
 
43.1 ± 0.4 ⚥ G x T x S 0.88 0.01  
WL F 41.4 ± 1.2 ⚥ 40.0 ± 3.5 †⚥ 40.7 ± 1.9 ⚥ 41.0 ± 1.2 ⚥ 40.8 ± 0.4 ⚥     
 M 43.4 ± 1.7 ⚥ 43.0 ± 1.3 ⚥ 43.3 ± 1.7 ⚥ 43.0 ± 1.1 ⚥ 43.2 ± 0.4 ⚥     
WL+C F 40.6 ± 2.9 ⚥ 41.2 ± 1.2 ⚥ 41.6 ± 1.5 ⚥ 40.8 ± 1.4 ⚥ 41.1 ± 0.4 ⚥     
  M 43.1 ± 2.4 ⚥ 43.3 ± 1.4 ⚥ 43.4 ± 1.3 ⚥ 43.2 ± 1.3 ⚥ 43.2 ± 0.4 ⚥       
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.70), Time (p=0.42), Group x Time (p=0.34), Sex (p<0.01), Sex x Time (p=0.29), and 
Group x Sex (p=0.43), Group x Time x Sex (p=0.75) effects for body water variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), Sex (S), Group 
x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following superscripts: † = 
p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; b = p<0.05 
difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group means only 
(excluding Time and Sex data), on the above table. 
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Biochemical Markers 
Blood Glucose and Lipid Profiles 
Blood Glucose. Overall Wilks' Lambda showed no significant Time (p=0.78), Group x 
Time (p=0.67), Sex x Time (p=0.34), or Group x Time x Sex (p=0.45) effects on glucose 
(mmol/L). Univariate analysis found no significant time, group x time, sex, sex x time, or 
group x time x sex interaction effects for glucose as well. In following, pairwise analysis 
indicated no real effects on blood glucose from any of the treatment groups. 
Lipid Profile. Overall Wilks' Lambda revealed effects of Time (p<0.05) and Sex 
(p<0.01), with no Group (p=0.93), Group x Time (p=0.21), Sex x Time (p=0.14), Group 
x Sex (p=0.98), or Group x Time x Sex (p=0.26) effects for lipid variables, triglycerides 
(mmol/L), total cholesterol (Chol; mmol/L), low or high density lipoprotein (LDL; U/L | 
HDL; mmol/L). Univariate analysis had significant sex (p<0.001) effects for HDL and 
triglycerides as well as time (p<0.01) and group x time (p<0.05) interaction effects for 
HDL but, were not present in other lipid measures. No significant group, sex x time, group 
x sex, or group x time x sex interactions were observed for any lipid measure. 
Pairwise analysis exhibited no significant differences in triglycerides, total 
cholesterol, or LDL. However, supplement groups both presented significant baseline 
changes in HDL at weeks 8 and 12 wherein, WL increased (WL 1.23±0.39; Wk8 
1.31±0.36; Wk12 1.35±0.38 mmol/L) and WL+C decreased (WL+C 1.18±0.36; Wk8 
1.31±0.38; Wk12 1.28±0.35 mmol/L). Moreover, males overall had greater triglyceride 
(F 1.00±0.15; M 1.82±0.17 mmol/L) and lesser HDL (F 1.47±0.06; M 1.09±0.06 mmol/L) 
levels than females. 
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Hormones. Overall Wilks' Lambda indicated a significant effect of Sex (p<0.01) but, 
no Group (p=0.53), Time (p=0.15), Group x Time (p=0.83), Sex x Time (p=0.48), Group 
x Sex (p=0.87), or Group x Time x Sex (p=0.15) effects for hormone variables, insulin 
(µU/mL), homeostatic model of insulin resistance (HOMA-IR), or leptin (ng/mL). 
Univariate analysis showed significant sex (p<0.001) interaction effects for leptin only, 
with no group, time, group x time, sex x time, group x sex, or group x time x sex effects 
for any of the hormone variables. 
Pairwise analysis showed WL+C as greater than WL at baseline for insulin (WL+C 
15.84±7.32; WL 10.83±7.23 µU/mL) and HOMA-IR (WL+C 3.65±1.81; WL 2.43±1.88 
µU/mL). The differences were primarily between males for both insulin (WL+C 
18.37±7.58; WL 9.66±9.57 µU/mL) and HOMA-IR (WL+C 4.32±1.92; WL 2.23±2.48 
µU/mL). Subsequently, only males of WL increased from baseline to week 12, albeit in 
just insulin (WL 9.66±9.57; WL 15.88±15.19 µU/mL). Sex differences were present for 
Leptin at all time points, where females, overall, had greater levels than males (F 
55.44±3.51; M 21.42±3.84 ng/mL), in each group. Otherwise, no other differences were 
observed. Table 10 presents glucose and lipid related data in each group. 
Serum and Whole Blood Clinical Markers 
Serum.  An Overall Wilks' Lambda revealed Time (p<0.01), Sex (p<0.01), and Sex 
x Time (p=0.06), with no Group (p=0.52), Group x Time (p=0.24), Group x Sex (p=0.57), 
or Group x Time x Sex (p=0.43) effects for liver function related variables, creatine kinase 
(CK; U/L), lactate dehydrogenase (LDH; U/L), alanine aminotransferase [transaminase] 
(ALT; U/L), blood urea nitrogen (BUN; mmol/L), creatinine (Cr; µmol/L), or blood urea 
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nitrogen to creatinine ratio (BUN:Cr). Univariate analysis indicated effects of group 
(p≤0.05) for BUN:Cr, sex (p<0.001) for CK, ALT, BUN, Cr, and LDH (p<0.05) as well 
as time (p<0.001) for BUN, Cr, and BUN:Cr with no group x time, sex x time, or group x 
time x sex effects among any of the liver function related variables. Other clinical markers 
measured but excluded from the previous analysis are aspartate aminotransferase (AST; 
U/L) and alkaline phosphatase (ALP; U/L). 
Pairwise analysis indicated some variation in serum markers, all of which stayed 
within normal ranges. This is further evidenced by an assessment of change from baseline 
to week 12 (Table 12), showing no change in kidney, muscle, or liver markers for ≥78% 
of the participants in any given group; with the other ≤22% comprised of those whom 
increased from normal to high (≤13%) or decreased high to normal (≤13%). Chi-squared 
analysis showed no significant change in any serum marker among treatments. 
Nevertheless, males had generally greater values than females for CK (F 95.36±11.39; M 
168.43±12.45 U/L), LDH (F 143.07±3.36; M 153.23±3.67 U/L), ALT (F 20.18±2.45; M 
33.80±2.68 U/L), BUN (F 3.05±0.12; M 3.64±0.13 mmol/L), and Cr (F 70.92±2.10; M 
88.50±2.30 µmol/L). Table 11 presents the serum chemistry results within each group. 
Table 12 shows chi-squared analysis of changes from baseline values observed; Note: ALP 
has an N of 58 (PLA 18; WL 21; WL+C 19) due to the discontinuation of the reagent near the 
end of data collection. 
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Table 10: Glucose and Lipid Responses 
           Weeks           Mean       
  Group   0   4   8   12   (SEM) Effect p-Level 𝛈𝒑
𝟐 
Glucose PLA  5.05 ± 0.47 
 
5.15 ± 0.53 
 
4.95 ± 0.31 ‡ 4.99 ± 0.47 
 
5.04 ± 0.09 
 
Group 0.27 0.04 
(mmol/L) WL  4.90 ± 0.54 
 
4.91 ± 0.52 
 
4.91 ± 0.42 ᶜ  4.99 ± 0.63 
 
4.94 ± 0.09 
 
Time 0.77 0.01 
 WL+C  5.14 ± 0.60 
 
5.12 ± 0.71 
 
5.15 ± 0.45 ᵇ  5.11 ± 0.46 
 
5.14 ± 0.09 
 
G x T 0.63 0.02 
 Time    5.03 ± 0.54   5.06 ± 0.59   5.00 ± 0.41   5.03 ± 0.52                 
 F  4.96 ± 0.52 
 
4.92 ± 0.60 ⚥ 4.97 ± 0.38 
 
4.93 ± 0.62 
 
4.95 ± 0.07 
 
Sex 0.08 0.05 
 M   5.12 ± 0.55   5.22 ± 0.55 ⚥ 5.05 ± 0.44   5.14 ± 0.36   5.13 ± 0.07   S x T 0.37 0.02 
 PLA F 5.05 ± 0.43 
 
5.15 ± 0.47 
 
5.03 ± 0.31 
 
4.88 ± 0.49 
 
5.03 ± 0.12 
 
G x S 0.40 0.03 
  M 5.05 ± 0.54 
 
5.16 ± 0.62 
 
4.85 ± 0.30 ᶜ ‡ 5.12 ± 0.43 ‡ 5.05 ± 0.13 
 
G x T x S 0.59 0.02 
 WL F 4.84 ± 0.57 
 
4.79 ± 0.63 
 
4.83 ± 0.44 
 
4.95 ± 0.81 
 
4.86 ± 0.11 
 
   
  M 4.98 ± 0.51 
 
5.06 ± 0.29 
 
5.01 ± 0.40 
 
5.03 ± 0.27 
 
5.02 ± 0.13 
 
   
 WL+C F 4.98 ± 0.57 
 
4.84 ± 0.67 ⚥ 5.05 ± 0.37 
 
4.97 ± 0.52 
 
4.86 ± 0.12 ⚥    
    M 5.31 ± 0.60   5.41 ± 0.65 ⚥ 5.27 ± 0.52 ᵃ  5.27 ± 0.35 ‡ 5.31 ± 0.12 ⚥       
Insulin  PLA  13.06 ± 8.56 
 
-   
 
-   
 
14.56 ± 10.15 
 
13.96 ± 1.73 
 
Group 0.25 0.04 
(µU/mL) WL  10.83 ± 7.23 ᶜ -   
 
-   
 
13.64 ± 11.87 
 
12.30 ± 1.70 
 
Time 0.07 0.05  
WL+C  15.84 ± 7.32 ᵇ -   
 
-   
 
16.62 ± 8.48 
 
16.30 ± 1.69 
 
G x T 0.60 0.02  
Time    13.24 ± 7.88   -       -       14.95 ± 10.18                  
F  12.49 ± 6.17 
 
-   
 
-   
 
13.29 ± 7.43 
 
12.92 ± 1.33 
 
Sex 0.20 0.03  
M   14.14 ± 9.56   -       -       16.92 ± 12.57   15.45 ± 1.46   S x T 0.31 0.02  
PLA F 12.29 ± 7.23 
 
-   
 
-   
 
12.22 ± 6.93 
 
12.26 ± 2.34 
 
G x S 0.85 0.01  
 M 13.97 ± 10.26 
 
-   
 
-   
 
17.37 ± 12.87 
 
15.67 ± 2.56 
 
G x T x S 0.16 0.06  
WL F 11.73 ± 5.03 
 
-   
 
-   
 
11.92 ± 8.83 
 
11.82 ± 2.25 
 
   
 
 M 9.66 ± 9.57 ᶜ -   
 
-   
 
15.88 ± 15.19 † 12.77 ± 2.56 
 
   
 
WL+C F 13.52 ± 6.54 
 
-   
 
-   
 
15.85 ± 6.07 
 
14.69 ± 2.34 
 
   
 
  M 18.37 ± 7.58 ᵇ -       -       17.45 ± 10.77   17.91 ± 2.44         
Insulin Sensitivity PLA  2.92 ± 1.92 
 
-   
 
-   
 
3.30 ± 2.42 
 
3.15 ± 0.41 
 
Group 0.26 0.04 
(HOMA-IR) WL  2.43 ± 1.88 ᶜ -   
 
-   
 
3.16 ± 3.06 
 
2.81 ± 0.41 
 
Time 0.11 0.04  
WL+C  3.65 ± 1.81 ᵇ -   
 
-   
 
3.79 ± 1.99 
 
3.74 ± 0.40 
 
G x T 0.59 0.02  
Time    3.00 ± 1.91   -       -       3.42 ± 2.51                  
F  2.78 ± 1.44 
 
-   
 
-   
 
3.02 ± 2.08 
 
2.90 ± 0.32 
 
Sex 0.17 0.03  
M   3.27 ± 2.35   -       -       3.89 ± 2.90   3.56 ± 0.35   S x T 0.46 0.01  
PLA F 2.74 ± 1.53 
 
-   
 
-   
 
2.70 ± 1.62 
 
2.72 ± 0.56 
 
G x S 0.78 0.01  
 M 3.15 ± 2.37 
 
-   
 
-   
 
4.01 ± 3.07 
 
3.58 ± 0.61 
 
G x T x S 0.33 0.03  
WL F 2.58 ± 1.34 
 
-   
 
-   
 
2.85 ± 2.88 
 
2.71 ± 0.54 
 
   
 
 M 2.23 ± 2.48 ᶜ -   
 
-   
 
3.57 ± 3.40 
 
2.90 ± 0.61 
 
   
 
WL+C F 3.03 ± 1.52 
 
-   
 
-   
 
3.53 ± 1.45 
 
3.28 ± 0.56 
 
   
 
  M 4.32 ± 1.92 ᵇ -       -       4.07 ± 2.49   4.19 ± 0.58         
Leptin PLA  41.88 ± 28.60 
 
-   
 
-   
 
46.50 ± 33.74 
 
42.44 ± 4.57 
 
Group 0.56 0.02 
(ng/mL) WL  38.24 ± 26.78 
 
-   
 
-   
 
39.83 ± 29.04 
 
36.57 ± 4.49 
 
Time 0.16 0.03  
WL+C  36.93 ± 25.28 
 
-   
 
-   
 
36.75 ± 22.73 
 
36.28 ± 4.45 
 
G x T 0.43 0.03  
Time    38.97 ± 26.57   -       -       40.95 ± 28.63                 
 F  54.58 ± 22.53 ⚥ -   
 
-   
 
56.30 ± 26.97 ⚥ 55.44 ± 3.51 ⚥ Sex <0.001 0.41 
 M   20.34 ± 17.56 ⚥ -       -       22.62 ± 17.90 ⚥ 21.42 ± 3.84 ⚥ S x T 0.84 <0.001 
 PLA F 58.81 ± 21.45 ⚥ -   
 
-   
 
64.66 ± 31.34 ⚥ 61.73 ± 6.16 ⚥ G x S 0.53 0.02 
  M 21.56 ± 22.49 ⚥ -   
 
-   
 
24.72 ± 22.10 ⚥ 23.14 ± 6.75 ⚥ G x T x S 0.71 0.01 
 WL F 55.33 ± 21.57 ⚥ -   
 
-   
 
55.55 ± 26.92 ⚥ 55.44 ± 5.92 ⚥    
  M 16.02 ± 12.74 ⚥ -   
 
-   
 
19.40 ± 16.54 ⚥ 17.71 ± 6.75 ⚥    
 WL+C F 49.55 ± 25.42 ⚥ -   
 
-   
 
48.76 ± 21.65 ⚥ 49.16 ± 6.16 ⚥    
   M 23.16 ± 17.18 ⚥ -       -       23.64 ± 16.10 ⚥ 23.40 ± 6.43 ⚥    
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Table 10 – Continued       
Weeks 
     
Mean 
   
 
Group 
 
0 
 
4 
 
8 
 
12 
 
(SEM) Effect p-Level 𝛈𝒑
𝟐 
Triglycerides PLA  1.48 ± 0.72 
 
1.35 ± 0.94 
 
1.41 ± 1.33 
 
1.20 ± 0.76 
 
1.40 ± 0.20 
 
Group 0.75 0.01 
(mmol/L) WL  1.35 ± 0.73 
 
1.37 ± 0.90 
 
1.20 ± 0.78 
 
1.14 ± 0.82 
 
1.31 ± 0.19 
 
Time 0.07 0.04 
 WL+C  1.53 ± 1.73 
 
1.59 ± 1.23 
 
1.42 ± 1.40 
 
1.45 ± 1.04 
 
1.52 ± 0.19 
 
G x T 0.76 0.02 
 Time    1.45 ± 1.15   1.44 ± 1.03   1.34 ± 1.18   1.27 ± 0.88                 
 F  1.05 ± 0.44 ⚥ 1.02 ± 0.43 ⚥ 0.91 ± 0.40 ⚥ 1.01 ± 0.72 ⚥ 1.00 ± 0.15 ⚥ Sex <0.001 0.18 
 M   1.93 ± 1.52 ⚥ 1.94 ± 1.28 ⚥ 1.86 ± 1.56 ⚥ 1.58 ± 0.96 †‡⚥ 1.82 ± 0.17 ⚥ S x T 0.09 0.04 
 PLA F 1.13 ± 0.46 
 
1.05 ± 0.44 
 
0.86 ± 0.36 ⚥ 0.88 ± 0.33 
 
0.98 ± 0.27 ⚥ G x S 0.94 0.002 
  M 1.90 ± 0.78 
 
1.72 ± 1.24 
 
2.08 ± 1.75 ⚥‡ 1.59 ± 0.96 
 
1.82 ± 0.29 ⚥ G x T x S 0.13 0.05 
 WL F 1.05 ± 0.35 
 
1.00 ± 0.36 ⚥ 0.90 ± 0.26 
 
0.86 ± 0.32 
 
0.95 ± 0.26 
 
   
  M 1.73 ± 0.93 
 
1.85 ± 1.16 ⚥ 1.60 ± 1.04 
 
1.50 ± 1.13 
 
1.67 ± 0.29 
 
   
 WL+C F 0.98 ± 0.52 ⚥ 1.01 ± 0.53 ⚥ 0.98 ± 0.56 
 
1.29 ± 1.17 
 
1.06 ± 0.27 ⚥    
   M 2.14 ± 2.35 ⚥ 2.22 ± 1.48 ⚥ 1.89 ± 1.86   1.63 ± 0.91 † 1.97 ± 0.28 ⚥       
Total Cholesterol PLA  5.07 ± 0.74 
 
4.89 ± 0.95 
 
4.87 ± 0.78 
 
4.83 ± 0.90 
 
4.92 ± 0.18 
 
Group 0.63 0.01 
(mmol/L) WL  4.71 ± 0.89 
 
4.88 ± 0.91 
 
4.90 ± 1.04 
 
4.88 ± 0.95 
 
4.85 ± 0.18 
 
Time 0.86 0.004 
 WL+C  4.94 ± 0.83 
 
5.10 ± 0.91 
 
5.14 ± 0.74 
 
5.14 ± 0.94 
 
5.08 ± 0.17 
 
G x T 0.11 0.05 
 Time    4.90 ± 0.82   4.96 ± 0.92   4.97 ± 0.86   4.95 ± 0.93                 
 F  4.82 ± 0.71 
 
4.93 ± 0.93 
 
4.99 ± 0.84 
 
4.88 ± 0.95 
 
4.91 ± 0.14 
 
Sex 0.70 0.002 
 M   5.00 ± 0.94   4.98 ± 0.92   4.94 ± 0.90   5.03 ± 0.91   4.99 ± 0.15   S x T 0.31 0.02 
 PLA F 4.95 ± 0.68 
 
4.88 ± 1.04 
 
4.89 ± 0.88 
 
4.75 ± 1.04 
 
4.87 ± 0.24 
 
G x S 1.00 <0.001 
  M 5.20 ± 0.82 
 
4.90 ± 0.89 
 
4.85 ± 0.69 † 4.91 ± 0.74 
 
4.96 ± 0.26 
 
G x T x S 0.86 0.01 
 WL F 4.63 ± 0.71 
 
4.83 ± 0.84 
 
4.87 ± 0.95 
 
4.87 ± 0.82 
 
4.80 ± 0.23 
 
   
  M 4.81 ± 1.11 
 
4.93 ± 1.03 
 
4.93 ± 1.21 
 
4.89 ± 1.14 
 
4.89 ± 0.26 
 
   
 WL+C F 4.88 ± 0.76 
 
5.09 ± 0.95 
 
5.23 ± 0.70 † 5.01 ± 1.04 
 
5.05 ± 0.24 
 
   
   M 5.00 ± 0.93   5.12 ± 0.91   5.04 ± 0.81   5.27 ± 0.84   5.11 ± 0.25         
Low Density PLA  3.42 ± 0.84 
 
3.26 ± 1.01 
 
3.27 ± 0.85 
 
3.24 ± 0.85 
 
3.32 ± 0.18 
 
Group 0.55 0.02 
Lipoprotein WL  3.21 ± 0.82 
 
3.30 ± 0.84 
 
3.35 ± 0.96 
 
3.30 ± 0.91 
 
3.30 ± 0.17 
 
Time 0.99 <0.001 
(U/L) WL+C  3.45 ± 0.84 
 
3.58 ± 0.84 
 
3.55 ± 0.72 
 
3.56 ± 0.95 
 
3.54 ± 0.17 
 
G x T 0.30 0.04  
Time    3.36 ± 0.83   3.38 ± 0.89   3.39 ± 0.84   3.37 ± 0.90                  
F  3.20 ± 0.78 
 
3.26 ± 0.95 
 
3.30 ± 0.89 
 
3.19 ± 0.93 
 
3.24 ± 0.13 
 
Sex 0.15 0.03  
M   3.56 ± 0.85   3.52 ± 0.81   3.49 ± 0.78   3.58 ± 0.84   3.53 ± 0.15   S x T 0.37 0.02  
PLA F 3.17 ± 0.84 
 
3.11 ± 1.12 
 
3.17 ± 1.01 
 
3.07 ± 0.91 
 
3.13 ± 0.24 
 
G x S 0.93 0.002  
 M 3.73 ± 0.76 
 
3.45 ± 0.88 
 
3.38 ± 0.63 † 3.44 ± 0.76 
 
3.50 ± 0.26 
 
G x T x S 0.58 0.02  
WL F 3.12 ± 0.73 
 
3.22 ± 0.83 
 
3.26 ± 0.94 
 
3.23 ± 0.91 
 
3.21 ± 0.23 
 
   
 
 M 3.33 ± 0.94 
 
3.42 ± 0.89 
 
3.46 ± 1.02 
 
3.40 ± 0.95 
 
3.40 ± 0.26 
 
   
 
WL+C F 3.31 ± 0.83 
 
3.47 ± 0.94 
 
3.48 ± 0.75 
 
3.28 ± 1.02 
 
3.21 ± 0.24 
 
   
 
  M 3.61 ± 0.87   3.69 ± 0.73   3.62 ± 0.72   3.87 ± 0.81   3.70 ± 0.25         
High Density PLA  1.35 ± 0.47 
 
1.36 ± 0.43 
 
1.32 ± 0.46 
 
1.35 ± 0.47 
 
1.32 ± 0.07 
 
Group 0.70 0.01 
Lipoprotein WL  1.23 ± 0.39 
 
1.30 ± 0.38 
 
1.31 ± 0.36 † 1.35 ± 0.38 † 1.28 ± 0.07 
 
Time <0.01 0.07 
(mmol/L) WL+C  1.18 ± 0.36 
 
1.21 ± 0.36 
 
1.31 ± 0.38 †‡ 1.28 ± 0.35 † 1.24 ± 0.07 
 
G x T 0.04 0.07  
Time    1.25 ± 0.41   1.29 ± 0.39   1.31 ± 0.40 † 1.33 ± 0.40 †                
F  1.41 ± 0.42 ⚥ 1.47 ± 0.37 †⚥ 1.51 ± 0.37 †⚥ 1.48 ± 0.37 †⚥ 1.47 ± 0.06 ⚥ Sex <0.001 0.25  
M   1.06 ± 0.31 ⚥ 1.07 ± 0.29 ⚥ 1.08 ± 0.29 ⚥ 1.14 ± 0.34 †⚥ 1.09 ± 0.06 ⚥ S x T 0.13 0.03  
PLA F 1.56 ± 0.50 ⚥ 1.57 ± 0.41 ⚥ 1.54 ± 0.47 ⚥ 1.51 ± 0.47 ⚥ 1.54 ± 0.10 ⚥ G x S 0.56 0.02  
 M 1.09 ± 0.30 ⚥ 1.10 ± 0.30 ⚥ 1.05 ± 0.29 ⚥ 1.15 ± 0.40 ⚥ 1.10 ± 0.11 ⚥ G x T x S 0.52 0.03  
WL F 1.30 ± 0.38 
 
1.42 ± 0.37 † 1.43 ± 0.34 † 1.47 ± 0.35 † 1.41 ± 0.09 
 
   
 
 M 1.13 ± 0.40 
 
1.14 ± 0.34 
 
1.15 ± 0.34 
 
1.20 ± 0.38 
 
1.16 ± 0.11 
 
   
 
WL+C F 1.37 ± 0.36 ⚥ 1.42 ± 0.33 ⚥ 1.55 ± 0.31 †‡⚥ 1.47 ± 0.31 ⚥ 1.45 ± 0.10 ⚥    
    M 0.97 ± 0.22 ⚥ 0.98 ± 0.23 ⚥ 1.04 ± 0.25 ⚥ 1.08 ± 0.27 †⚥ 1.02 ± 0.10 ⚥       
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Time (p=0.78), Group x Time (p=0.67), Sex x Time (p=0.34), and Group x Time x Sex (p=0.45) effects 
for glucose; overall Wilks' Lambda Group (p=0.93), Time (p<0.05), Group x Time (p=0.21), Sex (p<0.01), Sex x Time (p=0.14), Group x Sex (p=0.98), and Group x Time x Sex 
(p=0.26) effects for lipid variables; and an overall Wilks' Lambda Group (p=0.53), Time (p=0.15), Group x Time (p=0.83), Sex (p<0.01), Sex x Time (p=0.48), Group x Sex 
(p=0.87), and Group x Time x Sex (p=0.15) effects for hormone variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), Sex (S), Group x Time (G x 
T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by superscripts: †=p<0.05 difference from 
baseline; ‡=p<0.05 difference from previous time point; ⚥=p<0.05 difference between Sexes; a=p<0.05 difference from PLA; b=p<0.05 difference from WL; c= p<0.05 difference 
from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group means only (excluding Time and Sex data), on the above 
table. 
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Table 11: Metabolic and Clinical Safety Markers 
 
      
Weeks 
     
Mean 
   
 
 
Group 
 
0 
 
4 
 
8 
 
12 
 
(SEM) Effect p-Level 𝛈𝒑
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Creatine Kinase PLA  130.60 ± 79.56  115.05 ± 58.17  115.20 ± 53.80  127.90 ± 91.76  126.10 ± 14.83  Group 0.89 0.004 
(U/L) WL  140.08 ± 117.77  116.34 ± 67.25  148.56 ± 134.51  114.63 ± 67.63  134.54 ± 14.56  Time 0.13 0.03 
 WL+C  137.84 ± 103.96  115.53 ± 72.65  151.18 ± 145.96  130.20 ± 86.89  135.04 ± 14.45  G x T 0.52 0.03 
 Time    136.26 ± 100.52   115.65 ± 65.41   138.66 ± 118.79   124.19 ± 81.66                 
 F  105.01 ± 96.34 ⚥ 88.96 ± 53.62 ⚥ 96.89 ± 84.86 ⚥ 90.97 ± 48.58 ⚥ 95.36 ± 11.39 ⚥ Sex <0.001 0.23 
 M   173.55 ± 93.73 ⚥ 147.51 ± 64.64 †⚥ 188.51 ± 134.74 ⚥‡ 163.85 ± 95.26 ⚥ 168.43 ± 12.45 ⚥ S x T 0.43 0.01 
 PLA F 102.31 ± 70.77  76.75 ± 13.71 ⚥ 75.98 ± 20.10  77.31 ± 20.24 ⚥ 83.09 ± 19.99 ⚥ G x S 0.84 0.01 
  M 164.56 ± 79.37  161.01 ± 57.99 ⚥ 162.27 ± 41.81  188.61 ± 107.88 ⚥ 169.11 ± 21.90 ⚥ G x T x S 0.10 0.06 
 WL F 124.98 ± 139.88  91.60 ± 62.22  89.63 ± 45.87 ⚥ 89.86 ± 53.57  99.02 ± 19.21 ⚥    
  M 159.70 ± 84.04  148.51 ± 62.12  225.18 ± 172.86 ⚥‡ 146.83 ± 72.92 ‡ 170.06 ± 21.90 ⚥    
 WL+C F 86.07 ± 56.15 ⚥ 98.30 ± 68.80  125.67 ± 139.37  105.82 ± 61.14  103.97 ± 19.99 ⚥    
   M 194.31 ± 116.55 ⚥ 134.32 ± 75.24 † 179.02 ± 154.49   156.80 ± 104.91   166.11 ± 20.88 ⚥       
Lactate PLA  146.01 ± 20.93  144.90 ± 21.48  146.03 ± 22.73  146.24 ± 17.36  146.11 ± 4.37  Group 0.81 0.01 
Dehydrogenase WL  146.78 ± 27.63  144.40 ± 20.27  151.35 ± 27.93 ‡ 148.85 ± 23.04  148.32 ± 4.29  Time 0.07 0.04 
(U/L) WL+C  145.59 ± 23.77  148.46 ± 22.63  154.97 ± 27.13 † 149.65 ± 19.77  150.02 ± 4.26  G x T 0.61 0.02 
 Time    146.13 ± 23.95   145.93 ± 21.24   150.86 ± 25.95 ‡ 148.28 ± 19.98                 
 F  140.39 ± 20.91 ⚥ 141.16 ± 20.37 ⚥ 147.13 ± 24.99 †‡ 143.79 ± 20.00 ⚥ 143.07 ± 3.36 ⚥ Sex 0.05 0.06 
 M   152.99 ± 25.83 ⚥ 151.63 ± 21.16 ⚥ 155.30 ± 26.77   153.63 ± 18.90 ⚥ 153.23 ± 3.67 ⚥ S x T 0.74 0.01 
 PLA F 142.75 ± 19.07  141.23 ± 21.97  143.82 ± 24.56  142.80 ± 20.23  142.65 ± 5.89  G x S 0.68 0.01 
  M 149.92 ± 23.37  149.30 ± 21.15  148.69 ± 21.30  150.36 ± 12.99  149.57 ± 6.45  G x T x S 0.41 0.03 
 WL F 143.71 ± 23.39  143.29 ± 22.87  148.43 ± 27.96  143.42 ± 21.45  144.71 ± 5.66     
  M 150.78 ± 33.25  145.84 ± 17.41  155.16 ± 28.91  155.92 ± 24.21  151.92 ± 6.45     
 WL+C F 134.42 ± 20.31 ⚥ 138.78 ± 17.14 ⚥ 149.04 ± 23.87 †‡ 145.18 ± 19.87 † 141.86 ± 5.89     
   M 157.77 ± 21.83 ⚥ 159.02 ± 23.83 ⚥ 161.45 ± 30.06   154.54 ± 19.37   158.19 ± 6.15         
Alanine PLA  27.03 ± 20.46  26.50 ± 20.15  28.42 ± 23.41  29.26 ± 17.26  28.40 ± 3.19  Group 0.86 0.005 
Aminotransferase WL  22.89 ± 15.04  24.26 ± 14.63  26.77 ± 17.39 † 26.07 ± 16.36 † 26.02 ± 3.14  Time 0.15 0.03 
(U/L) WL+C  26.43 ± 14.70  26.68 ± 13.79  26.81 ± 14.16  25.24 ± 12.42  26.55 ± 3.11  G x T 0.34 0.04 
 Time    25.43 ± 16.73   25.80 ± 16.16   27.32 ± 18.37 † 26.82 ± 15.32                 
 F  18.48 ± 6.78 ⚥ 20.33 ± 10.62 ⚥ 20.48 ± 9.29 ⚥ 21.22 ± 9.32 †⚥ 20.18 ± 2.45 ⚥ Sex <0.001 0.18 
 M   33.72 ± 20.95 ⚥ 32.33 ± 19.16 ⚥ 35.48 ± 22.88 ⚥‡ 33.51 ± 18.31 ⚥ 33.80 ± 2.68 ⚥ S x T 0.19 0.03 
 PLA F 20.13 ± 8.21  21.22 ± 11.40  21.25 ± 11.58  24.59 ± 12.56 † 21.80 ± 4.31 ⚥ G x S 0.91 0.003 
  M 35.31 ± 27.47  32.84 ± 26.59  37.03 ± 31.04  34.87 ± 20.93  35.01 ± 4.72 ⚥ G x T x S 0.25 0.04 
 WL F 16.92 ± 4.72 ⚥ 17.84 ± 6.34 ⚥ 18.39 ± 4.50 ⚥ 19.45 ± 6.25 ⚥ 18.15 ± 4.14 ⚥    
  M 30.66 ± 20.11 ⚥ 32.60 ± 18.24 ⚥ 37.67 ± 21.88 †⚥ 34.67 ± 21.36 ⚥ 33.90 ± 4.72 ⚥    
 WL+C F 18.52 ± 7.28 ⚥ 22.13 ± 13.56  21.98 ± 10.87  19.77 ± 8.11  20.60 ± 4.31     
   M 35.06 ± 16.13 ⚥ 31.63 ± 12.82   32.09 ± 15.89   31.21 ± 13.85   32.50 ± 4.50         
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Table 11 – Continued 
     
 
      Weeks           Mean     
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Blood Urea PLA 
 
4.18 ± 1.24 
 
3.89 ± 1.01 ᵇᶜ 3.30 ± 0.77 †‡ 3.12 ± 0.98 † 3.64 ± 0.16 ᵇᶜ Group 0.07 0.08 
Nitrogen WL 
 
3.63 ± 0.94 
 
3.08 ± 0.96 ᵃ† 3.08 ± 0.78 † 2.84 ± 1.02 † 3.21 ± 0.15 ᵃ Time <0.001 0.35 
(mmol/L) WL+C 
 
3.61 ± 0.88 
 
3.32 ± 0.83 ᵃ 3.01 ± 0.70 †‡ 2.71 ± 0.73 †‡ 3.17 ± 0.15 ᵃ G x T 0.17 0.05  
Time    3.80 ± 1.05   3.42 ± 0.98 † 3.13 ± 0.75 †‡ 2.88 ± 0.92 †‡           
  
 
F 
 
3.57 ± 0.87 ⚥ 3.13 ± 0.76 †⚥ 2.88 ± 0.62 †‡⚥ 2.58 ± 0.61 †‡⚥ 3.05 ± 0.12 ⚥ Sex 0.00 0.15  
M   4.08 ± 1.18 ⚥ 3.77 ± 1.10 †⚥ 3.42 ± 0.79 †‡⚥ 3.25 ± 1.09 †⚥ 3.64 ± 0.13 ⚥ S x T 0.81 0.00  
PLA F 3.96 ± 0.99 
 
3.57 ± 0.87 ᵇ 3.11 ± 0.62 †‡ 2.97 ± 0.60 † 3.40 ± 0.21 ᵇ G x S 0.68 0.01   
M 4.45 ± 1.51 
 
4.26 ± 1.07 ᵇ 3.52 ± 0.91 †‡ 3.30 ± 1.32 † 3.88 ± 0.23 
 
G x T x S 0.70 0.02  
WL F 3.37 ± 0.81 
 
2.79 ± 0.59 ᵃ† 2.70 ± 0.46 †⚥ 2.36 ± 0.57 †⚥ 2.80 ± 0.20 ᵃ⚥ 
  
  
M 3.97 ± 1.03 
 
3.47 ± 1.22 ᵃ 3.58 ± 0.84 ⚥ 3.45 ± 1.16 ⚥ 3.62 ± 0.23 ⚥ 
   
 
WL+C F 3.38 ± 0.73 
 
3.05 ± 0.62 
 
2.85 ± 0.74 † 2.43 ± 0.51 †‡ 2.80 ± 0.21 
    
 
  M 3.85 ± 1.00   3.61 ± 0.96   3.19 ± 0.63 † 3.02 ± 0.82 † 3.42 ± 0.22     
  
Creatinine  PLA 
 
78.19 ± 14.48 
 
72.22 ± 10.63 † 78.89 ± 17.70 ‡ 81.95 ± 14.47 
 
78.29 ± 2.74 
 
Group 0.40 0.03 
(µmol/L) WL 
 
74.94 ± 17.15 
 
74.00 ± 18.66 
 
75.31 ± 20.84 
 
83.11 ± 14.01 †‡ 78.12 ± 2.69 
 
Time <0.001 0.17  
WL+C 
 
77.40 ± 18.75 
 
79.14 ± 20.68 
 
85.16 ± 20.32 †‡ 87.17 ± 17.10 † 82.71 ± 2.67 
 
G x T 0.18 0.05  
Time    76.82 ± 16.72   75.16 ± 17.29   79.80 ± 19.83 ‡ 84.11 ± 15.20 †‡           
  
 
F 
 
67.47 ± 12.18 ⚥ 67.08 ± 13.32 ⚥ 71.96 ± 17.01 †‡⚥ 76.87 ± 12.27 †‡⚥ 70.92 ± 2.10 ⚥ Sex <0.001 0.34  
M   87.98 ± 14.49 ⚥ 84.82 ± 16.67 ⚥ 89.16 ± 19.11 ⚥ 92.75 ± 13.93 †⚥ 88.50 ± 2.30 ⚥ S x T 0.46 0.01  
PLA F 72.13 ± 12.58 ⚥ 68.71 ± 10.74 
 
75.15 ± 19.32 
 
76.05 ± 15.89 ⚥ 73.01 ± 3.69 
 
G x S 0.27 0.04   
M 85.47 ± 13.70 ⚥ 76.43 ± 9.30 ᵃ† 83.38 ± 15.30 
 
89.02 ± 8.83 ⚥ 83.58 ± 4.04 
 
G x T x S 0.72 0.02  
WL F 65.12 ± 12.84 ⚥ 64.82 ± 13.94 ⚥ 67.44 ± 17.98 ⚥ 75.76 ± 7.73 †‡⚥ 68.29 ± 3.55 ⚥ 
   
  
M 87.71 ± 13.37 ⚥ 85.93 ± 17.67 ⚥ 85.55 ± 20.60 ⚥ 92.66 ± 14.86 ⚥ 87.96 ± 4.04 ⚥ 
   
 
WL+C F 65.36 ± 10.60 ⚥ 67.88 ± 15.60 ⚥ 73.67 ± 13.52 †⚥ 78.89 ± 12.96 †⚥ 71.45 ± 3.69 ⚥ 
   
 
  M 90.52 ± 16.92 ⚥ 91.43 ± 18.84 ᵃ⚥ 97.69 ± 19.40 †⚥ 96.21 ± 16.92 ⚥ 93.96 ± 3.86 ⚥   
  
BUN:Creatinine PLA 
 
13.71 ± 4.79 
 
13.56 ± 3.87 ᵇᶜ 10.87 ± 3.58 ᶜ†‡ 9.80 ± 3.68 ᶜ† 48.38 ± 2.33 ᶜ Group 0.03 0.10 
Ratio WL 
 
12.46 ± 3.92 
 
10.60 ± 2.96 ᵃ† 10.65 ± 3.26 † 8.39 ± 2.36 †‡ 42.40 ± 2.29 
 
Time <0.001 0.38  
WL+C 
 
11.87 ± 2.82 
 
10.83 ± 3.16 ᵃ 9.04 ± 2.39 ᵃ†‡ 7.89 ± 2.37 ᵃ† 39.90 ± 2.28 ᵃ G x T 0.15 0.05  
Time    12.66 ± 3.93   11.63 ± 3.56 † 10.18 ± 3.17 †‡ 8.68 ± 2.93 †‡         
   
 
F 
 
13.43 ± 3.86 
 
11.92 ± 3.44 † 10.37 ± 3.00 †‡ 8.56 ± 2.67 †‡ 44.74 ± 1.79 
 
Sex 0.38 0.01  
M   11.75 ± 3.88   11.30 ± 3.72   9.94 ± 3.40 †‡ 8.82 ± 3.25 †‡ 42.38 ± 1.96   S x T 0.11 0.03  
PLA F 14.04 ± 4.54 
 
13.11 ± 3.53 
 
10.79 ± 3.05 †‡ 10.11 ± 2.99 ᵇ† 48.51 ± 3.15 
 
G x S 0.73 0.01   
M 13.31 ± 5.31 
 
14.10 ± 4.37 ᵇᶜ 10.96 ± 4.30 †‡ 9.43 ± 4.51 † 48.25 ± 3.45 ᶜ G x T x S 0.39 0.03  
WL F 13.36 ± 4.45 
 
11.08 ± 3.29 † 10.60 ± 3.47 † 7.76 ± 1.83 ᵃ†‡ 43.21 ± 3.02 
    
  
M 11.30 ± 2.93 
 
9.97 ± 2.49 ᵃ 10.72 ± 3.13 
 
9.22 ± 2.79 
 
41.60 ± 3.45 
    
 
WL+C F 12.88 ± 2.43 
 
11.64 ± 3.46 
 
9.70 ± 2.49 †‡ 7.88 ± 2.61 †‡ 42.51 ± 3.15 
    
 
  M 10.76 ± 2.90   9.96 ± 2.69 ᵃ 8.32 ± 2.15 † 7.89 ± 2.21 † 37.28 ± 3.29 ᵃ       
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; 
Partial ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.52), Time (p<0.01), Group x Time (p=0.24), Sex (p<0.01), Sex x Time (p=0.06), 
and Group x Sex (p=0.57), Group x Time x Sex (p=0.43) effects for liver function related variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), 
Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from 
PLA; b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for 
group means only (excluding Time and Sex data), on the above table. 
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Table 12: Blood Chemistry Changes from Baseline    
PLA WL WL+C 
 
   (Normal Range) Baseline/Week12 N % N % N % χ2 
L
ip
id
s 
&
 G
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se
 
Total-C Normal/Normal 8 36% 13 57% 10 43% 0.46 
<5.2 mmol/L Normal/High 2 9% 2 9% 5 22%  
 High/Normal 7 32% 3 13% 3 13%  
  High/High 5 23% 5 22% 5 22%  
HDL-C Normal/Normal 5 23% 5 22% 5 22% 0.84 
>1.45 mmol/L Normal/High 1 5% 4 17% 3 13%  
 High/Normal 1 5% 0 0% 1 4%  
  High/High 15 68% 14 61% 14 61%   
LDL-C Normal/Normal 9 41% 12 52% 9 39% 0.93 
<2.59 mmol/L Normal/High 1 5% 2 9% 2 9%  
 High/Normal 3 14% 2 9% 4 17%  
  High/High 9 41% 7 30% 8 35%   
Triglyceride Normal/Normal 19 86% 20 87% 20 87% 0.75 
<2.3 mmol/L Normal/High 1 5% 0 0% 2 9%  
 High/Normal 1 5% 1 4% 0 0%  
  High/High 1 5% 2 9% 1 4%   
Glucose Normal/Normal 21 95% 20 87% 19 83% 0.75 
4.11-6.05 mmol/L Normal/High 0 0% 1 4% 1 4%  
 High/Normal 1 5% 2 9% 2 9%  
 High/High 0 0% 0 0% 1 4%  
L
iv
er
 
ALP Normal/Normal 18 100% 18 86% 16 84% 0.55 
35-129 U/L Normal/High 0 0% 2 10% 2 11%  
 High/Normal 0 0% 0 0% 0 0%  
 High/High 0 0% 1 5% 1 5%  
ALT Normal/Normal 16 73% 19 83% 18 78% 0.66 
10-50 U/L Normal/High 1 5% 2 9% 1 4%  
 High/Normal 0 0% 0 0% 1 4%  
  High/High 5 23% 2 9% 3 13%   
AST Normal/Normal 21 95% 22 96% 22 96% 0.56 
10-50 U/L Normal/High 0 0% 0 0% 1 4%  
 High/Normal 0 0% 0 0% 0 0%  
 High/High 1 5% 1 4% 0 0%  
M
u
sc
le
 
CK Normal/Normal 15 68% 18 78% 14 61% 0.91 
26-308 U/L Normal/High 1 5% 1 4% 2 9%  
 High/Normal 2 9% 2 9% 3 13%  
  High/High 4 18% 2 9% 4 17%   
LDH Normal/Normal 16 73% 15 65% 15 65% 0.98 
135-250 U/L Normal/High 1 5% 3 13% 3 13%  
 High/Normal 2 9% 2 9% 2 9%  
 High/High 3 14% 3 13% 3 13%  
K
id
n
ey
 
BUN Normal/Normal 21 95% 23 100% 23 100% 0.35 
2.14-7.14 mmol/L Normal/High 0 0% 0 0% 0 0%  
 High/Normal 1 5% 0 0% 0 0%  
  High/High 0 0% 0 0% 0 0%   
Creatinine Normal/Normal 22 100% 22 96% 22 96% 0.61 
45-104 µmol/L Normal/High 0 0% 0 0% 0 0%  
 High/Normal 0 0% 0 0% 0 0%  
  High/High 0 0% 1 4% 1 4%   
Data are presented as frequencies and percent N. Statistical significance is detailed from chi-squared analysis. Rows report total number of people that were normal or high at 
baseline and at week 12 (i.e. Normal/High; baseline normal, wk12 high). Percent represents the portion of total people in each group. 
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Whole blood. Wilks' Lambda revealed Time (p<0.01), Sex (p<0.01), and Sex x Time 
(p<0.01) but, no Group (p=0.83), Group x Time (p=0.90), Group x Sex (p=0.52), or Group 
x Time x Sex (p=0.45) effects for the whole blood variables, white blood cells (WBC; 
K/uL), lymphocytes (LYM; K/uL), MID cells [monocytes/eosinophils/basophils] (MID; 
K/uL), granulocytes (GRAN; K/uL), red blood cells (RBC; M/uL), hemoglobin (HGB; 
g/dL), hematocrit (HCT; %), mean corpuscular-volume (MCV; fL); -hemoglobin (MCH; 
pg); -hemoglobin concentration (MCHC; g/dL), red cell distribution width (RDW; %), 
platelets (PLT; K/uL), or mean platelet volume (MPV; fL). Univariate analysis indicated 
interaction effects of sex (p<0.001) for RBC, HGB, HCT, MCHC, PLT, and (p<0.05) 
MCH as well as time (p<0.01) for MCV, MCH, and MCHC plus, sex x time (p<0.01) for 
MCV, MCHC, (p≤0.05) RBC, HGB, and MCH only. No group, group x time, or group x 
time x sex effects were observed among any of the whole blood variables, apart from 
RDW (p≤0.05) with group x sex and group x sex x time effects.  
Pairwise analysis showed overall sex differences in RBC (F 4.7±0.1; M 5.1±0.1 
M/uL), HGB (F 13.3±0.2; M 15.2±0.2 g/dL), HCT (F 41.5±0.5; M 46.2±0.5 %), MCH (F 
28.6±0.3; M 29.8±0.4 pg), MCHC (F 32.0±0.1; M 32.8±0.1 g/dL), and PLT (F 240.8±7.9; 
M 199.5±8.9 K/uL). WL exhibited sex differences for WBC (F 7.0±0.3; M 5.8±0.4 K/uL), 
GRAN (F 4.2±0.3; M 3.2±0.3 K/uL), HGB (F 13.0±0.3; M 14.8±0.3 g/dL), HCT (F 
40.6±0.8; M 45.4±0.9 %), MCV (F 86.5±1.4; M 91.6±1.6 fL), MCH (F 27.6±0.5; M 
29.9±0.6 pg), MCHC (F 31.9±0.2; M 32.7±0.2 g/dL), RDW (F 14.3±0.3; M 13.2±0.3 %), 
and PLT (F 256.2±13.3; M 199.8±15.9 K/uL). Despite some fluctuation between time 
points, no significant differences existed, as all measures were in normal reference ranges, 
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defined as; WBC 4.1-10.9 (K/uL), LYM 0.6-4.1 (K/uL), MID 0-1.8 (K/uL), GRAN 2-7.8 
(K/uL), RBC 4.2-6.3 (M/uL), HGB 12-18 (g/dL), HCT 37-51 (%), MCV 80-97 (fL), MCH 
26-32 (pg), MCHC 31-36 (g/dL), RDW 11.5-14.5 (%), PLT 140-440 (K/uL), MPV 0-99.8 
(fL). Table 13 presents whole blood cell count assessment data within each group. 
Hemodynamics 
Overall Wilks' Lambda revealed significant effects of Sex (p<0.01) with no Group 
(p=0.24), Time (p=0.88), Group x Time (p=0.30), Sex x Time (p=0.52), Group x Sex 
(p=0.99), or Group x Time x Sex (p=0.65) effects for the resting hemodynamic variables 
of heart rate (HR; bpm), systolic and diastolic blood pressure (SBP, DBP; mmHg). 
Univariate analysis indicated significant sex (p<0.01) interaction effects for HR and SBP 
only, with no group, time, group x time, sex x time, or group x time x sex effects for any 
resting hemodynamic measure. Pairwise analysis showed males generally having a lower 
HR (F 68±1; M 59±2) and greater SBP (F 116±2; M 123±2) at every time point. HR for 
WL+C also showed a significant decrease from baseline at week 8 (WL+C 67±11; WL+C 
63±10 bpm). The supplement groups differed in blood pressure (
𝑆𝐵𝑃
𝐷𝐵𝑃
) at week 4 (WL+C 
[124±16]
[81±9]
; WL 
[115±10]
[75±6]
 mmHg) yet, only in DBP by week 12 (WL+C 80±6; WL 75±9). 
Although, HR and BP remained within normal ranges (HR ~60-100 bpm; BP 
[90 to 130]
[60 to 80]
 mmHg) for all groups with no differences between them. Table 14 presents 
resting hemodynamic data within each group. 
These data reject H03: Clinical health and safety markers will improve significantly in 
treatment groups compared to baseline and/or placebo. 
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Table 13: Whole Blood Cell Counts 
      Weeks      Mean      
Group 
  
0 
   
4 
   
8 
  
12 
 
(SEM) 
 
Effect p-Level 𝛈𝒑
𝟐 
 WBC PLA  6.0 ± 1.3 
 
6.2 ± 1.2 
 
6.2 ± 1.3 
 
6.0 ± 1.0 
 
6.1 ± 0.3 
 
Group 0.70 0.01 
(K/uL) WL  6.4 ± 1.5 
 
6.7 ± 1.6 
 
6.4 ± 1.6 
 
6.5 ± 1.2 
 
6.4 ± 0.3 
 
Time 0.30 0.02 
 WL+C  6.0 ± 1.4 
 
6.5 ± 2.0 
 
6.2 ± 1.7 
 
6.2 ± 1.8 
 
6.2 ± 0.3 
 
G x T 0.86 0.01  
Time    6.1 ± 1.4   6.5 ± 1.6   6.3 ± 1.6   6.3 ± 1.4                  
F  6.3 ± 1.6 
 
6.8 ± 1.9 † 6.6 ± 1.5 ⚥ 6.4 ± 1.6 
 
6.5 ± 0.2 
 
Sex 0.07 0.05  
M   6.0 ± 1.2   6.1 ± 1.3   5.8 ± 1.5 ⚥ 6.0 ± 1.1   6.0 ± 0.2   S x T 0.44 0.01  
PLA F 6.4 ± 1.1 
 
6.4 ± 1.1 
 
6.5 ± 1.3 
 
6.2 ± 1.1 
 
6.4 ± 0.4 
 
G x S 0.25 0.04  
 M 5.6 ± 1.5 
 
6.0 ± 1.3 
 
5.9 ± 1.3 
 
5.7 ± 0.8 
 
5.8 ± 0.4 
 
G x T x S 0.18 0.05  
WL F 6.6 ± 1.8 
 
7.3 ± 1.8 ⚥ 7.3 ± 1.4 ⚥ 6.8 ± 1.0 
 
7.0 ± 0.3 ⚥     
 M 6.2 ± 1.2 
 
5.8 ± 0.8 ⚥ 5.1 ± 1.0 †⚥ 6.2 ± 1.4 ‡ 5.8 ± 0.4 ⚥     
WL+C F 5.8 ± 1.8 
 
6.6 ± 2.5 
 
6.1 ± 1.6 
 
6.3 ± 2.4 
 
6.2 ± 0.4 
 
   
 
  M 6.1 ± 0.9   6.5 ± 1.5   6.3 ± 1.9   6.1 ± 1.0   6.3 ± 0.4         
 LYM PLA  1.7 ± 0.5 ᵇ 1.9 ± 0.5 
 
1.8 ± 0.4 
 
1.7 ± 0.4 
 
1.8 ± 0.1 
 
Group 0.24 0.05 
(K/uL) WL  2.1 ± 0.5 ᵃ 2.0 ± 0.6 
 
1.9 ± 0.5 
 
2.0 ± 0.5 
 
2.0 ± 0.1 
 
Time 0.14 0.03 
 WL+C  1.9 ± 0.4 
 
2.0 ± 0.4 
 
1.8 ± 0.5 
 
1.9 ± 0.5 
 
1.9 ± 0.1 
 
G x T 0.83 0.02  
Time    1.9 ± 0.5   2.0 ± 0.5   1.8 ± 0.5 ‡ 1.9 ± 0.5                  
F  1.9 ± 0.5 
 
2.1 ± 0.5 
 
1.9 ± 0.4 ‡ 1.9 ± 0.5 
 
1.9 ± 0.1 
 
Sex 0.44 0.01  
M   1.9 ± 0.5   1.9 ± 0.4   1.8 ± 0.5   1.9 ± 0.5   1.8 ± 0.1   S x T 0.23 0.02  
PLA F 1.8 ± 0.4 
 
2.1 ± 0.5 
 
1.9 ± 0.4 
 
1.7 ± 0.4 
 
1.9 ± 0.1 
 
G x S 0.68 0.01  
 M 1.6 ± 0.6 
 
1.7 ± 0.4 
 
1.7 ± 0.4 
 
1.8 ± 0.3 
 
1.7 ± 0.1 
 
G x T x S 0.77 0.02  
WL F 2.1 ± 0.5 
 
2.1 ± 0.6 
 
1.9 ± 0.4 
 
2.0 ± 0.4 
 
2.0 ± 0.1 
 
   
 
 M 2.0 ± 0.6 
 
1.9 ± 0.6 
 
1.9 ± 0.7 
 
1.9 ± 0.6 
 
2.0 ± 0.1 
 
   
 
WL+C F 1.8 ± 0.4 
 
2.0 ± 0.5 
 
1.8 ± 0.5 
 
1.9 ± 0.6 
 
1.9 ± 0.1 
 
   
 
  M 1.9 ± 0.3   2.0 ± 0.3   1.8 ± 0.5   2.0 ± 0.5   1.9 ± 0.1         
 MID PLA  0.6 ± 0.3 ᵇ 0.7 ± 0.4 
 
0.5 ± 0.1 ‡ 0.6 ± 0.2 
 
0.6 ± 0.0 
 
Group 0.14 0.06 
(K/uL) WL  0.8 ± 0.3 ᵃᶜ 0.7 ± 0.3 
 
0.6 ± 0.2 † 0.7 ± 0.4 
 
0.7 ± 0.0 
 
Time 0.13 0.03 
 WL+C  0.6 ± 0.2 ᵇ 0.6 ± 0.2 
 
0.6 ± 0.1 
 
0.7 ± 0.6 
 
0.6 ± 0.0 
 
G x T 0.53 0.03  
Time    0.7 ± 0.2   0.7 ± 0.3   0.6 ± 0.2 †‡ 0.7 ± 0.4                  
F  0.7 ± 0.3 
 
0.7 ± 0.4 
 
0.6 ± 0.2 †‡ 0.7 ± 0.3 
 
0.7 ± 0.0 
 
Sex 0.22 0.02  
M   0.6 ± 0.2   0.6 ± 0.2   0.6 ± 0.2   0.7 ± 0.5   0.6 ± 0.0   S x T 0.68 0.01  
PLA F 0.7 ± 0.3 
 
0.7 ± 0.4 
 
0.5 ± 0.2 †‡ 0.6 ± 0.3 
 
0.6 ± 0.1 
 
G x S 0.48 0.02  
 M 0.5 ± 0.1 
 
0.7 ± 0.3 
 
0.5 ± 0.1 
 
0.5 ± 0.2 
 
0.6 ± 0.1 
 
G x T x S 0.97 0.01  
WL F 0.8 ± 0.3 ᶜ 0.8 ± 0.4 
 
0.6 ± 0.2 † 0.8 ± 0.3 
 
0.8 ± 0.0 ᶜ     
 M 0.7 ± 0.2 
 
0.6 ± 0.2 
 
0.6 ± 0.3 
 
0.7 ± 0.4 
 
0.7 ± 0.1 
 
   
 
WL+C F 0.6 ± 0.2 ᵇ 0.6 ± 0.3 
 
0.6 ± 0.2 
 
0.6 ± 0.4 
 
0.6 ± 0.1 ᵇ     
  M 0.6 ± 0.2   0.6 ± 0.1   0.6 ± 0.1   0.7 ± 0.7   0.6 ± 0.1         
 GRAN PLA  3.7 ± 1.0 
 
3.7 ± 1.2 
 
3.9 ± 1.0 
 
3.7 ± 0.8 
 
3.7 ± 0.2 
 
Group 1.00 <0.001 
(K/uL) WL  3.6 ± 1.4 
 
3.9 ± 1.2 
 
3.8 ± 1.5 
 
3.8 ± 1.1 
 
3.7 ± 0.2 
 
Time 0.48 0.01 
 WL+C  3.5 ± 1.2 
 
3.9 ± 1.7 
 
3.8 ± 1.5 
 
3.6 ± 1.5 
 
3.7 ± 0.2 
 
G x T 0.90 0.01  
Time    3.6 ± 1.2   3.8 ± 1.4   3.8 ± 1.3   3.7 ± 1.2                  
F  3.7 ± 1.4 
 
4.0 ± 1.6 
 
4.2 ± 1.3 †⚥ 3.9 ± 1.3 
 
3.9 ± 0.2 
 
Sex 0.09 0.05  
M   3.5 ± 1.0   3.7 ± 1.1   3.4 ± 1.4 ⚥ 3.4 ± 1.0   3.5 ± 0.2   S x T 0.29 0.02  
PLA F 3.9 ± 1.1 
 
3.6 ± 1.2 
 
4.1 ± 1.0 
 
3.8 ± 0.9 
 
3.9 ± 0.3 
 
G x S 0.21 0.05  
 M 3.4 ± 1.0 
 
3.7 ± 1.2 
 
3.7 ± 1.0 
 
3.4 ± 0.6 
 
3.6 ± 0.3 
 
G x T x S 0.07 0.06  
WL F 3.8 ± 1.5 
 
4.4 ± 1.4 
 
4.7 ± 1.2 ᶜ†⚥ 4.0 ± 0.7 
 
4.2 ± 0.3 ⚥     
 M 3.4 ± 1.1 
 
3.3 ± 0.3 
 
2.6 ± 0.8 ᶜ†⚥ 3.5 ± 1.4 
 
3.2 ± 0.3 ⚥     
WL+C F 3.4 ± 1.5 
 
3.9 ± 2.0 
 
3.7 ± 1.4 ᵇ 3.8 ± 1.9 
 
3.7 ± 0.3 
 
   
 
  M 3.7 ± 0.8   3.9 ± 1.5   3.9 ± 1.7 ᵇ 3.4 ± 0.8   3.7 ± 0.3         
 
 
 73 
 
Table 13 – Continued 
      Weeks      Mean      
Group 
  
0 
   
4 
   
8 
  
12 
 
(SEM) 
 
Effect p-Level 𝛈𝒑
𝟐 
 RBC PLA  4.9 ± 0.7 
 
4.7 ± 0.5 † 4.8 ± 0.4 
 
4.8 ± 0.7 
 
4.9 ± 0.1 
 
Group 0.61 0.02 
(M/uL) WL  4.8 ± 0.4 
 
4.8 ± 0.5 
 
4.7 ± 0.4 
 
4.9 ± 0.5 
 
4.8 ± 0.1 
 
Time 0.27 0.02 
 WL+C  4.9 ± 0.5 
 
5.0 ± 0.6 
 
4.8 ± 0.8 
 
5.0 ± 0.7 
 
4.9 ± 0.1 
 
G x T 0.47 0.03  
Time    4.9 ± 0.5   4.8 ± 0.5   4.8 ± 0.6   4.9 ± 0.6                  
F  4.6 ± 0.3 ⚥ 4.7 ± 0.5 ⚥ 4.7 ± 0.4 ⚥ 4.7 ± 0.7 ⚥ 4.7 ± 0.1 ⚥ Sex <0.001 0.28  
M   5.3 ± 0.5 ⚥ 5.1 ± 0.5 †⚥ 5.0 ± 0.7 †⚥ 5.1 ± 0.4 ⚥ 5.1 ± 0.1 ⚥ S x T 0.05 0.04  
PLA F 4.5 ± 0.3 ⚥ 4.4 ± 0.3 ᶜ⚥ 4.6 ± 0.3 ⚥ 4.6 ± 0.8 
 
4.5 ± 0.1 ⚥ G x S 0.21 0.05  
 M 5.5 ± 0.6 ᵇ⚥ 5.1 ± 0.4 †⚥ 5.1 ± 0.4 †⚥ 5.1 ± 0.3 † 5.2 ± 0.1 ⚥ G x T x S 0.54 0.03  
WL F 4.7 ± 0.3 ⚥ 4.7 ± 0.4 
 
4.7 ± 0.3 
 
4.8 ± 0.7 
 
4.7 ± 0.1 
 
   
 
 M 5.1 ± 0.4 ᵃ⚥ 5.0 ± 0.6 
 
4.8 ± 0.5 
 
5.0 ± 0.3 
 
5.0 ± 0.1 
 
   
 
WL+C F 4.6 ± 0.3 ⚥ 4.9 ± 0.7 ᵃ† 4.7 ± 0.5 
 
4.7 ± 0.7 ⚥ 4.7 ± 0.1 ⚥     
  M 5.2 ± 0.4 ⚥ 5.1 ± 0.5   5.0 ± 1.0   5.3 ± 0.5 ⚥ 5.2 ± 0.1 ⚥       
 HGB PLA  14.4 ± 1.9 ᵇ 13.8 ± 1.2 
 
14.2 ± 1.2 
 
14.2 ± 2.2 
 
14.3 ± 0.2 
 
Group 0.16 0.06 
(g/dL) WL  13.7 ± 1.7 ᵃ 13.7 ± 1.8 
 
13.5 ± 1.4 
 
14.1 ± 1.7 
 
13.9 ± 0.2 
 
Time 0.37 0.02 
 WL+C  14.2 ± 1.5 
 
14.7 ± 2.0 
 
14.2 ± 2.1 
 
14.7 ± 1.9 
 
14.5 ± 0.2 
 
G x T 0.42 0.03  
Time    14.1 ± 1.7   14.1 ± 1.7   14.0 ± 1.6   14.3 ± 1.9                  
F  12.9 ± 0.9 ⚥ 13.3 ± 1.6 †⚥ 13.3 ± 1.1 ⚥ 13.6 ± 2.0 †⚥ 13.3 ± 0.2 ⚥ Sex <0.001 0.48  
M   15.6 ± 1.2 ⚥ 15.1 ± 1.4 †⚥ 14.7 ± 1.9 †⚥ 15.3 ± 1.4 ⚥ 15.2 ± 0.2 ⚥ S x T 0.02 0.06  
PLA F 13.1 ± 0.7 ⚥ 13.0 ± 0.8 ⚥ 13.7 ± 1.1 ⚥ 13.8 ± 2.9 
 
13.4 ± 0.3 ⚥ G x S 0.99 <0.001  
 M 16.1 ± 1.7 ⚥ 14.9 ± 0.8 †⚥ 15.0 ± 0.9 †⚥ 14.8 ± 0.4 † 15.2 ± 0.3 ⚥ G x T x S 0.46 0.03  
WL F 12.6 ± 1.1 ⚥ 12.9 ± 1.6 ⚥ 12.9 ± 1.2 ⚥ 13.4 ± 1.7 ⚥ 13.0 ± 0.3 ⚥     
 M 15.2 ± 1.1 ⚥ 14.9 ± 1.5 ⚥ 14.3 ± 1.2 ⚥ 15.0 ± 1.1 ⚥ 14.8 ± 0.3 ⚥     
WL+C F 13.0 ± 0.8 ⚥ 14.1 ± 2.0 †⚥ 13.5 ± 1.0 ⚥ 13.5 ± 1.1 ⚥ 13.5 ± 0.3 ⚥     
  M 15.5 ± 0.8 ⚥ 15.4 ± 1.7 ⚥ 14.9 ± 2.8 ⚥ 16.0 ± 1.8 ⚥ 15.4 ± 0.3 ⚥       
 HCT PLA  44.9 ± 5.9 
 
42.6 ± 3.4 † 43.5 ± 3.4 
 
43.2 ± 6.1 
 
43.9 ± 0.6 
 
Group 0.17 0.06 
(%) WL  42.9 ± 4.1 
 
42.4 ± 4.5 
 
41.8 ± 3.8 
 
43.2 ± 4.7 
 
43.0 ± 0.6 ᶜ Time 0.14 0.03 
 WL+C  44.8 ± 3.7 
 
45.1 ± 5.4 
 
43.3 ± 6.0 
 
44.9 ± 5.8 
 
44.6 ± 0.6 ᵇ G x T 0.51 0.03  
Time    44.2 ± 4.6   43.4 ± 4.6   42.9 ± 4.6 † 43.8 ± 5.5                  
F  41.3 ± 2.5 ⚥ 41.7 ± 4.6 ⚥ 41.3 ± 3.1 ⚥ 41.7 ± 5.7 ⚥ 41.5 ± 0.5 ⚥ Sex <0.001 0.43  
M   47.8 ± 4.1 ⚥ 45.6 ± 3.7 †⚥ 44.8 ± 5.4 †⚥ 46.4 ± 4.1 ⚥ 46.2 ± 0.5 ⚥ S x T 0.11 0.03  
PLA F 41.6 ± 2.8 ⚥ 40.6 ± 2.6 ᶜ⚥ 42.0 ± 3.4 
 
41.7 ± 7.8 
 
41.4 ± 0.8 ⚥ G x S 0.90 0.004  
 M 49.4 ± 6.1 ⚥ 45.2 ± 2.2 †⚥ 45.6 ± 2.1 † 45.2 ± 0.9 † 46.3 ± 0.9 ⚥ G x T x S 0.53 0.03  
WL F 40.4 ± 2.5 ⚥ 40.3 ± 3.5 ᶜ⚥ 40.2 ± 3.2 ⚥ 41.6 ± 4.9 
 
40.6 ± 0.8 ⚥     
 M 46.6 ± 2.9 ⚥ 45.5 ± 4.0 ⚥ 44.0 ± 3.6 ⚥ 45.5 ± 3.4 
 
45.4 ± 0.9 ⚥     
WL+C F 42.1 ± 1.9 ⚥ 44.3 ± 6.2 ᵃᵇ 41.9 ± 2.7 
 
41.9 ± 4.2 ⚥ 42.5 ± 0.8 ⚥     
  M 47.7 ± 2.9 ⚥ 46.1 ± 4.5   45.0 ± 8.1   48.2 ± 5.6 ⚥ 46.7 ± 0.8 ⚥       
 MCV PLA  91.0 ± 3.9 
 
90.9 ± 3.8 
 
90.5 ± 3.4 
 
90.2 ± 3.7 
 
90.5 ± 1.1 
 
Group 0.52 0.02 
(fL) WL  88.8 ± 5.7 
 
88.6 ± 5.7 
 
88.2 ± 6.4 
 
88.6 ± 6.4 
 
89.0 ± 1.1 
 
Time 0.004 0.08 
 WL+C  91.2 ± 5.1 
 
90.5 ± 5.1 † 90.3 ± 5.4 † 90.3 ± 5.6 † 90.6 ± 1.0 
 
G x T 0.51 0.03  
Time    90.4 ± 5.0   90.0 ± 5.0 † 89.7 ± 5.3 † 89.7 ± 5.4 †                
F  90.0 ± 5.5 
 
89.6 ± 5.6 
 
88.9 ± 5.9 †‡ 88.9 ± 6.0 † 89.4 ± 0.8 
 
Sex 0.34 0.02  
M   90.8 ± 4.4   90.4 ± 4.1   90.6 ± 4.1   90.7 ± 4.2   90.6 ± 0.9   S x T 0.008 0.07  
PLA F 92.1 ± 2.5 ᵇ 92.1 ± 2.6 ᵇ 91.1 ± 2.1 ᵇ†‡ 90.8 ± 2.6 ᵇ† 91.5 ± 1.4 ᵇ G x S 0.06 0.09  
 M 89.5 ± 5.1 
 
89.3 ± 4.7 
 
89.6 ± 4.6 
 
89.4 ± 4.9 
 
89.5 ± 1.6 
 
G x T x S 0.88 0.01  
WL F 86.8 ± 6.4 ᵃᶜ⚥ 86.6 ± 6.3 ᵃᶜ⚥ 86.1 ± 7.1 ᵃ⚥ 86.3 ± 7.1 ᵃ⚥ 86.5 ± 1.4 ᵃ⚥     
 M 91.7 ± 3.0 ⚥ 91.6 ± 3.2 ⚥ 91.3 ± 3.8 ⚥ 91.9 ± 3.5 ⚥ 91.6 ± 1.6 ⚥     
WL+C F 91.3 ± 5.5 ᵇ 90.5 ± 5.8 ᵇ 89.8 ± 6.4 † 89.8 ± 6.7 † 90.4 ± 1.4 
 
   
 
  M 91.1 ± 5.0   90.4 ± 4.4   90.8 ± 4.3   90.8 ± 4.3   90.8 ± 1.5         
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Table 13 – Continued 
      Weeks      Mean      
Group 
  
0 
   
4 
   
8 
  
12 
 
(SEM) 
 
Effect p-Level 𝛈𝒑
𝟐 
 MCH PLA  29.1 ± 1.6 
 
29.6 ± 1.4 † 29.6 ± 1.5 † 29.7 ± 1.4 † 29.5 ± 0.4 
 
Group 0.43 0.03 
(pg) WL  28.3 ± 2.6 
 
28.6 ± 2.5 
 
28.5 ± 2.7 
 
28.8 ± 2.6 †‡ 28.8 ± 0.4 
 
Time <0.001 0.16 
 WL+C  28.8 ± 2.0 
 
29.4 ± 2.1 † 29.4 ± 1.8 † 29.6 ± 2.1 † 29.4 ± 0.4 
 
G x T 0.67 0.02  
Time    28.7 ± 2.1   29.2 ± 2.1 † 29.2 ± 2.1 † 29.4 ± 2.1 †‡                
F  28.0 ± 2.3 ⚥ 28.7 ± 2.2 †⚥ 28.7 ± 2.3 † 28.9 ± 2.4 † 28.6 ± 0.3 ⚥ Sex 0.02 0.09  
M   29.6 ± 1.5 ⚥ 29.9 ± 1.7 ⚥ 29.8 ± 1.6   29.9 ± 1.4   29.8 ± 0.4 ⚥ S x T 0.04 0.04  
PLA F 29.0 ± 1.3 ᵇ 29.6 ± 0.9 ᵇ† 29.7 ± 0.9 ᵇ† 30.0 ± 1.2 ᵇ† 29.6 ± 0.5 ᵇ G x S 0.11 0.07  
 M 29.3 ± 1.9 
 
29.5 ± 2.0 
 
29.5 ± 2.0 
 
29.3 ± 1.5 
 
29.4 ± 0.6 
 
G x T x S 0.54 0.03  
WL F 27.2 ± 2.8 ᵃ⚥ 27.7 ± 2.8 ᵃ†⚥ 27.7 ± 3.1 ᵃ†⚥ 27.8 ± 2.8 ᵃ†⚥ 27.6 ± 0.5 ᵃ⚥     
 M 29.9 ± 0.8 ⚥ 30.0 ± 1.1 ⚥ 29.6 ± 1.5 ⚥ 30.3 ± 1.1 ‡⚥ 29.9 ± 0.6 ⚥     
WL+C F 28.1 ± 2.2 
 
28.8 ± 2.1 † 28.9 ± 2.1 † 29.1 ± 2.6 † 28.7 ± 0.5 
 
   
 
  M 29.6 ± 1.6   30.1 ± 1.9   30.0 ± 1.3   30.2 ± 1.4 † 30.0 ± 0.6         
 MCHC PLA  32.0 ± 1.4 
 
32.5 ± 0.9 
 
32.7 ± 0.7 † 32.9 ± 0.7 † 32.6 ± 0.2 
 
Group 0.44 0.03 
(g/dL) WL  31.8 ± 1.4 
 
32.3 ± 1.3 
 
32.2 ± 1.0 
 
32.5 ± 1.0 † 32.3 ± 0.2 
 
Time <0.001 0.20 
 WL+C  31.6 ± 1.5 
 
32.5 ± 1.2 † 32.6 ± 0.9 † 32.8 ± 0.9 † 32.4 ± 0.2 
 
G x T 0.58 0.03  
Time    31.8 ± 1.4   32.4 ± 1.2 † 32.5 ± 0.9 † 32.7 ± 0.9 †                
F  31.2 ± 1.4 ⚥ 32.0 ± 1.1 †⚥ 32.3 ± 0.9 †⚥ 32.5 ± 1.0 †⚥ 32.0 ± 0.1 ⚥ Sex <0.001 0.27  
M   32.6 ± 1.0 ⚥ 33.0 ± 1.0 ⚥ 32.9 ± 0.8 ⚥ 33.0 ± 0.6 ⚥ 32.8 ± 0.1 ⚥ S x T <0.001 0.09  
PLA F 31.5 ± 1.4 ⚥ 32.1 ± 0.9 
 
32.5 ± 0.6 † 33.0 ± 0.8 †ᵇ 32.3 ± 0.2 
 
G x S 0.28 0.04  
 M 32.7 ± 1.2 ⚥ 33.0 ± 0.8 
 
32.9 ± 0.8 
 
32.7 ± 0.7 
 
32.8 ± 0.2 
 
G x T x S 0.70 0.02  
WL F 31.2 ± 1.5 ⚥ 31.9 ± 1.4 † 32.1 ± 1.2 † 32.2 ± 1.1 ᵃ†⚥ 31.9 ± 0.2 ⚥     
 M 32.6 ± 0.6 ⚥ 32.7 ± 0.8 
 
32.5 ± 0.7 
 
32.9 ± 0.7 ⚥ 32.7 ± 0.2 ⚥     
WL+C F 30.8 ± 1.3 ⚥ 31.8 ± 0.9 †⚥ 32.2 ± 0.8 †⚥ 32.4 ± 1.0 †⚥ 31.8 ± 0.2 ⚥     
  M 32.5 ± 1.2 ⚥ 33.3 ± 1.2 †⚥ 33.1 ± 0.7 ⚥ 33.2 ± 0.4 †⚥ 33.0 ± 0.2 ⚥       
 RDW PLA  13.5 ± 1.2 
 
13.4 ± 1.3 
 
13.4 ± 1.3 
 
13.4 ± 1.0 
 
13.5 ± 0.2 
 
Group 0.58 0.02 
(%) WL  13.8 ± 1.2 
 
14.0 ± 1.5 
 
13.7 ± 1.3 
 
14.0 ± 1.4 ‡ 13.8 ± 0.2 
 
Time 0.22 0.02 
 WL+C  13.7 ± 0.8 
 
13.7 ± 0.9 
 
13.6 ± 0.9 
 
13.8 ± 1.0 
 
13.7 ± 0.2 
 
G x T 0.82 0.02  
Time    13.7 ± 1.1   13.7 ± 1.2   13.6 ± 1.1   13.7 ± 1.1 ‡                
F  13.8 ± 1.2 
 
13.9 ± 1.4 
 
13.7 ± 1.1 
 
13.9 ± 1.3 
 
13.8 ± 0.2 
 
Sex 0.21 0.03  
M   13.5 ± 0.8   13.5 ± 1.0   13.4 ± 1.2   13.6 ± 0.9   13.5 ± 0.2   S x T 0.88 0.003  
PLA F 13.4 ± 1.1 
 
13.2 ± 1.1 ᵇ 13.1 ± 0.6 ᵇ 13.1 ± 0.6 ᶜ 13.2 ± 0.3 ᵇ G x S 0.03 0.11  
 M 13.5 ± 1.4 
 
13.7 ± 1.5 
 
13.8 ± 1.8 
 
13.9 ± 1.3 
 
13.7 ± 0.3 
 
G x T x S 0.05 0.07  
WL F 14.1 ± 1.4 
 
14.5 ± 1.6 ᵃ†⚥ 14.2 ± 1.3 ᵃ⚥ 14.5 ± 1.6 ⚥ 14.3 ± 0.3 ᵃ⚥     
 M 13.3 ± 0.3 
 
13.1 ± 0.8 ⚥ 12.9 ± 0.7 ⚥ 13.4 ± 0.7 ‡⚥ 13.2 ± 0.3 ⚥     
WL+C F 13.8 ± 1.0 
 
13.9 ± 1.0 
 
13.8 ± 1.0 
 
14.0 ± 1.2 ᵃ 13.9 ± 0.3 
 
   
 
  M 13.6 ± 0.6   13.6 ± 0.7   13.4 ± 0.7   13.5 ± 0.7   13.5 ± 0.3         
 PLT PLA  219.0 ± 73.1 
 
215.3 ± 47.0 
 
224.8 ± 60.2 
 
218.4 ± 62.0 
 
217.6 ± 10.5 
 
Group 0.64 0.01 
(K/uL) WL  244.5 ± 57.8 
 
222.2 ± 65.3 
 
237.5 ± 67.9 
 
228.1 ± 62.7 
 
228.0 ± 10.4 
 
Time 0.70 0.01 
 WL+C  218.6 ± 59.8 
 
218.6 ± 62.4 
 
210.2 ± 58.6 
 
216.1 ± 55.6 
 
215.0 ± 10.0 
 
G x T 0.70 0.02  
Time    227.4 ± 63.9   218.8 ± 58.1   224.0 ± 62.4   220.8 ± 59.4                  
F  250.6 ± 65.8 ⚥ 231.5 ± 64.7 
 
246.1 ± 59.8 ⚥ 236.7 ± 63.4 ⚥ 240.8 ± 7.9 ⚥ Sex <0.001 0.17  
M   197.8 ± 48.1 ⚥ 202.5 ± 44.4   195.7 ± 54.5 ⚥ 200.6 ± 47.6 ⚥ 199.5 ± 8.9 ⚥ S x T 0.27 0.02  
PLA F 238.5 ± 74.8 
 
228.8 ± 45.6 
 
233.4 ± 68.7 
 
220.2 ± 73.0 
 
230.2 ± 13.8 
 
G x S 0.58 0.02  
 M 193.1 ± 65.9 
 
197.3 ± 45.1 
 
213.2 ± 48.1 
 
216.1 ± 47.7 
 
204.9 ± 15.9 
 
G x T x S 0.46 0.03  
WL F 270.1 ± 52.3 ⚥ 232.4 ± 79.2 
 
269.6 ± 55.1 ⚥ 252.6 ± 58.9 ⚥ 256.2 ± 13.3 ⚥     
 M 207.7 ± 45.7 ⚥ 207.6 ± 36.8 
 
191.2 ± 59.0 ⚥ 192.7 ± 52.2 ⚥ 199.8 ± 15.9 ⚥     
WL+C F 241.5 ± 69.8 
 
233.3 ± 69.1 
 
233.4 ± 51.7 ‡⚥ 236.0 ± 58.8 
 
236.1 ± 13.8 ⚥     
  M 193.6 ± 34.6   202.5 ± 52.6   184.9 ± 57.1 ⚥ 194.4 ± 44.9   193.9 ± 14.4 ⚥       
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Table 13 – Continued 
      Weeks      Mean      
Group 
  
0 
   
4 
   
8 
  
12 
 
(SEM) 
 
Effect p-Level 𝛈𝒑
𝟐 
 MPV PLA  10.0 ± 1.6 
 
9.7 ± 1.1 
 
9.9 ± 1.6 
 
9.8 ± 1.3 
 
9.8 ± 0.2 
 
Group 0.33 0.04 
(fL) WL  9.5 ± 1.0 
 
9.5 ± 0.7 
 
9.4 ± 0.7 
 
9.6 ± 0.8 
 
9.5 ± 0.2 
 
Time 0.96 0.00 
 WL+C  9.8 ± 1.1 
 
10.0 ± 1.1 
 
9.9 ± 1.1 
 
10.1 ± 1.2 
 
9.9 ± 0.2 
 
G x T 0.57 0.03  
Time    9.8 ± 1.3   9.8 ± 1.0   9.7 ± 1.2   9.8 ± 1.1                  
F  9.9 ± 1.3 
 
9.7 ± 1.0 
 
9.7 ± 1.0 
 
10.0 ± 1.2 
 
9.8 ± 0.2 
 
Sex 0.49 0.01  
M   9.6 ± 1.2   9.8 ± 1.0   9.7 ± 1.5   9.6 ± 1.0   9.7 ± 0.2   S x T 0.19 0.03  
PLA F 10.3 ± 1.6 
 
9.5 ± 1.0 † 9.9 ± 1.0 
 
10.0 ± 1.4 
 
9.9 ± 0.3 
 
G x S 0.42 0.03  
 M 9.7 ± 1.7 
 
9.9 ± 1.2 
 
10.0 ± 2.3 
 
9.5 ± 1.2 
 
9.8 ± 0.3 
 
G x T x S 0.55 0.03  
WL F 9.4 ± 1.1 
 
9.5 ± 0.7 
 
9.2 ± 0.7 ᶜ 9.6 ± 1.0 
 
9.4 ± 0.3 ᶜ     
 M 9.5 ± 0.8 
 
9.6 ± 0.8 
 
9.7 ± 0.7 
 
9.6 ± 0.4 
 
9.6 ± 0.3 
 
   
 
WL+C F 10.1 ± 1.0 
 
10.2 ± 1.1 
 
10.2 ± 1.1 ᵇ 10.4 ± 1.2 
 
10.2 ± 0.3 ᵇ     
  M 9.5 ± 1.2   9.8 ± 1.1   9.6 ± 1.2   9.7 ± 1.2   9.6 ± 0.3         
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.83), Time (p<0.01), Group x Time (p=0.90), Sex (p<0.01), Sex x Time (p<0.01), and 
Group x Sex (p=0.52), Group x Time x Sex (p=0.45) effects for whole blood variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), Sex (S), Group 
x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following superscripts: † = 
p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; b = p<0.05 
difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group means only 
(excluding Time and Sex data), on the above table. 
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Table 14: Resting Hemodynamics 
     Weeks  Mean       
  Group     0       4       8     12 (SEM) Effect p-Level 𝛈𝒑
𝟐 
Heart Rate PLA  62 ± 13 
 
62 ± 12 
 
63 ± 14 
 
61 ± 11 
 
62 ± 2 
 
Group 0.44 0.03 
(bpm) WL  64 ± 8 
 
63 ± 10 
 
66 ± 10 
 
63 ± 8 
 
64 ± 2 
 
Time 0.73 0.01 
 WL+C  67 ± 11 
 
66 ± 10 
 
63 ± 10 † 65 ± 10 
 
65 ± 2 
 
G x T 0.17 0.05  
Time    65 ± 11   64 ± 11   64 ± 12   63 ± 10                  
F  69 ± 9 ⚥ 67 ± 9 ⚥ 67 ± 12 ⚥ 68 ± 9 ⚥ 68 ± 1 ⚥ Sex <0.001 0.20  
M   60 ± 11 ⚥ 60 ± 11 ⚥ 60 ± 10 ⚥ 58 ± 9 ⚥ 59 ± 2 ⚥ S x T 0.53 0.01  
PLA F 68 ± 10 ⚥ 67 ± 10 ⚥ 67 ± 14 
 
66 ± 8 ⚥ 67 ± 2 ⚥ G x S 0.79 0.01  
 M 56 ± 14 ⚥ 57 ± 12 ⚥ 59 ± 14 
 
55 ± 11 ⚥ 57 ± 3 ⚥ G x T x S 0.17 0.05  
WL F 68 ± 8 
 
67 ± 10 
 
70 ± 10 ⚥ 65 ± 9 
 
67 ± 2 ⚥     
 M 60 ± 7 
 
59 ± 8 
 
61 ± 8 ⚥ 61 ± 8 
 
60 ± 3 ⚥     
WL+C F 71 ± 11 ⚥ 67 ± 10 
 
65 ± 11 † 71 ± 8 ‡⚥ 67 ± 2 
 
   
 
  M 63 ± 10 ⚥ 64 ± 10   60 ± 9   59 ± 9 ⚥ 62 ± 3         
Systolic Blood PLA  120 ± 11 
 
120 ± 11 
 
118 ± 10 
 
118 ± 11 
 
119 ± 2 
 
Group 0.15 0.06 
Pressure WL  117 ± 10 
 
115 ± 10 ᶜ 118 ± 11 
 
117 ± 12 
 
117 ± 2 ᶜ Time 0.67 0.01 
(mmHg) WL+C  123 ± 15 
 
124 ± 16 ᵇ 121 ± 13 
 
122 ± 13 
 
123 ± 2 ᵇ G x T 0.75 0.02  
Time    120 ± 12   120 ± 13   119 ± 11   119 ± 12                  
F  115 ± 8 ⚥ 116 ± 12 ⚥ 116 ± 10 ⚥ 116 ± 11 ⚥ 116 ± 2 ⚥ Sex <0.01 0.14  
M   126 ± 14 ⚥ 124 ± 13 ⚥ 122 ± 12 ⚥ 123 ± 12 †⚥ 123 ± 2 ⚥ S x T 0.24 0.02  
PLA F 116 ± 8 
 
116 ± 12 
 
114 ± 9 ⚥ 115 ± 11 
 
115 ± 3 ⚥ G x S 0.88 0.004  
 M 125 ± 12 
 
124 ± 8 
 
123 ± 8 ⚥ 122 ± 10 
 
123 ± 3 ⚥ G x T x S 0.80 0.02  
WL F 112 ± 7 ⚥ 113 ± 11 
 
117 ± 13 
 
114 ± 12 
 
114 ± 3 
 
   
 
 M 123 ± 11 ⚥ 118 ± 8 
 
119 ± 9 
 
120 ± 12 
 
120 ± 3 
 
   
 
WL+C F 117 ± 9 ⚥ 120 ± 13 
 
118 ± 9 
 
118 ± 10 
 
118 ± 3 ⚥     
  M 129 ± 18 ⚥ 128 ± 18   125 ± 15   126 ± 15   127 ± 3 ⚥       
Diastolic Blood PLA  78 ± 8 
 
77 ± 6 
 
79 ± 6 
 
77 ± 7 
 
78 ± 1 
 
Group 0.06 0.09 
Pressure WL  76 ± 5 
 
75 ± 6 ᶜ 76 ± 6 
 
75 ± 9 ᶜ 76 ± 1 ᶜ Time 0.65 0.01 
(mmHg) WL+C  80 ± 7 
 
81 ± 9 ᵇ 79 ± 6 
 
80 ± 6 ᵇ 80 ± 1 ᵇ G x T 0.40 0.03  
Time    78 ± 7   78 ± 8   78 ± 6   77 ± 7                  
F  77 ± 6 
 
77 ± 7 
 
78 ± 6 
 
77 ± 8 
 
77 ± 1 
 
Sex 0.78 0.001  
M   79 ± 8   78 ± 8   78 ± 6   77 ± 7   78 ± 1   S x T 0.76 0.01  
PLA F 78 ± 7 
 
77 ± 8 
 
77 ± 6 
 
77 ± 8 
 
77 ± 2 
 
G x S 0.88 0.004  
 M 78 ± 10 
 
77 ± 3 
 
81 ± 5 ᵇ 76 ± 7 ‡ 78 ± 2 
 
G x T x S 0.54 0.03  
WL F 76 ± 6 
 
76 ± 8 
 
77 ± 7 
 
75 ± 9 
 
76 ± 2 
 
   
 
 M 77 ± 4 
 
75 ± 5 ᶜ 75 ± 6 ᵃ 74 ± 8 
 
75 ± 2 
 
   
 
WL+C F 79 ± 7 
 
80 ± 7 
 
79 ± 4 
 
80 ± 6 
 
79 ± 2 
 
   
 
  M 81 ± 8   82 ± 12 ᵇ 78 ± 7   79 ± 5   80 ± 2      
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.24), Time (p=0.88), Group x Time (p=0.30), Sex (p<0.01), Sex x Time (p=0.52), and 
Group x Sex (p=0.99), Group x Time x Sex (p=0.65) effects for resting hemodynamic variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), Sex 
(S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; 
b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group 
means only (excluding Time and Sex data), on the above table. 
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Psychosocial Evaluation 
Questionnaires 
Hunger/Satiety. Overall Wilks' Lambda revealed effects of Sex (p<0.01) and Group x Time 
x Sex (p=0.06), with no Group (p=0.53), Time (p=0.34), Group x Time (p=0.20), Sex x 
Time (p=0.21), or Group x Sex (p=0.23) effects for hunger and satiety variables. 
Univariate analysis indicated sex (p≤0.05) interactions effects for amount of energy and 
diet quality, with no group, time, group x time, sex x time, or group x time x sex effects 
among any of the variables. 
Pairwise analysis showed overall sex differences in appetite (F 5.5±0.2; M 
6.4±0.2), satisfaction from food (F 6.4±0.2; M 7.3±0.2), amount of energy (F 5.8±0.2; M 
6.4±0.2), and diet quality (F 5.4±0.2; M 6.0±0.2) where men had overall greater values 
(Table 15). Moreover, compared to baseline, WL had a greater reported appetite (WL 
5.3±2.2; Wk12 6.2±1.6), satisfaction from food (WL 6.2±1.3; Wk8 7.0±1.5), feeling of 
fullness (WL 6.2±1.7; Wk8 7.1±1.2; Wk12 7.1±1.6), and females were less hungry (WL 
5.5±1.7; Wk12 4.5±1.9). WL+C females also reported being less hungry than baseline 
(WL+C 5.0±1.0; Wk12 4.5±1.7). Subsequently, females in the supplement groups had 
significantly lower reported hunger than PLA females, at week 12 (PLA 6.1±1.2; WL 
4.5±1.9; WL+C 4.5±1.7). Lastly, WL+C saw a decrease from baseline for satisfaction 
from food at weeks 4 and 8, followed by an increase at week 12 (WL+C 7.1±1.5; Wk4 
6.3±1.8; Wk8 6.1±1.4; Wk12 6.8±1.4). These data fail to reject H06: Reported hunger and 
satiety will significantly decrease and increase, respectively, in treatment groups 
compared to baseline and/or placebo. 
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Sleep Quality. Overall Wilks' Lambda revealed Group (p<0.05) but, no Time (p=0.09), 
Group x Time (p=0.39), Sex (p=0.20), Sex x Time (p=0.53), Group x Sex (p=0.66), or 
Group x Time x Sex (p=0.82) effects for sleep quality questionnaire variables. Univariate 
analysis indicated group (p=0.03) effects for hours of sleep only, with no time, group x 
time, sex, sex x time, or group x time x sex effects among the sleep quality variables. 
Pairwise analysis indicated WL fell asleep faster compared to baseline at weeks 8 
and 12 (WL 18.85±18.02; Wk8 13.67±13.70; Wk12 13.83±10.65 min). WL+C went to 
sleep later and took longer than PLA at week 4 (PLA 11.32±7.78; WL+C 29.02±47.52 
min) and week 12 (PLA 10.93±7.40; WL+C 18.22±13.48 min). Tables 16-16.1 shows 
sleep quality and Chi square analysis of values observed by week. This analysis indicated 
a difference between groups in; bathroom use at night at week 12 (p=0.03 [PLA 41; WL 
13; WL+C 48 %]); nighttime coughing or snoring at week 4 (p=0.02 [PLA 0; WL 22; 
WL+C 4 %]); feeling too hot while sleeping at week 8 (p=0.02 [PLA 9; WL 13; WL+C 
39 %]); and unspecified other reasons at baseline (p=0.04 [PLA 23; WL 9; WL+C 0%]). 
No other significant differences were observed for sleep quality values among treatments. 
These data reject H07: Reported sleep quality in treatment groups will not significantly 
differ from baseline and/or placebo. 
Side Effects. Tables 17-18 shows Chi square analysis of symptom frequency and 
severity values observed by week. This analysis had no significant differences among 
treatments. These data fail to reject H08: Reported side effects in treatment groups will not 
significantly differ from baseline and/or placebo. 
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Table 15: Hunger and Satiety Questionnaire 
     Weeks Mean 
       
Variable Group     0       4       8     12   (SEM) 
  Effect p-Level 𝛈𝒑
𝟐 
Appetite PLA  6.2 ± 1.3 
 
6.0 ± 1.2 
 
6.0 ± 1.6 
 
6.3 ± 1.4 
 
6.2 ± 0.2 
 
Group 0.44 0.03 
WL  5.3 ± 2.2 
 
5.5 ± 1.6 
 
5.9 ± 1.4 
 
6.2 ± 1.6 † 5.8 ± 0.2 
 
Time 0.32 0.02 
WL+C  6.0 ± 1.5 
 
5.6 ± 1.6 
 
5.9 ± 1.3 ‡ 5.7 ± 1.4 
 
5.8 ± 0.2 
 
G x T 0.37 0.03 
Time    5.8 ± 1.7   5.7 ± 1.5   5.9 ± 1.5   6.1 ± 1.5                  
F  5.5 ± 1.7 
 
5.4 ± 1.4 ⚥ 5.6 ± 1.5 ⚥ 5.5 ± 1.5 ⚥ 5.5 ± 0.2 ⚥ Sex 0.001 0.16  
M   6.2 ± 1.8   6.1 ± 1.4 ⚥ 6.4 ± 1.3 ⚥ 6.8 ± 1.2 ⚥ 6.4 ± 0.2 ⚥ S x T 0.40 0.02  
PLA F 6.3 ± 1.4 
 
5.6 ± 1.2 
 
5.6 ± 1.7 
 
5.8 ± 1.4 ⚥ 5.8 ± 0.3 
 
G x S 0.65 0.01  
 M 6.2 ± 1.4 
 
6.6 ± 1.0 
 
6.5 ± 1.4 
 
6.9 ± 1.2 ⚥ 6.6 ± 0.3 
 
G x T x S 0.13 0.05  
WL F 5.0 ± 2.2 
 
5.0 ± 1.8 ⚥ 5.2 ± 1.3 ⚥ 5.7 ± 1.7 ⚥ 5.2 ± 0.3 ⚥     
 M 5.8 ± 2.3 
 
6.2 ± 1.0 ⚥ 6.9 ± 1.0 †⚥ 6.9 ± 1.2 †⚥ 6.4 ± 0.3 ⚥     
WL+C F 5.4 ± 1.2 
 
5.5 ± 1.3 
 
6.0 ± 1.5 
 
5.0 ± 1.3 ‡⚥ 5.5 ± 0.3 
 
   
 
  M 6.5 ± 1.6   5.7 ± 1.9   5.8 ± 1.2   6.5 ± 1.1 ‡⚥ 6.1 ± 0.3         
Hunger PLA  5.5 ± 1.7 
 
5.6 ± 1.7 
 
5.6 ± 2.0 
 
6.0 ± 1.3 
 
5.7 ± 0.3 
 
Group 0.66 0.01 
WL  5.6 ± 1.6 
 
5.1 ± 1.7 
 
5.3 ± 2.0 
 
5.5 ± 2.1 
 
5.4 ± 0.3 
 
Time 0.31 0.02 
WL+C  5.6 ± 1.5 
 
5.0 ± 1.6 
 
5.8 ± 1.3 
 
5.1 ± 1.6 
 
5.4 ± 0.2 
 
G x T 0.41 0.03 
Time    5.6 ± 1.6   5.2 ± 1.7   5.6 ± 1.8   5.5 ± 1.7                  
F  5.4 ± 1.3 
 
5.1 ± 1.6 
 
5.5 ± 1.7 
 
5.0 ± 1.8 ⚥ 5.3 ± 0.2 
 
Sex 0.09 0.05  
M   5.8 ± 1.9   5.4 ± 1.7   5.7 ± 1.9   6.1 ± 1.5 ⚥ 5.8 ± 0.2   S x T 0.18 0.03  
PLA F 5.7 ± 1.1 
 
5.6 ± 1.5 
 
5.8 ± 1.6 
 
6.1 ± 1.2 ᵇᶜ 5.8 ± 0.3 
 
G x S 0.30 0.04  
 M 5.4 ± 2.3 
 
5.6 ± 1.9 
 
5.5 ± 2.5 
 
6.0 ± 1.3 
 
5.6 ± 0.4 
 
G x T x S 0.53 0.03  
WL F 5.5 ± 1.7 
 
4.8 ± 1.9 
 
5.1 ± 2.1 
 
4.5 ± 1.9 ᵃ⚥ 5.0 ± 0.3 
 
   
 
 M 5.8 ± 1.6 
 
5.5 ± 1.3 
 
5.6 ± 2.0 
 
6.7 ± 1.9 ‡⚥ 5.9 ± 0.4 
 
   
 
WL+C F 5.0 ± 1.0 
 
4.8 ± 1.2 
 
5.8 ± 1.5 
 
4.5 ± 1.7 ᵃ‡⚥ 5.0 ± 0.3 
 
   
 
  M 6.2 ± 1.7   5.1 ± 2.1   5.9 ± 1.1   5.8 ± 1.2 ⚥ 5.8 ± 0.4         
Satisfaction from Food PLA  7.3 ± 1.0 ᵇ 7.3 ± 1.1 ᵇᶜ 7.1 ± 1.4 ᶜ 7.1 ± 1.3 
 
7.2 ± 0.2 ᵇᶜ Group 0.07 0.08 
WL  6.2 ± 1.3 ᵃᶜ 6.3 ± 1.4 ᵃ 7.0 ± 1.5 ᶜ†‡ 6.8 ± 1.6 
 
6.6 ± 0.2 ᵃ Time 0.33 0.02 
WL+C  7.1 ± 1.5 ᵇ 6.3 ± 1.8 ᵃ† 6.1 ± 1.4 ᵃᵇ† 6.8 ± 1.4 ‡ 6.6 ± 0.2 ᵃ G x T 0.004 0.10 
Time    6.9 ± 1.4   6.6 ± 1.5   6.8 ± 1.5   6.9 ± 1.4                  
F  6.4 ± 1.3 ⚥ 6.5 ± 1.4 
 
6.2 ± 1.7 ⚥ 6.5 ± 1.3 ⚥ 6.4 ± 0.2 ⚥ Sex <0.001 0.17  
M   7.4 ± 1.3 ⚥ 6.8 ± 1.6 † 7.4 ± 0.9 ‡⚥ 7.4 ± 1.4 ⚥ 7.3 ± 0.2 ⚥ S x T 0.15 0.03  
PLA F 7.2 ± 0.7 ᵇ 7.1 ± 1.0 
 
6.8 ± 1.7 ᶜ 6.6 ± 1.2 
 
6.9 ± 0.3 ᶜ G x S 0.69 0.01  
 M 7.6 ± 1.3 
 
7.5 ± 1.2 
 
7.6 ± 0.7 
 
7.7 ± 1.3 
 
7.6 ± 0.3 
 
G x T x S 0.67 0.02  
WL F 5.7 ± 1.3 ᵃ⚥ 6.2 ± 1.3 
 
6.6 ± 1.7 ᶜ† 6.6 ± 1.3 † 6.3 ± 0.3 
 
   
 
 M 6.9 ± 1.2 ⚥ 6.5 ± 1.4 
 
7.6 ± 1.1 ‡ 7.1 ± 2.0 
 
7.0 ± 0.3 
 
   
 
WL+C F 6.5 ± 1.5 ⚥ 6.2 ± 1.8 
 
5.3 ± 1.3 ᵃᵇ†‡⚥ 6.2 ± 1.5 ‡⚥ 6.0 ± 0.3 ᵃ⚥     
  M 7.8 ± 1.2 ⚥ 6.5 ± 1.9 † 7.0 ± 1.0 ⚥ 7.5 ± 1.0 ⚥ 7.2 ± 0.3 ⚥       
Feeling of Fullness PLA  6.8 ± 1.4 
 
7.2 ± 1.5 
 
7.1 ± 1.1 
 
7.0 ± 1.4 
 
7.0 ± 0.2 
 
Group 0.58 0.02 
WL  6.2 ± 1.7 
 
6.6 ± 1.6 
 
7.1 ± 1.2 † 7.1 ± 1.6 † 6.7 ± 0.2 
 
Time 0.49 0.01 
WL+C  6.9 ± 1.9 
 
6.8 ± 1.6 
 
6.4 ± 1.8 
 
6.7 ± 1.3 
 
6.7 ± 0.2 
 
G x T 0.16 0.05 
Time    6.6 ± 1.7   6.8 ± 1.6   6.9 ± 1.4   6.9 ± 1.4                  
F  6.4 ± 1.6 
 
6.7 ± 1.7 
 
6.7 ± 1.5 
 
6.8 ± 1.3 
 
6.6 ± 0.2 
 
Sex 0.20 0.03  
M   6.8 ± 1.8   7.0 ± 1.4   7.1 ± 1.2   7.0 ± 1.5   7.0 ± 0.2   S x T 0.99 <0.001  
PLA F 7.0 ± 1.0 
 
7.6 ± 1.3 ᵇᶜ 6.9 ± 0.9 
 
6.9 ± 1.1 
 
7.1 ± 0.3 ᶜ G x S 0.16 0.06  
 M 6.5 ± 1.8 
 
6.8 ± 1.6 
 
7.3 ± 1.3 
 
7.0 ± 1.8 
 
6.9 ± 0.3 
 
G x T x S 0.46 0.03  
WL F 6.1 ± 1.5 
 
6.2 ± 1.8 ᵃ 7.0 ± 1.4 
 
7.2 ± 1.6 † 6.6 ± 0.3 
 
   
 
 M 6.3 ± 2.0 
 
7.0 ± 1.3 
 
7.2 ± 1.0 
 
7.0 ± 1.7 
 
6.9 ± 0.3 
 
   
 
WL+C F 6.3 ± 2.1 
 
6.3 ± 1.8 ᵃ 6.1 ± 2.0 
 
6.2 ± 1.1 
 
6.2 ± 0.3 ᵃ⚥     
  M 7.5 ± 1.4   7.3 ± 1.3   6.7 ± 1.4   7.2 ± 1.3   7.2 ± 0.3 ⚥       
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Table 15 – Continued 
     Weeks Mean 
       
Variable Group     0       4       8     12   (SEM) 
  Effect p-Level 𝛈𝒑
𝟐 
Amount of Energy PLA  5.8 ± 1.5 
 
6.4 ± 1.7 
 
6.1 ± 1.5 
 
5.7 ± 1.6 
 
6.0 ± 0.3 
 
Group 0.66 0.01 
WL  6.1 ± 1.5 
 
6.2 ± 1.3 
 
6.6 ± 1.4 
 
6.3 ± 1.7 
 
6.3 ± 0.3 
 
Time 0.61 0.01 
WL+C  6.0 ± 1.6 
 
5.9 ± 2.0 
 
5.8 ± 1.7 
 
6.1 ± 2.0 
 
6.0 ± 0.2 
 
G x T 0.40 0.03 
Time    5.9 ± 1.5   6.1 ± 1.7   6.2 ± 1.5   6.1 ± 1.7                  
F  5.6 ± 1.6 
 
5.9 ± 1.6 
 
6.2 ± 1.5 
 
5.6 ± 1.8 ‡⚥ 5.8 ± 0.2 ⚥ Sex 0.05 0.06  
M   6.3 ± 1.4   6.4 ± 1.8   6.2 ± 1.6   6.6 ± 1.5 ⚥ 6.4 ± 0.2 ⚥ S x T 0.17 0.03  
PLA F 5.3 ± 1.4 ᵇ⚥ 5.9 ± 1.7 
 
6.1 ± 1.3 
 
5.3 ± 1.4 
 
5.6 ± 0.3 
 
G x S 0.08 0.08  
 M 6.5 ± 1.4 ⚥ 6.9 ± 1.7 
 
6.2 ± 1.8 
 
6.2 ± 1.8 
 
6.4 ± 0.4 
 
G x T x S 0.22 0.04  
WL F 6.5 ± 1.6 ᵃᶜ 6.3 ± 1.3 
 
6.7 ± 1.5 
 
6.2 ± 1.9 
 
6.4 ± 0.3 ᶜ     
 M 5.5 ± 1.2 ᶜ 6.1 ± 1.4 
 
6.5 ± 1.4 
 
6.5 ± 1.4 
 
6.1 ± 0.4 
 
   
 
WL+C F 5.1 ± 1.4 ᵇ⚥ 5.5 ± 1.7 
 
5.7 ± 1.6 
 
5.2 ± 2.0 ⚥ 5.4 ± 0.3 ᵇ⚥     
  M 6.9 ± 1.4 ᵇ⚥ 6.3 ± 2.2   6.0 ± 1.9   7.2 ± 1.3 ‡⚥ 6.6 ± 0.4 ⚥       
Overall Quality of Diet PLA  5.5 ± 1.3 
 
5.8 ± 1.7 
 
6.2 ± 1.6 
 
6.2 ± 1.5 
 
6.0 ± 0.3 
 
Group 0.37 0.03 
WL  5.4 ± 2.0 
 
5.4 ± 1.6 
 
5.7 ± 1.7 
 
5.8 ± 2.0 
 
5.6 ± 0.3 
 
Time 0.22 0.02 
WL+C  5.5 ± 2.0 
 
5.4 ± 1.6 
 
5.3 ± 1.7 
 
5.7 ± 1.6 
 
5.5 ± 0.3 
 
G x T 0.79 0.02 
Time    5.5 ± 1.8   5.5 ± 1.6   5.7 ± 1.7   5.9 ± 1.7                  
F  5.1 ± 1.6 ⚥ 5.4 ± 1.4 
 
5.4 ± 1.6 
 
5.7 ± 1.5 † 5.4 ± 0.2 ⚥ Sex 0.05 0.06  
M   6.0 ± 1.9 ⚥ 5.8 ± 1.9   6.1 ± 1.7   6.1 ± 1.9   6.0 ± 0.2 ⚥ S x T 0.62 0.01  
PLA F 5.0 ± 1.0 
 
4.9 ± 1.4 ⚥ 5.5 ± 1.4 ⚥ 5.8 ± 1.5 
 
5.3 ± 0.4 ⚥ G x S 0.07 0.08  
 M 6.2 ± 1.5 
 
6.9 ± 1.4 ᵇᶜ⚥ 7.0 ± 1.3 ᵇ⚥ 6.7 ± 1.4 
 
6.7 ± 0.4 ᵇ⚥ G x T x S 0.28 0.04  
WL F 5.1 ± 1.7 
 
5.8 ± 1.3 
 
5.9 ± 1.8 
 
6.1 ± 1.7 † 5.7 ± 0.4 
 
   
 
 M 5.8 ± 2.3 
 
4.9 ± 1.7 ᵃ 5.4 ± 1.7 ᵃ 5.5 ± 2.3 
 
5.4 ± 0.4 ᵃ     
WL+C F 5.1 ± 2.0 
 
5.3 ± 1.2 
 
4.8 ± 1.4 
 
5.3 ± 1.3 
 
5.7 ± 0.4 
 
   
 
  M 6.0 ± 2.0   5.5 ± 2.0 ᵃ 5.9 ± 1.9   6.2 ± 1.8   5.9 ± 0.4      
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p=0.53), Time (p=0.34), Group x Time (p=0.20), Sex (p<0.01), Sex x Time (p=0.21), and 
Group x Sex (p=0.23), Group x Time x Sex (p=0.06) effects for hunger and satiety questionnaire variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time 
(T), Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; 
b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group 
means only (excluding Time and Sex data), on the above table. 
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Table 16: Sleep Quality Index 
    
 
Weeks Mean     
 
Variable Group     0      4      8    12   (SEM) Effect p-Level 𝛈𝒑
𝟐 
Bed Time PLA 
 
22:51 ± 00:54 
 
22:36 ± 00:52 ᶜ  22:45 ± 00:53 
 
22:37 ± 00:41 ᶜ  22:44 ± 00:11 ᶜ  Group 0.09 0.07 
(00:00 - hr:min) WL 
 
23:21 ± 01:36 
 
23:01 ± 01:05 
 
23:13 ± 01:10 
 
23:11 ± 01:14 
 
23:13 ± 00:11 
 
Time 0.46 0.01  
WL+C 
 
23:14 ± 01:09 
 
23:14 ± 01:03 ᵃ  23:06 ± 01:14 
 
23:33 ± 01:08 ᵃ ‡ 23:17 ± 00:11 ᵃ  G x T 0.48 0.03  
Time    23:09 ± 01:15   22:58 ± 01:01   23:01 ± 01:07   23:07 ± 01:06                 
 
F 
 
23:02 ± 01:21 
 
22:41 ± 00:55 ⚥ 22:42 ± 01:03 ⚥ 22:53 ± 01:06 ⚥ 22:49 ± 00:08 ⚥ Sex 0.02 0.08  
M   23:16 ± 01:08   23:17 ± 01:04 ⚥ 23:24 ± 01:05 ⚥ 23:24 ± 01:04 ⚥ 23:20 ± 00:09 ⚥ S x T 0.31 0.02  
PLA F 22:28 ± 00:44 
 
22:20 ± 00:43 
 
22:20 ± 00:46 ⚥ 22:20 ± 00:39 ᶜ  22:22 ± 00:15 ᶜ  G x S 0.71 0.01   
M 23:18 ± 00:55 
 
22:57 ± 00:57 
 
23:15 ± 00:47 ⚥ 22:58 ± 00:34 
 
23:07 ± 00:16 
 
G x T x S 0.55 0.03  
WL F 23:20 ± 01:54 
 
22:45 ± 01:03 † 23:01 ± 01:18 
 
22:50 ± 01:06 
 
22:59 ± 00:14 
    
  
M 23:22 ± 01:13 
 
23:24 ± 01:06 
 
23:32 ± 00:58 
 
23:37 ± 01:18 
 
23:28 ± 00:16 
    
 
WL+C F 23:17 ± 01:00 
 
23:00 ± 00:53 
 
22:45 ± 00:57 
 
23:30 ± 01:12 ᵃ ‡ 23:08 ± 00:15 ᵃ  
   
 
  M 23:10 ± 01:20   23:30 ± 01:10   23:29 ± 01:26   23:36 ± 01:08   23:26 ± 00:16         
Time to Fall PLA 
 
13.86 ± 12.24 
 
11.32 ± 7.78 ᶜ 12.93 ± 8.28 
 
10.93 ± 7.40 ᶜ 12.45 ± 2.99 ᶜ Group 0.14 0.06 
Asleep WL 
 
18.85 ± 18.02 
 
16.57 ± 12.48 
 
13.67 ± 13.70 † 13.83 ± 10.65 † 15.76 ± 2.94 
 
Time 0.23 0.02 
(minutes) WL+C 
 
17.35 ± 12.80 
 
29.02 ± 47.52 ᵃ † 19.52 ± 15.10 
 
18.22 ± 13.48 ᵃ  20.86 ± 2.92 ᵃ G x T 0.22 0.05  
Time    16.73 ± 14.55   19.08 ± 29.45   15.41 ± 12.92   14.38 ± 11.09                 
 
F 
 
15.43 ± 13.17 
 
20.32 ± 38.20 
 
16.62 ± 13.40 
 
14.81 ± 12.17 
 
16.83 ± 2.30 
 
Sex 0.78 0.001  
M   18.27 ± 16.13   17.60 ± 13.51   13.97 ± 12.37   13.85 ± 9.82 † 15.88 ± 2.51   S x T 0.50 0.01 
 
PLA F 10.83 ± 6.69 
 
9.25 ± 5.04 ᶜ 11.79 ± 7.64 
 
9.58 ± 7.89 ᶜ 10.36 ± 4.03 ᶜ G x S 0.36 0.03   
M 17.50 ± 16.37 
 
13.80 ± 9.89 
 
14.30 ± 9.21 
 
12.55 ± 6.79 
 
14.54 ± 4.42 
 
G x T x S 0.42 0.03  
WL F 17.00 ± 16.07 
 
14.69 ± 10.59 
 
17.00 ± 16.12 
 
13.31 ± 8.72 
 
15.50 ± 3.88 
    
  
M 21.25 ± 20.92 
 
19.00 ± 14.82 
 
9.35 ± 8.71 † 14.50 ± 13.22 
 
16.03 ± 4.42 
    
 
WL+C F 18.33 ± 14.35 
 
37.50 ± 64.30 ᵃ † 21.04 ± 14.12 ‡ 21.67 ± 16.00 ᵃ  24.64 ± 4.03 ᵃ 
   
 
  M 16.27 ± 11.47   19.77 ± 15.51   17.86 ± 16.62   14.45 ± 9.38   17.09 ± 4.21         
Waking Time PLA 
 
06:53 ± 00:46 
 
06:49 ± 00:55 
 
06:37 ± 00:55 
 
07:00 ± 01:11 
 
06:30 ± 00:09 
 
Group 0.26 0.04 
(00:00 - hr:min) WL 
 
06:45 ± 01:07 
 
06:21 ± 01:01 † 06:25 ± 01:02 
 
06:24 ± 01:01 
 
06:30 ± 00:09 
 
Time 0.24 0.02  
WL+C 
 
06:28 ± 00:43 
 
06:30 ± 00:50 
 
06:27 ± 00:39 
 
06:30 ± 00:52 ‡ 06:50 ± 00:09 
 
G x T 0.43 0.03  
Time    06:42 ± 00:53   06:33 ± 00:56   06:30 ± 00:52   06:38 ± 01:03                 
 
F 
 
06:34 ± 00:51 
 
06:27 ± 01:01 
 
06:23 ± 01:00 
 
06:21 ± 00:57 ⚥ 06:27 ± 00:07 
 
Sex 0.08 0.05  
M   06:51 ± 00:55   06:41 ± 00:50   06:38 ± 00:42   06:58 ± 01:05 ‡⚥ 06:47 ± 00:08   S x T 0.26 0.02  
PLA F 06:56 ± 00:42 ᶜ  07:02 ± 00:58 ᶜ  06:40 ± 01:08 
 
06:47 ± 01:09 
 
06:11 ± 00:13 ᶜ ⚥ G x S 0.31 0.04   
M 06:50 ± 00:52 
 
06:35 ± 00:51 
 
06:35 ± 00:42 
 
07:13 ± 01:15 
 
06:50 ± 00:14 ⚥ G x T x S 0.68 0.02  
WL F 06:36 ± 01:06 
 
06:10 ± 01:01 ᶜ † 06:20 ± 01:11 
 
06:06 ± 00:49 
 
06:18 ± 00:12 
    
  
M 06:55 ± 01:10 
 
06:35 ± 01:01 
 
06:35 ± 00:49 
 
06:47 ± 01:10 
 
06:42 ± 00:14 
    
 
WL+C F 06:10 ± 00:31 ᵃ  06:10 ± 00:52 ᵃ ᵇ 06:11 ± 00:34 
 
06:12 ± 00:48 
 
06:51 ± 00:13 ᵃ  
   
 
  M 06:49 ± 00:47   06:53 ± 00:39   06:46 ± 00:37   06:52 ± 00:50 ‡ 06:48 ± 00:13         
Hours Sleeping PLA 
 
7.09 ± 1.35 
 
6.80 ± 0.97 
 
6.95 ± 0.75 ᵇ 7.09 ± 0.87 ᵇ 6.98 ± 0.17 ᵇ Group 0.03 0.10 
Nightly WL 
 
6.48 ± 1.20 
 
6.47 ± 0.82 
 
6.37 ± 0.87 ᵃ 6.28 ± 1.19 ᵃ 6.38 ± 0.16 ᵃ Time 0.14 0.03 
(hours) WL+C 
 
6.87 ± 1.02 
 
6.26 ± 1.00 † 6.48 ± 1.07 
 
6.54 ± 1.16 
 
6.53 ± 0.16 
 
G x T 0.61 0.02  
Time    6.81 ± 1.21   6.50 ± 0.94 † 6.60 ± 0.93   6.63 ± 1.12                  
F 
 
6.78 ± 1.10 
 
6.61 ± 0.96 
 
6.75 ± 0.90 
 
6.69 ± 1.13 
 
6.71 ± 0.13 
 
Sex 0.39 0.01  
M   6.84 ± 1.34   6.37 ± 0.92 † 6.41 ± 0.95 † 6.56 ± 1.12   6.55 ± 0.14   S x T 0.54 0.01  
PLA F 7.00 ± 1.03 
 
6.75 ± 1.16 
 
7.02 ± 0.79 
 
7.13 ± 0.96 
 
6.97 ± 0.23 
 
G x S 0.78 0.008   
M 7.20 ± 1.72 
 
6.85 ± 0.75 
 
6.88 ± 0.74 
 
7.05 ± 0.80 ᵇ 6.99 ± 0.25 ᵇ G x T x S 0.66 0.02  
WL F 6.42 ± 1.34 
 
6.63 ± 0.93 
 
6.54 ± 0.95 
 
6.54 ± 1.14 
 
6.53 ± 0.22 
    
  
M 6.55 ± 1.07 
 
6.25 ± 0.63 
 
6.15 ± 0.75 
 
5.95 ± 1.21 ᵃ 6.23 ± 0.25 ᵃ 
   
 
WL+C F 6.96 ± 0.84 
 
6.46 ± 0.84 
 
6.71 ± 0.96 
 
6.42 ± 1.24 
 
6.64 ± 0.23 
    
    M 6.77 ± 1.23   6.05 ± 1.15 † 6.23 ± 1.17   6.68 ± 1.10   6.43 ± 0.24         
Data are expressed as means ± standard deviations for the placebo (PLA), weight loss formula (WL), and weight loss formula with caffeine (WL+C); M=male, F=female; Partial 
ETA2 (η𝑝
2). General Linear Model analysis revealed overall Wilks' Lambda Group (p<0.05), Time (p=0.09), Group x Time (p=0.39), Sex (p=0.20), Sex x Time (p=0.53), and 
Group x Sex (p=0.66), Group x Time x Sex (p=0.82) effects for sleep quality questionnaire variables. Greenhouse-Geisser univariate p-levels are listed for Group (G), Time (T), 
Sex (S), Group x Time (G x T), Sex x Time (S x T), Group x Sex (G x S), Group x Time x Sex (G x T x S) interaction effects. Pairwise comparison is indicated by the following 
superscripts: † = p<0.05 difference from baseline value; ‡ = p<0.05 difference from previous time point; ⚥ = p<0.05 difference between Sexes; a = p<0.05 difference from PLA; 
b = p<0.05 difference from WL; c = p<0.05 difference from WL+C. LSD post hoc analysis was used to show group differences, indicated by subscripts a, b, and c, for group 
means only (excluding Time and Sex data), on the above table. 
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Table 16.1 – Sleep Quality Index Continued (Frequency data) 
    0  
 
 4  
 
 8  
 
12    
Variable   Group N   %   N   %   N   %   N   % 
  χ2 
Cannot Sleep within 30 min? PLA 2 
 
9% 
 
0 
 
0% 
 
1 
 
5% 
 
1 
 
5% 
 
Week 0 0.27 
WL 6 
 
26% 
 
3 
 
13% 
 
4 
 
17% 
 
2 
 
9% 
 
Week 4 0.21 
  WL+C 3 
 
13% 
 
3 
 
13% 
 
2 
 
9% 
 
4 
 
17% 
 
Week 8 0.35 
Time  11   16%   6   9%   7   10%   7   10% 
  Week 12 0.35 
Wake Up in the Middle of Night? PLA 7 
 
32% 
 
8 
 
36% 
 
6 
 
27% 
 
7 
 
32% 
 
Week 0 0.87 
WL 8 
 
35% 
 
13 
 
57% 
 
10 
 
43% 
 
7 
 
30% 
 
Week 4 0.33 
  WL+C 9 
 
39% 
 
9 
 
39% 
 
12 
 
52% 
 
11 
 
48% 
 
Week 8 0.23 
Time  24   35%   30   44%   28   41%   25   37% 
  Week 12 0.40 
Have to Get up to Use Bathroom? PLA 8 
 
36% 
 
8 
 
36% 
 
5 
 
23% 
 
9 
 
41% 
 
Week 0 0.56 
WL 10 
 
43% 
 
8 
 
35% 
 
6 
 
26% 
 
3 
 
13% 
 
Week 4 0.95 
  WL+C 12 
 
52% 
 
9 
 
39% 
 
11 
 
48% 
 
11 
 
48% 
 
Week 8 0.15 
Time  30   44%   25   37%   22   32%   23   34% 
  Week 12 0.03 
Cannot Breathe Comfortably? PLA 0 
 
0% 
 
1 
 
5% 
 
0 
 
0% 
 
1 
 
5% 
 
Week 0 0.37 
WL 1 
 
4% 
 
1 
 
4% 
 
1 
 
4% 
 
0 
 
0% 
 
Week 4 0.59 
  WL+C 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
Week 8 0.37 
Time  1   1%   2   3%   1   1%   1   1% 
  Week 12 0.35 
Cough or Snore Badly? 
  
PLA 2 
 
9% 
 
0 
 
0% 
 
0 
 
0% 
 
1 
 
5% 
 
Week 0 0.74 
WL 1 
 
4% 
 
5 
 
22% 
 
1 
 
4% 
 
0 
 
0% 
 
Week 4 0.02 
  WL+C 1 
 
4% 
 
1 
 
4% 
 
0 
 
0% 
 
1 
 
4% 
 
Week 8 0.37 
Time  4   6%   6   9%   1   1%   2   3% 
  Week 12 0.59 
Feel Too Cold? 
  
PLA 1 
 
5% 
 
0 
 
0% 
 
2 
 
9% 
 
2 
 
9% 
 
Week 0 0.35 
WL 2 
 
9% 
 
1 
 
4% 
 
2 
 
9% 
 
3 
 
13% 
 
Week 4 0.07 
  WL+C 4 
 
17% 
 
4 
 
17% 
 
3 
 
13% 
 
3 
 
13% 
 
Week 8 0.87 
Time  7   10%   5   7%   7   10%   8   12% 
  Week 12 0.89 
Feel Too Hot? 
  
PLA 1 
 
5% 
 
5 
 
23% 
 
2 
 
9% 
 
4 
 
18% 
 
Week 0 0.14 
WL 4 
 
17% 
 
3 
 
13% 
 
3 
 
13% 
 
6 
 
26% 
 
Week 4 0.36 
  WL+C 6 
 
26% 
 
7 
 
30% 
 
9 
 
39% 
 
5 
 
22% 
 
Week 8 0.02 
Time  11   16%   15   22%   14   21%   15   22% 
  Week 12 0.81 
Had Bad Dreams? 
  
PLA 1 
 
5% 
 
1 
 
5% 
 
3 
 
14% 
 
1 
 
5% 
 
Week 0 0.59 
WL 1 
 
4% 
 
2 
 
9% 
 
2 
 
9% 
 
1 
 
4% 
 
Week 4 0.78 
  WL+C 0 
 
0% 
 
1 
 
4% 
 
2 
 
9% 
 
2 
 
9% 
 
Week 8 0.82 
Time  2   3%   4   6%   7   10%   4   6% 
  Week 12 0.78 
Have Pain? 
  
PLA 2 
 
9% 
 
1 
 
5% 
 
1 
 
5% 
 
1 
 
5% 
 
Week 0 0.87 
WL 2 
 
9% 
 
1 
 
4% 
 
4 
 
17% 
 
2 
 
9% 
 
Week 4 0.44 
  WL+C 3 
 
13% 
 
3 
 
13% 
 
1 
 
4% 
 
1 
 
4% 
 
Week 8 0.20 
Time  7   10%   5   7%   6   9%   4   6% 
  Week 12 0.78 
Other Reasons? 
  
PLA 5 
 
23% 
 
3 
 
14% 
 
4 
 
18% 
 
5 
 
23% 
 
Week 0 0.04 
WL 2 
 
9% 
 
3 
 
13% 
 
2 
 
9% 
 
1 
 
4% 
 
Week 4 0.85 
  WL+C 0 
 
0% 
 
2 
 
9% 
 
1 
 
4% 
 
1 
 
4% 
 
Week 8 0.30 
Time  7   10%   8   12%   7   10%   7   10% 
  Week 12 0.07 
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Table 16.1 – Continued 
    0  
 
 4  
 
 8  
 
12    
Variable   Group N   %   N   %   N   %   N   %   χ2 
Quality of Sleep 
Rating?  
Very PLA 5 
 
23% 
 
6 
 
27% 
 
7 
 
32% 
 
6 
 
27% 
 
Week 0 0.39 
Good WL 6 
 
26% 
 
3 
 
13% 
 
7 
 
30% 
 
4 
 
17% 
 
Week 4 0.35  
WL+C 2 
 
9% 
 
1 
 
4% 
 
1 
 
4% 
 
2 
 
9% 
 
Week 8 0.16 
  Time  13   19%   10   15%   15   22%   12   18%   Week 12 0.22 
  Fairly PLA 13 
 
59% 
 
15 
 
68% 
 
14 
 
64% 
 
13 
 
59% 
 
  
  Good WL 15 
 
65% 
 
18 
 
78% 
 
14 
 
61% 
 
17 
 
74% 
 
  
  
 
WL+C 19 
 
83% 
 
19 
 
83% 
 
20 
 
87% 
 
15 
 
65% 
 
  
    Time  47   69%   52   76%   48   71%   45   66%     
  Fairly PLA 4 
 
18% 
 
1 
 
5% 
 
1 
 
5% 
 
3 
 
14% 
 
  
 Bad WL 2 
 
9% 
 
2 
 
9% 
 
2 
 
9% 
 
1 
 
4% 
 
  
 
 
WL+C 2 
 
9% 
 
2 
 
9% 
 
2 
 
9% 
 
6 
 
26% 
 
  
   Time  8   12%   5   7%   5   7%   10   15% 
    
  Very PLA 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
  
 Bad WL 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
1 
 
4% 
 
  
 
 
WL+C 0 
 
0% 
 
1 
 
4% 
 
0 
 
0% 
 
0 
 
0% 
   
   Time  0   0%   1   1%   0   0%   1   1% 
      
Enthusiasm to Get 
Things Done?  
No PLA 8 
 
36% 
 
15 
 
68% 
 
11 
 
50% 
 
12 
 
55% 
 
Week 0 0.43 
problem WL 13 
 
57% 
 
12 
 
52% 
 
11 
 
48% 
 
12 
 
52% 
 
Week 4 0.53  
WL+C 12 
 
52% 
 
12 
 
52% 
 
13 
 
57% 
 
13 
 
57% 
 
Week 8 0.43 
  Time  33   49%   39   57%   35   51%   37   54%   Week 12 0.81 
  Slight PLA 10 
 
45% 
 
4 
 
18% 
 
9 
 
41% 
 
8 
 
36% 
 
  
  problem WL 6 
 
26% 
 
9 
 
39% 
 
7 
 
30% 
 
9 
 
39% 
 
  
 
 
WL+C 5 
 
22% 
 
6 
 
26% 
 
8 
 
35% 
 
6 
 
26% 
 
  
   Time  21   31%   19   28%   24   35%   23   34% 
    
  Somewhat PLA 4 
 
18% 
 
3 
 
14% 
 
1 
 
5% 
 
2 
 
9% 
 
  
 of a WL 4 
 
17% 
 
2 
 
9% 
 
5 
 
22% 
 
2 
 
9% 
 
  
 problem WL+C 6 
 
26% 
 
4 
 
17% 
 
1 
 
4% 
 
4 
 
17% 
 
  
   Time  14   21%   9   13%   7   10%   8   12% 
    
  Big PLA 0 
 
0% 
 
0 
 
0% 
 
1 
 
5% 
 
0 
 
0% 
 
  
 problem WL 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
   
 
 
WL+C 0 
 
0% 
 
1 
 
4% 
 
1 
 
4% 
 
0 
 
0% 
   
   Time  0   0%   1   1%   2   3%   0   0% 
      
Frequency of snoring loudly?  PLA 4 
 
18% 
 
2 
 
9% 
 
2 
 
9% 
 
2 
 
9% 
 
Week 0 0.64 
WL 2 
 
9% 
 
4 
 
17% 
 
2 
 
9% 
 
4 
 
17% 
 
Week 4 0.71 
  WL+C 3 
 
13% 
 
3 
 
13% 
 
1 
 
4% 
 
1 
 
4% 
 
Week 8 0.79 
Time  9   13%   9   13%   5   7%   7   10% 
  Week 12 0.34 
Frequency of long pauses in your 
breathing? 
PLA 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
Week 0 0.36 
WL 1 
 
4% 
 
1 
 
4% 
 
1 
 
4% 
 
0 
 
0% 
 
Week 4 0.37 
  WL+C 2 
 
9% 
 
0 
 
0% 
 
0 
 
0% 
 
1 
 
4% 
 
Week 8 0.37 
Time  3   4%   1   1%   1   1%   1   1% 
  Week 12 0.37 
Frequency of leg twitching while 
sleeping? 
PLA 2 
 
9% 
 
3 
 
14% 
 
3 
 
14% 
 
3 
 
14% 
 
Week 0 1.00 
WL 2 
 
9% 
 
2 
 
9% 
 
2 
 
9% 
 
1 
 
4% 
 
Week 4 0.82 
  WL+C 2 
 
9% 
 
2 
 
9% 
 
2 
 
9% 
 
2 
 
9% 
 
Week 8 0.82 
Time  6   9%   7   10%   7   10%   6   9% 
  Week 12 0.55 
Frequency of disorientation or 
confusion during sleep?  
PLA 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
Week 0 - 
WL 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
Week 4 - 
  WL+C 0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
0 
 
0% 
 
Week 8 - 
Time  0   0%   0   0%   0   0%   0   0% 
  Week 12 - 
Other restlessness while sleeping? PLA 4 
 
18% 
 
4 
 
18% 
 
2 
 
9% 
 
4 
 
18% 
 
Week 0 0.52 
WL 2 
 
9% 
 
1 
 
4% 
 
1 
 
4% 
 
1 
 
4% 
 
Week 4 0.17 
  WL+C 2 
 
9% 
 
1 
 
4% 
 
1 
 
4% 
 
0 
 
0% 
 
Week 8 0.74 
Time  8   12%   6   9%   4   6%   5   7%   Week 12 0.05 
Data are presented as frequencies and percent N (N=68). Statistical significance is detailed from chi-squared analysis. Columns report the number of people whom responded 
and the percent of total number within each group. Time reports the total number of responders and the percent of total number of participants. 
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Table 17: Side Effects Frequency 
      Rating of Symptom   
Symptom Weeks Group 0 1 2 3 4 5 χ2 
Dizziness 0 PLA 18 4 0 0 0 0 0.52 
 WL 20 2 1 0 0 0  
  WL+C 21 1 1 0 0 0   
4 PLA 19 3 0 0 0 0 0.69 
 WL 20 3 0 0 0 0  
  WL+C 20 2 0 0 0 1   
8 PLA 20 1 0 0 1 0 0.47 
 WL 19 3 1 0 0 0  
  WL+C 21 1 0 0 0 1   
12 PLA 19 2 1 0 0 0 0.75 
 WL 20 2 0 0 1 0  
  WL+C 21 1 1 0 0 0   
Headache 0 PLA 13 7 2 0 0 0 0.22 
 WL 19 3 1 0 0 0  
  WL+C 15 5 0 1 2 0   
4 PLA 13 5 2 2 0 0 0.53 
 WL 15 7 1 0 0 0  
  WL+C 14 6 1 0 1 1   
8 PLA 14 6 0 1 1 0 0.77 
 WL 17 5 1 0 0 0  
  WL+C 14 6 1 1 0 1   
12 PLA 18 3 0 0 1 0 0.17 
 WL 16 5 1 0 1 0  
  WL+C 15 4 0 4 0 0   
Tachycardia 0 PLA 20 2 0 0 0 0 0.24 
 WL 21 1 0 1 0 0  
  WL+C 21 0 2 0 0 0   
4 PLA 21 1 0 0 0 0 0.45 
 WL 20 2 1 0 0 0  
  WL+C 17 2 1 2 0 1   
8 PLA 22 0 0 0 0 0 0.07 
 WL 21 2 0 0 0 0  
  WL+C 18 0 2 2 0 1   
12 PLA 21 1 0 0 0 0 0.66 
 WL 21 1 1 0 0 0  
  WL+C 19 1 2 0 0 1   
Heart Palpitations 0 PLA 20 2 0 0 0 0 0.39 
 WL 22 1 0 0 0 0  
  WL+C 22 0 1 0 0 0   
4 PLA 22 0 0 0 0 0 0.43 
 WL 22 1 0 0 0 0  
  WL+C 21 0 0 1 1 0   
8 PLA 22 0 0 0 0 0 0.43 
 WL 22 1 0 0 0 0  
  WL+C 21 0 1 0 0 1   
12 PLA 21 1 0 0 0 0 0.67 
 WL 22 1 0 0 0 0  
  WL+C 20 1 1 0 0 1   
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Table 17 – Continued 
      Rating of Symptom   
Symptom Weeks Group 0 1 2 3 4 5 χ2 
Dyspnea 0 PLA 20 1 1 0 0 0 0.86 
 WL 21 1 0 1 0 0  
  WL+C 19 2 1 1 0 0   
4 PLA 20 2 0 0 0 0 0.24 
 WL 20 1 2 0 0 0  
  WL+C 19 1 0 2 1 0   
8 PLA 21 1 0 0 0 0 0.59 
 WL 21 1 1 0 0 0  
  WL+C 19 2 0 1 0 1   
12 PLA 22 0 0 0 0 0 0.53 
 WL 22 0 1 0 0 0  
  WL+C 20 1 1 0 0 1   
Nervousness 0 PLA 16 4 1 0 1 0 0.37 
 WL 18 1 2 2 0 0  
  WL+C 17 3 0 3 0 0   
4 PLA 19 2 0 1 0 0 0.57 
 WL 18 2 1 1 1 0  
  WL+C 21 0 0 2 0 0   
8 PLA 17 3 2 0 0 0 0.78 
 WL 17 4 1 0 1 0  
  WL+C 19 1 2 0 1 0   
12 PLA 17 2 3 0 0 0 0.39 
 WL 20 0 2 0 0 1  
  WL+C 19 0 3 1 0 0   
Blurred Vision 0 PLA 21 1 0 0 0 0 0.64 
 WL 22 1 0 0 0 0  
  WL+C 20 2 0 1 0 0   
4 PLA 20 2 0 0 0 0 0.55 
 WL 20 2 1 0 0 0  
  WL+C 21 0 1 1 0 0   
8 PLA 19 2 1 0 0 0 0.67 
 WL 20 2 1 0 0 0  
  WL+C 21 0 1 1 0 0   
12 PLA 21 1 0 0 0 0 0.33 
 WL 21 0 2 0 0 0  
  WL+C 21 1 0 1 0 0   
Other 0 PLA 22 0 0 0 0 0 0.61 
 WL 22 1 0 0 0 0  
  WL+C 22 1 0 0 0 0   
4 PLA 22 0 0 0 0 0 0.40 
 WL 22 1 0 0 0 0  
  WL+C 19 2 0 0 1 1   
8 PLA 22 0 0 0 0 0 0.41 
 WL 22 1 0 0 0 0  
  WL+C 22 0 0 0 1 0   
12 PLA 22 0 0 0 0 0 0.13 
 WL 23 0 0 0 0 0  
  WL+C 21 0 0 2 0 0   
Data are presented as frequencies. Statistical significance is detailed from chi-squared analysis. 1: minimal (1-2 per/wk); 2: slight (3-4 per/wk); 3: occasional (5-6 per/wk); 4: 
frequent (7-8 per/wk); 5: severe (9 < per/wk) 
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Table 18: Side Effects Severity 
      Rating of Symptom   
Symptom Weeks Group 0 1 2 3 4 5 χ2 
Dizziness 0 PLA 19 2 0 1 0 0 0.66 
 WL 20 2 1 0 0 0  
  WL+C 21 2 0 0 0 0   
4 PLA 18 3 0 0 1 0 0.60 
 WL 20 2 0 1 0 0  
  WL+C 20 2 0 0 0 1   
8 PLA 21 0 0 0 1 0 0.29 
 WL 19 3 0 1 0 0  
  WL+C 21 1 0 0 0 1   
12 PLA 19 2 0 1 0 0 0.75 
 WL 20 1 0 1 0 1  
  WL+C 21 2 0 0 0 0   
Headache 0 PLA 12 1 6 3 0 0 0.57 
 WL 19 0 3 1 0 0  
  WL+C 15 1 4 3 0 0   
4 PLA 14 1 4 3 0 0 0.21 
 WL 15 6 1 1 0 0  
  WL+C 16 2 1 3 0 1   
8 PLA 15 2 3 2 0 0 0.52 
 WL 17 4 0 2 0 0  
  WL+C 16 1 2 3 0 1   
12 PLA 18 3 0 1 0 0 0.47 
 WL 18 2 0 1 1 1  
  WL+C 16 1 2 3 1 0   
Tachycardia 0 PLA 21 1 0 0 0 0 0.56 
 WL 22 0 1 0 0 0  
  WL+C 22 1 0 0 0 0   
4 PLA 21 1 0 0 0 0 0.34 
 WL 22 1 0 0 0 0  
  WL+C 18 2 2 0 1 0   
8 PLA 21 1 0 0 0 0 0.66 
 WL 21 1 1 0 0 0  
  WL+C 19 1 2 1 0 0   
12 PLA 21 1 0 0 0 0 0.40 
 WL 20 2 1 0 0 0  
  WL+C 18 1 3 0 1 0   
Heart Palpitations 0 PLA 20 2 0 0 0 0 0.18 
 WL 23 0 0 0 0 0  
  WL+C 22 0 1 0 0 0   
4 PLA 21 1 0 0 0 0 0.41 
 WL 22 0 1 0 0 0  
  WL+C 20 0 2 0 1 0   
8 PLA 22 0 0 0 0 0 0.24 
 WL 22 1 0 0 0 0  
  WL+C 20 0 2 1 0 0   
12 PLA 21 1 0 0 0 0 0.52 
 WL 23 0 0 0 0 0  
  WL+C 20 1 1 0 1 0   
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Table 18 – Continued 
      Rating of Symptom   
Symptom Weeks Group 0 1 2 3 4 5 χ2 
Dyspnea 0 PLA 20 2 0 0 0 0 0.41 
 WL 22 0 1 0 0 0  
  WL+C 19 3 1 0 0 0   
4 PLA 20 2 0 0 0 0 0.44 
 WL 20 1 1 1 0 0  
  WL+C 20 0 2 0 1 0   
8 PLA 21 1 0 0 0 0 0.61 
 WL 21 1 1 0 0 0  
  WL+C 20 2 0 0 1 0   
12 PLA 21 1 0 0 0 0 0.67 
 WL 22 1 0 0 0 0  
  WL+C 20 1 1 1 0 0   
Nervousness 0 PLA 17 2 2 1 0 0 0.69 
 WL 18 2 0 3 0 0  
  WL+C 17 3 2 1 0 0   
4 PLA 19 0 3 0 0 0 0.66 
 WL 18 1 2 2 0 0  
  WL+C 20 1 1 1 0 0   
8 PLA 17 4 1 0 0 0 0.79 
 WL 17 3 1 2 0 0  
  WL+C 18 2 1 1 1 0   
12 PLA 17 2 2 1 0 0 0.26 
 WL 20 2 0 0 0 1  
  WL+C 19 1 0 3 0 0   
Blurred Vision 0 PLA 21 1 0 0 0 0 0.55 
 WL 22 0 1 0 0 0  
  WL+C 20 2 1 0 0 0   
4 PLA 20 2 0 0 0 0 0.84 
 WL 20 2 1 0 0 0  
  WL+C 21 1 1 0 0 0   
8 PLA 19 2 1 0 0 0 0.73 
 WL 20 3 0 0 0 0  
  WL+C 21 1 1 0 0 0   
12 PLA 20 2 0 0 0 0 0.24 
 WL 21 0 2 0 0 0  
  WL+C 21 1 0 1 0 0   
Other 0 PLA 22 0 0 0 0 0 - 
 WL 23 0 0 0 0 0  
  WL+C 23 0 0 0 0 0   
4 PLA 22 0 0 0 0 0 0.53 
 WL 22 1 0 0 0 0  
  WL+C 20 1 1 0 0 1   
8 PLA 22 0 0 0 0 0 0.41 
 WL 22 0 1 0 0 0  
  WL+C 22 0 0 0 1 0   
12 PLA 22 0 0 0 0 0 0.13 
 WL 23 0 0 0 0 0  
  WL+C 21 0 0 2 0 0   
Data are presented as frequencies. Statistical significance is detailed from chi-squared analysis. 1: minimal; 2: slight; 3: moderate; 4: severe; 5: very severe 
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CHAPTER V  
DISCUSSION AND CONCLUSIONS 
 
Summary 
Weight loss remains a goal for people globally in an effort to improve health and 
reduce risk associated with obesity and related comorbidities such as cardiovascular 
disease and type-2 diabetes mellitus. While diet and exercise modification are primary 
recommendations, dietary supplements such as fiber, appetite suppressors, lipolytic 
agents, and stimulants like caffeine are commonly used. As such, there is a constant search 
for alternatives like Dichrostachys glomerata (DG). Previous research has reported that 
DG supplementation (200-800 mg/d) for 8 weeks (2-months) led to significant reductions 
in weight and fat between 7-11 kg and 3-5%, respectively, without exercise or diet 
intervention. In comparison, the placebo interventions were reported to have lost <1 kg of 
body weight and <1% body fat. These data come from three trials performed by Kuate et 
al. and are the only studies, to date, that have tested DG in this manner. Of them, the lowest 
dose appeared to be the most effective, reporting weight loss of ~11 kg. However, the 
amount they administered is unclear seeing as the paper’s abstract states 200 mg, twice a 
day (BID) but, the methods section implies only a single 200 mg/d dose. In addition, the 
aforementioned experiment sampled from a metabolic syndrome population.3 The only 
other trial looked at a normoglycemic obese population and type-2 diabetic population 
with 800 mg/d (400mg BID), resulting in weight loss of ~7.5 and ~6 kg, respectively.4,5 
Consequently, further investigation is required to corroborate these findings.  
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The current study examined two multi-ingredient weight loss supplements 
containing DG, with and without caffeine [WL+C, WL], compared to a placebo (6g 
dextrose) over a 12-week, or 3-month, period. This double-blind trial ran with parallel 
groups and was randomized using a stratification method. Participants were evaluated for 
body weight/composition, anthropometry, clinical health markers, reported hunger, 
satiety, side effects, and sleep effects. The results of which showed statistically significant 
(p<0.05) decrease in FM from baseline at week 4 (-0.56±0.95 kg, p=0.01) and week 8 (-
0.63±1.47 kg, p=0.04), for the non-caffeine group [WL], with a continued trend into week 
12 (-0.71±1.47 kg, p=0.08). It is worth noting that FM exhibited a steady decline while 
body weight did not change. In line with this, supplement groups displayed parallel trends 
in FFM, gaining small amounts consistently through week 12 from baseline (WL 0.26±2 
kg [p=0.5-0.9], WL+C 0.11±1.9 kg [p=0.7-0.8]), compared to the decline seen in placebo 
(-0.32±2 kg [p=0.4-0.6]). Moreover, BMC (g) showed little to no deviation or trend among 
treatment groups.  
The results of the present study are in direct contrast to previous literature by Kuate 
et al., purporting significant weight loss over 8 weeks of DG supplementation and were 
the primary templates this study was modeled after. In 2011, Kuate et al. examined the 
effects of DG supplementation on normoglycemic and type-2 diabetic obese populations 
with 25 males and 72 females, age 25-65, in a double-blind, randomized, placebo-
controlled fashion where both groups had 46 people split evenly into placebo or 
supplement for a total of 4 groups.4 A 2013 follow-up to this experiment by the same 
group utilized an identical protocol except this time sampling from a metabolic syndrome 
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population involving 116 males and 202 females, age 24-58, split into either placebo or 
supplement groups, looking at an aqueous DG extract.3 The amount of weight loss 
achieved in these trials far exceeds any observed in this present one, and in a shorter 
period. To elaborate, the first study4 examined a similar population and sample size to 
ours, showing both supplement groups had lost around 6-7 kg of body weight compared 
to -1 kg in placebo, then the second study3 resulted in loss of about 11 kg and the placebo 
lost <1 kg. Despite this, weight loss remained unaffected by DG in our current trial through 
8 weeks and continuing as far as 12 weeks, with <0.5 kg decrease in weight at both time 
points. What’s more, several of the other changes that accompanied the weight reduction 
in previous literature were not observed in this case. Generally, changes to BMI (-2 to -4 
kg/m2), waist and hip (-6 to -10, -3 to -9 cm) measurements, and body fat (-2 to -5%) 
paralleled the weight loss purported.3,4 As opposed to the current DG outcomes for BMI 
(-0.12, -0.14 kg/m2), waist (0.45, 1.52 cm) and hip (-0.25, -0.14 cm) at weeks 8 and 12, 
respectively, which are more comparable to that of the previous trials placebo results than 
their supplement group. The exception in this regard was the modest trend forming in 
reduction of fat mass as DG supplementation continued (-0.5, -0.6, -0.7 kg) through weeks 
4, 8, and 12, respectively. 
Blood pressure also showed little fluctuation with the current DG supplementation 
for 8 or 12 weeks, where systolic and diastolic pressure stayed within ±2 mmHg from 
baseline in all groups. Alternatively, the Kuate et al. trials reported comparable results 
with placebo but, DG saw significantly decreased blood pressure 
𝑆𝐵𝑃
𝐷𝐵𝑃
[−13 to −24]
[−10 to −15]
 mmHg. 
Similarly, the primary clinical health markers examined showed no significant changes by 
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week 8 or week 12, for our group respectively, including blood glucose (-0.1, -1.5 mg/dL), 
triglycerides (-5.3, 18.3 mg/dL), total cholesterol (-7.4, -6.7 mg/dL), LDL (12.8, -3.4 
mg/dL), and HDL (-3.2, -4.8 mg/dL) and did not differ from placebo. However, the Kuate 
et al. trials all presented large reductions after 8 weeks that were also significantly different 
from placebo for blood glucose (-28.9 to -104.1 mg/dL), triglycerides (-55.4 to -105.1 
mg/dL), total cholesterol (-43.1 to -96.8 mg/dL), and LDL (-50.2 to -84.8 mg/dL) with 
increased HDL (20.6 to 39.6 mg/dL).3,4 
In their 2011 study, Kuate et al. had a diabetic group with an average baseline 
“fasting” glucose of around 200 mg/dL for placebo and DG, which is typically the 
expected value for the same population, 2 hours post-prandial. Even the “normoglycemic” 
group in the same study was closer to, even within the range of, prediabetes (100-125 
mg/dL).203 Their 2013 trial had similar levels, except this was by design. Never the less, 
these trials, especially in 2011, seem as though hyperglycemia could have played a 
potential role in causing a sort of hypohydrated state, and subsequently water retention in 
the form of intracellular water, allowing these parameters to improve as drastically as they 
did. Water retention would also explain the reported drop in body fat percent over 8 weeks 
as participants began to correct their fluid balance, possibly due to monitoring, considering 
the measurements were obtained using bioelectric impedance which is known to report 
higher fat percent with water retention and lower fat percent with dehydration.204 Not to 
mention that it has been shown to be realistically possible and commonly done, to lose as 
much as 6% body mass in just 5 days, where nearly all of the weight was fluid yet, 
intracellular water remained unchanged.205 Therefore, the notion of such a process 
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occurring over an 8-week span is more than feasible. By comparison, Table 9 shows the 
fluid content and distribution, for this current trial, to have remained relatively consistent 
over the span of 12 weeks in all groups. Unfortunately, the hydration data is not reported 
for any of the previous trials, leaving no way to confirm or deny this theory but it is worth 
bearing in mind. 
With regards the other supplements used in this investigation, ashwaganda was 
another primary nutrient of interest and one whose previous literature shows to be in line 
with some of the findings in our current study. Cooley et al. showed an average weight 
loss of around 2 kg as well as a decrease in BMI of about 0.75 kg/m2 for 36 individuals 
ingesting 300 mg, BID with a multi-vitamin and naturopathic lifestyle encouragement 
spanning 12 weeks. This was weighed against a placebo control (-0.5 kg, -0.2 kg/m2), 
otherwise similar group.32 Then Raut et al. took eighteen apparently healthy volunteers 
(M 12; F 6, age: 20-27, 66.7±8.8 kg, BMI 24.3±2.7 kg/m2) and described an increase in 
muscle force by 2-6 kg (handgrip, quadriceps, back-extensor) with no exercise 
intervention, an increasing trend in lean body mass (1.8 kg), decreasing trend in body fat 
(-2.3%), reduced total cholesterol (-16.3 mg/dL), and a trend in lowering LDL (-15.2 
mg/dL), triglycerides (-7 mg/dL), and blood glucose (-4.6 mg/dL), after 30 days. This 
intervention used an increasing dose of 750 mg/d x10 days, 1,000 mg/d x 10 days, and 
1,250 mg/d x 10 days, exhibiting no change in body weight. However, note that body 
composition was assessed via skinfold thickness and, with it being exploratory, there 
lacked a placebo control.35 
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Along the same lines, a few other supplements have been reported to affect resting 
metabolism such as capsaicinoids and caffeine. As such, we sought to measure resting 
energy expenditure by utilizing an indirect calorimeter metabolic cart. There were no 
differences between any groups in terms of resting energy expenditure (kcals per day). 
Yet, there appeared to be a trend forming wherein REE fluctuated lower then increased in 
WL (-28±201; -44±200; 55±213 kcal/d) and even more so in WL+C (58±205; 18±256; 
111±220 kcal/d), at weeks 4, 8, and 12, respectively. In comparison, placebo looked to be 
on a downward trend after first increasing the number of kcals utilized at rest (162±277; 
135±310; 92±284 kcal/d), from weeks 4, 8, and 12, respectively. Similar trends were seen 
for REE/kg in WL (-0.16±2.40; -0.49±2.35; 0.62±2.65 kcal/kg/d), WL+C (1.01±2.02; 
0.59±2.61; 1.57±2.375 kcal/kg/d), and placebo (1.84±2.65; 1.38±2.75; 1.03±2.74 
kcal//kg/d) from weeks 4, 8, and 12, respectively. Additionally, we observed supplement 
groups reported hunger severity to be generally less than their baseline with satiety being 
greater than baseline mostly in the non-caffeinated group, while placebo showed no 
changes but was consistently greater than other groups. As expected, there were no 
differences in diet characteristics or reported side effects. This was the expectation simply 
because there is hardly, if any literature suggesting the opposite. 
The current results are seemingly in agreement with previous literature. For 
example, a systematic review performed by Whiting et al. in 2012 looked at 20 trials 
ranging from 1-135 mg/d, for 1 day 4 months, with samples sizes of 7-91. Of them, 13 
studies showed increased energy expenditure of around 50 kcal/d, 7 reported increased 
lipid oxidation, and 5 reported decreased appetite and increased satiety.11 A 2014 
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systematic review and meta-analysis by Whiting et al., concluded with 8 studies and 191 
participants having reduced ad libitum energy intake averaging -74 kcal per meal when 
consuming capsaicin (0.2-33 mg) approximately 30 minutes before a meal, essentially 
reducing energy consumption.10  
The non-caffeinated group, in the current trial, exhibited some slight sleep quality 
improvements in that they fell asleep between 5-6 minutes faster than when they started 
by weeks 8 and 12. In addition, they fell asleep a bit easier, with fewer interruptions such 
as waking to use the bathroom, in comparison to the caffeinated group that reported 
increased bathroom use. As well, the caffeine group reported to take longer to fall asleep 
than placebo at weeks 4 and 12 by approximately 18 and 8 minutes, respectively. These 
sleep quality results are supported by literature for both ashwaganda and theanine 
supplementation for help with sleep. Ashwaganda is traditionally used in ayurvedic 
medicine and puported within that literature to be a natural sleep aid.35 Whereas theanine 
by itself has been shown, for example, by Lyon et al. to improve sleep quality in boys 8-
12 years old diagnosed with ADHD, with administration of 400 mg/d.121 Furthermore, a 
review by Juneja et al. reported relaxing effects with as little as a one-time dose of 50 mg. 
116 For context, the current study’s non-caffeine group ingested 100 mg of theanine daily. 
However, when theanine has been paired with caffeine, there is an opposing stimulating 
effect following administrations of 40-150 mg of caffeine paired with 9-250 mg of 
theanine.105-109 Arguably, these outcomes could be the result of simply consuming 
caffeine, of which WL+C ingested around 350 mg/d, with no theanine.  
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Conclusions 
Supplementation of a weight loss formula containing DG showed to have no 
significant effect on body weight using the current dose (300 mg/d). The addition of 
caffeine did not alter this outcome. However, supplement groups did show a trend in loss 
of FM with a subsequent reduction in BF percent, while the placebo group stayed 
relatively stable throughout the study. Even so, there were no differences between groups 
for either weight or body composition.  
These trends in body composition are however in keeping with previous findings 
using one of the other primary nutrients of the current study, ashwaganda, where 
participants exhibited weight and body fat loss, as well as an increase in lean 
mass/muscular strength without exercise.32,35 Clinical health markers however, showed no 
change, in contrast to the evidence of previous literature, primarily of DG and capsaicin, 
suggesting improvements in glucose and other markers related to obesity and metabolic 
syndrome, such as lipid profiles.3-5,22,23 Other nutrients including capsaicin and caffeine, 
have shown to work either as primary driver or synergistically towards weight loss. 
Caffeine is commonly used in weight loss supplements as a way of increasing 
thermogenesis, energy expenditure, and fat oxidation.6-9 In the same way, capsaicin is 
looked at for its’ purported abilities to improve fat metabolism and as an appetite 
suppressant.10-25 When capsaicin is coupled with caffeine they have shown to suppress 
hunger, increase feelings of satiety, and increase postprandial thermogenesis.15,26 
Ultimately, these factors could contribute to weight loss and its’ continued maintenance. 
Our results would seem to agree with this literature, showing an increase in REE from 
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baseline. Supplement groups had increased REE from baseline with a greater 
improvement in the caffeinated group than the non-caffeinated group but, both groups 
more so than placebo. 
While moderate changes ingesting 300 mg/d of DG with other nutrients promoted 
modest effects on body composition, it was nowhere near those purported previously. A 
consideration to be made is the dose of 300 mg/d may not have been sufficient to induce 
larger changes in weight loss, especially in a relatively healthy obese population and based 
on an unclear dose in previous literature. Currently, there are just three trials that tested 
DG in similarly to this study, as such the results of this investigation further highlight the 
need to put forth data that come from a group besides Kuate et al. In particular, because 
we produced results that are not in agreement with the previous literature, as well as 
extended supplementation by 4 weeks to no avail. Lastly, this trial was the first of this 
design with DG to measure body composition via DEXA scans, provide potentially 
important hydration data, as well as test in conjunction with caffeine ingestion.  
In closing, further research is certainly required to determine an effective dose and 
subsequently paired with a diet and/or exercise intervention for functional assessment of 
the weight loss and metabolic aid potential. As well, the initial studies performed by Kuate 
et al. should be reproduced, taking into consideration the clinical populations that were 
examined, to confirm their results and tease out whether DG shows to be more effective 
in normal or clinical populations. Following that, similar testing could be done in different 
geographical regions, investigating how ubiquitous DG may or may not be in affecting 
people. 
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APPENDIX A 
Nonprotein Respiratory Quotient Calculation 
 
𝐸 = 𝐺 +  
GCO2 − CO2 ∙ 𝑅𝑄
FO2 ∙ 𝑅𝑄 − FCO2
∙ 𝐹 
_______________________________________________________________________ 
𝑂𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛: (1g glucose) 
 
𝐺 = 3.8683kcal/g 
GO2 = 0.7455 L of O2 (STPD)/g 
GCO2 = 0.7426 L of CO2 (STPD)/g 
 
𝑂𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛: (1g Fatty Acids) 
 
𝐹 = 9.746kcal/g 
FO2 = 2.0092 L of O2 (STPD)/g 
FCO2 = 1.4136 L of CO2 (STPD)/g 
 
𝐸 (energy produced) = (1g of glucose)+([x]g fatty acids) 
_______________________________________________________________________ 
𝐸 = 3.8683 +  
0.7426 − 0.7455 ∙ 𝑅𝑄
2.0092 ∙ 𝑅𝑄 − 1.4136
∙ 97460 
 
% glucose =
3.8683
𝐸
∙ 100                      % fatty acids = 100 − % glucose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 118 
 
APPENDIX B 
 119 
 
APPENDIX C 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial: An Examination of a Novel Weight Loss Formula on Anthropometry and 
Indices of Cardiovascular Disease Risk - Entrance Criteria 
 
Phone Script: 
“Exercise and Sport Nutrition Lab, this is [name] how may I help you? If you 
are interested in the study titled An Examination of 
a Novel Weight Loss Formula on Anthropometry and Indices of 
Cardiovascular Risk, I am going to ask you a series of questions.” 
 
Entrance Criteria: 
 
Age: 
1. Are you between the ages of 30 & 45? (they must be 45 when they sign the 
consent, they may turn 46 during the study) 
Yes – Possible FAM  No – Screen Failure 
 
Exercise History:  
1. Are you apparently healthy? 
Yes – Possible FAM  No – Screen Failure 
 
2. Are you moderately active and participate in low intensity 
recreational activity at least 3 to 4 d/wk? 
Yes – Possible FAM  No – Screen Failure 
 
BMI (kg/m2):  
1. Do you have a BMI between 25.0 and 34.9?  
Yes – Possible FAM  No – Screen Failure  
 120 
 
 
Exclusion Criteria:  
1. Have you experienced a recent history of weight change (+/- 10 
lbs. within 3 months)? 
Yes – Screen Failure  No – Possible FAM 
 
2. Do you have any uncontrolled metabolic or cardiovascular disorders 
including; heart disease, hypertension, arrhythmias, diabetes, 
hypogonadism, hepatorenal, musculoskeletal, autoimmune, 
neurological disease or thyroid disease, or known electrolyte 
abnormalities? 
Yes – Screen Failure  No – Possible FAM 
 
3. Are you currently taking medications or prescribed medications for 
less than six months? (birth control is allowed)? 
Yes – Screen Failure  No – Possible FAM 
 
4. Are you taking any dietary supplements for thyroid, hyperlipidemia, 
hypoglycemia, or weight loss (e.g., ephedra or thermogenic 
compounds, etc.) or have you within the past three months? 
Yes – Screen Failure  No – Possible FAM 
 
5. Are you pregnant or nursing or plan to become pregnant during the 
next month? 
Yes – Screen Failure  No – Possible FAM 
 
6. Do you have an intolerance to caffeine and/or other natural 
stimulants? 
Yes – Screen Failure  No – Possible FAM 
 
Summary:  
If the potential participant meets all conditions for a possible FAM, 
please schedule them for a familiarization.  
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